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Sex hormones are steroids that are key co-ordinators of sexual development 
and are principally formed in endocrine glands. The main types of sex 
hormones in females are estrogens: notably estrone (E1) and estradiol (E2), 
whereas in males, androgens, in particular testosterone, androstenedione and 
5α-dihydrotestosterone are the most prevalent. 
Obesity is one of the most important risk factors in development of metabolic 
diseases. Therefore, it is important to study factors that influence body weight 
in order to develop preventative and curative approaches. Many studies have 
investigated the role of sex hormones in the accumulation of body fat, given 
the differences in adiposity between sexes and, in particular, following the 
menopause. In general, abdominal fat has a stronger relationship than total 
body fat in the development of metabolic diseases, suggesting factors 
underlying these sex differences in fat distribution may be important in 
pathology. Investigations of sex hormone signalling in metabolic disease may 
therefore improve strategies to prevent abdominal fat accumulation and 
reduce the adverse impact of obesity on lifelong health. 
At the outset of this thesis, few studies existed assessing relationships between 
metabolic risk factors and exposure to sex steroids. Moreover, the data from 
cross-sectional studies were not consistent and some concerns raised over the 
validity of data due to the analytical methods used, often immunoassays in 
the older literature. An understanding of the effect of sex steroids on 
metabolism was needed but researchers emphasised the need for better 
profiling of androgens and estrogens to gain a clearer picture, recognising 
none of the commercially existing automatic immunoassay methods had 




Analysis of sex steroids is challenging due to their extremely low 
concentrations in different biological samples, dependent on age, sex and 
disease. Sex steroids suffer from interference from substances in the biological 
matrix such as endogenous isomers. This raises the importance of alternative 
analytical methods such as liquid chromatography mass spectrometry (LC-
MS). LC-MS is a gold standard analytical technique that is capable of 
measuring multiple analytes in a single sample. This thesis aimed to develop 
LC-MS approaches to allow sensitive measurements of estrogens and 
androgens to investigate the role of sex steroids in the distribution and 
function of adipose tissue and its association with metabolic diseases.  
In the first chapter, an initial analytical approach to quantify androgens in 
human and murine biological fluids by tandem mass spectrometry (MS/MS) 
was established, and a particular goal was to evaluate if the approach could 
quantify circulating steroids in samples with very low levels; including post-
menopausal females and small volume pre-clinical samples. Extraction was 
validated using solid phase extraction, in conjunction with LC–MS/MS 
analysis and the benefits and limitations of the method were assessed. This 
approach allowed robust measurement of testosterone and androstenedione 
across typical physiological ranges in plasma found in pre- and post-
menopausal women and men. The method was also found suitable for animal 
models to quantify testosterone in small volumes (30-50µL) of plasma. 
However, for the detection of 5α-dihydrotestosterone this method required 
much large volumes (>500µL), due to inefficient ionisation and therefore 





The next Chapter describes investigations of approaches to derivatisation of 
androgens - aiming to improve sensitivity by endowing the analyte with a 
chargeable or permanently charged group for MS ionisation. Prior to this 
thesis, 2-hydrazino-1-methylpyridine (HMP) had been applied for this 
purpose but the necessary chromatographic separation had not been achieved 
and was not ideal. Thus, methods had not progressed to full validation or 
biological application. We aimed to overcome the chromatographic challenges 
faced with the hydrazine derivatives and validated an analytical approach to 
detect low abundance 5α-dihydrotestosterone by derivatisation in plasma, 
comparing several different reagents. 
Derivatisation to form HMP androgens, in conjunction with LC-MS/MS, 
proved highly suitable for quantitative analysis of androgens in low 
abundance in human plasma with low volumes (10-200µL), offering clear 
advantages in sensitivity over analysis of underivatised steroids. The 
approach allows concomitant analysis of testosterone, androstenedione and 
5α-dihydrotestosterone and this method could be expanded to include further 
ketone containing steroids. Robust measurement was achieved across typical 
physiological ranges found in post-menopausal women and men, comparing 
to immunoassays. 
Next the sensitivity of analysis for estrogens was enhanced using a 
methylpyridinium derivative to detect these steroids in low abundance in 
human plasma and, in particular, to evaluate if the approach could quantify 
circulating steroids in post-menopausal females. A highly sensitive method 
with lower limits of quantitation (LOQs) than previous methods was validated 
using ion-exchange solid phase extraction in conjunction with LC-MS/MS. 
Derivatisation by reaction of 2-fluoro-1-methylpyridinium-p-toluenesulfonate 
(FMP-TS) with phenolic estrogens, in conjunction with LC-MS/MS, was found 
to be suitable for quantitative analysis of E1 and E2 in low abundance in 
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plasma. The derivatisation reaction may be applicable to other naturally 
occurring phenolic steroids. 
Finally, using these novel analytical approaches sex steroid profiles were 
investigated in relation to metabolic parameters in a cohort of healthy men 
across the age range 20-80years, using correlation and multiple regression 
statistics. Generally, results show a stronger correlation of androgens than 
estrogens to metabolic parameters such as glucose disposal and adiposity.  
In conclusion, sensitive measurements of sex steroids were achieved using 
solid phase extraction and enhanced with derivatisation, in conjunction with 
LC-MS/MS. The approaches developed allow robust quantitative analysis of 
androgens and estrogens in low abundance in biological fluids across typical 
physiological ranges found in pre- and post-menopausal women and men, 
overcoming concerns over use of non-specific immunoassays. These methods 
developed may also be used in applied to rodent models with low plasma 
volumes. The derivatisation methods could be further applied to other ketone 
and phenol containing steroids. Use of this analytical method development 
approach has allowed insight into relationships between sex steroids, adipose 





Obesity is one of the biggest risk factors in development of life-threatening 
health problems, including cancer and heart disease. It is therefore important 
to understand factors that can influence body weight. Specifically, body shape 
plays a role in risk of disease. Belly fat has a greater impact than total body fat 
alone in the risks of development of obesity related diseases. Some studies 
suggest sex hormones can control the accumulation of fat around the midriff. 
These hormones are needed by the body for sexual development and 
reproduction and change in amounts in the blood throughout life. The main 
sex hormones in females are called estrogens and in males they are androgens. 
Researchers are interested in understanding if drugs or lifestyle can alter sex 
hormones to understand ways to reduce belly fat. Historically, measurements 
of these hormones are unreliable, particularly when their amounts are low. 
These problems are made worse by lots of very similar hormones being 
present in blood making it difficult to home in on the ones of interest. 
Therefore, better methods are needed to measure individual androgens and 
estrogens. These studies used an instrument called a mass spectrometer that 
allowed multiple hormones to be tracked in one sample.  
In brief, new tests were developed to measure sex hormones in women, men 
and animals. The tests were more accurate than previous approaches. In 
particular highly efficient ways to harvest specific hormone from blood were 
developed and novel chemicals were explored which could tag on to the 
hormones to help them be identified and detected. Using the data collected it 
was then possible to relate sex hormone levels to body fat amounts and 
location, showing for example that androgen levels were related to a range of 




The tools developed in this thesis are now available to medical researchers to 
help to investigate how sex hormones play a role in our health and diseases. 
Developing better methods to measure sex hormones opens up doors to 
understand the role of sex hormones in fat distribution and its relationship 
with health.  
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FMP-TS 2-fluoro-1-methylpyridinium-p-toluenesulfonate 
FSH  follicle-stimulating hormone 
FT-ICR MS fourier transform ion cyclotron resonance mass spectrometry  
GC-MS gas chromatography mass spectrometry 
GGT  gamma-glutamyl transferase (GGT) 
HbA1c glycated hemoglobin 
HDL  high density lipoprotein 
HDS  hydroxysteroid dehydrogenase 
HMP  2-hydrazino-1-methylpyridine 
HP  2-hydrazinopyridine 
HPLC  high performance liquid chromatography 
HTP  2-hydrazino-4-(trifluoromethyl)-pyrimidine 
IEM  ion evaporation model 
IM  ion mobility 
IS  internal standards 
LH  luteinizing hormone 
LC-MS/MS liquid chromatography tandem mass spectrometry 
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LLE  liquid-liquid extraction 
LODs  limits of detection 
LOQs  limits of quantitation 
LSIMS liquid secondary ion mass spectrometry 
MALDI matrix-assisted laser desorption ionisation 
MD  mean difference 
MLR  multiple linear regression 
MRM  multiple reaction monitoring 
MS  mass spectrometry 
MS3  third stage mass spectrometry 
MSn  multiple reaction mass spectrometric 
NEFAs non-esterified fatty acids 
NEQAS National External Quality Assessment Scheme 
NHS  National Health Service 
OFN  oxygen-free nitrogen  
Q  quadrupole 
Q-ToF  quadrupole time of flight 
Q-Q  quantile-quantile 
QIT  quadrupole ion trap 
QQQ  triple quadrupole (QQQ) 
 
RD  rate of disposal 
rf  radiofrequency 
RME  relative mean error 
RSD  relative standard deviation 
RSE  relative standard error 
Rt  retention time 
SD  standard deviation 
SIM  single ion monitoring 
SLE  liquid-solid extraction 
SNR  signal/noise 
SPE  solid-phase extraction 
SRM  selective reaction monitoring 
T  testosterone 
TEA  triethylamine 
TFA  trifluoroacetic acid 
TMS  trimethylsilyl 
UHPLC ultra high performance liquid chromatography 
UHPSFC ultra high performance supercritical fluid chromatography 
ULOQ upper limits of quantitation 
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1.1 Sex steroids 
1.1.1 Biochemistry 
Sex hormones are lipophilic steroids principally known to organise sexual 
development and formed mainly in endocrine glands (Miller and Auchus, 
2011). In mammalian species, synthesis occurs primarily in ovaries (females) 
and testes (males) (Miller and Auchus, 2011), generating eggs, and fertile 
sperm by spermatogenesis respectively. The hypothalamus gland in the brain 
regulates the production of hormones by increasing amounts of gonadotropin-
releasing hormone that stimulates the pituitary gland to secrete follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) which together 
stimulate the reproductive glands to generate the sex hormones (Sanderson, 
2006). Both testes and ovaries secrete sex steroids for regulating reproductive 
functions and sexual development. 
Sex steroids are biosynthesised from cholesterol (Figure 1.1) (Miller and 
Auchus, 2011, Sanderson, 2006, Krone et al., 2007, Parker and Schimmer, 1995). 
Steroidogenesis  is an enzymatic process involving cytochrome P450s, 
hydroxysteroid dehydrogenases (HSD), and steroid reductase enzymes 
(Sanderson, 2006, Parker and Schimmer, 1995). The main types of sex 
hormones in females are the estrogens: estrone (E1), estradiol (E2) and 
progesterone, whereas in males, the androgens: testosterone (T) and 
androstenedione (A4) are most abundant and can be converted to estrogens 
by aromatase (Sanderson, 2006, Parker and Schimmer, 1995). Aromatase is 
expressed mainly in reproductive organs but also in the brain and peripherally 
in fat and bone (Miller and Auchus, 2011). The more potent androgen, 
dihydrotestosterone (DHT) is formed mainly by 5α-reductase which has three 
types 1,2 and 3 (Krone et al., 2007) and DHT can be formed alternatively by 
3β-HSD. (Figure 1.1). DHT originates mainly from male reproductive organs, 
such as testes and prostate, but again it can form in brain and peripheral 
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tissues such as liver (Mak et al., 2019). In addition, dehydroepiandrosterone 
(DHEA) is an inactive metabolite of T and circulates in high concentrations. 
Epitestosterone (EpiT) and 17β-estradiol (17β-E2) are endogenous inert 17α-
isomers for T and E2 respectively.  
 
Figure 1.1: Classic and alternative pathways of the biosynthesis of sex 
steroids; HSD, hydroxysteroid dehydrogenase. 
 
 
         
            
             
                 




















































1.1.2 Sex steroids and obesity 
Obesity is one of the most important risk factors in the development of adverse 
health conditions such as cardiovascular diseases (CVD) and diabetes 
(Tchernof et al., 1995). Therefore, it is important to study any factors that could 
influence body weight to develop preventative and curative approaches. In 
the last two decades, many studies have tried to demonstrate a role of key 
parameters, such as the relationship between sex hormones and the 
accumulation of body fat (Kulle et al., 2010). Generally, body abdominal 
(visceral) fat has a stronger relationship than total fat body in the worsening 
of metabolic diseases (Tchernof et al., 1995). Body fat distribution is different 
among genders possibly driven by differences in sex steroid profiles and 
concentrations, which affect physiological responses such as eating habits and 
adipose metabolism (Tchernof et al., 1995, Grebe and Singh, 2011). 
In men, fat tends to accumulate in the abdomen while fat in the femoral area 
is more prevalent in pre-menopausal women (Tchernof et al., 1995). This 
difference in distribution tracks with the lower rates of CVD in premenopausal 
females than males. Postmenopausal women with low estrogens have similar 
body fat accumulation to men, as well as a similar incidence of obesity, type 2 
diabetes and CVD (Grebe and Singh, 2011). Hormone replacement therapy in 
older males and post-menopausal females has shown beneficial effects to 
attenuate central obesity. However, these approaches have limited use 
because of their side effects. For example, treatment with high T doses can 
enhance arterial rigidity and therefore increase risk of CVD (Arnlöv et al., 
2006, Bray, 2003). Moreover, research indicates that androgen therapy is 
related to fatty liver (McKenzie et al., 2006, Klair et al., 2016). Thus, further 
information is needed about the relationship between hormones level and 
metabolic diseases and, to achieve this, the field needs suitable methods to 
measure sex hormones and their metabolites in different biological matrixes. 
Results from such investigations may help to improve strategies of preventing 
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abdominal fat accumulation, aid in personalising treatment of obesity by 
gender and reducing the impact of obesity as a risk factor for CVD. 
1.1.3 Sex steroids and metabolism 
Sex steroids play a role in regulating glucose and lipid metabolism and 
therefore may impact on metabolic diseases, such as obesity, and diabetes. It 
is thus important to study how differences in sex hormones levels relate to 
differences in human metabolism  (Varlamov et al., 2014, Siemińska et al., 
2006) . Metabolism is markedly different between males and females. Females 
have greater amounts of body fat and less muscle than males. They have 
higher rates of triglyceride synthesis in subcutaneous fat and more sensitive 
to insulin and its effects on lipolysis than males, releasing more free fatty acids 
(FFAs) from visceral fat (Varlamov et al., 2014). The combination of less FFA 
flux in visceral fat but more in liver may alter susceptibility to insulin 
resistance in females (Varlamov et al., 2014). In contrast men receiving T 
therapy showed higher FFA flux in subcutaneous fat and lower in visceral fat 
tissue (Varlamov et al., 2014).  
Glucose metabolism likewise is different between men and women. Even 
though, men generally have lower fat mass, at least compared to pre-
menopausal women, the occurrence of diabetes and insulin resistance is 
higher (Varlamov et al., 2014). Women have higher circulating estrogens that 
is thought to cause greater muscle glycogen consumption, with lower hepatic 
glucose production (Varlamov et al., 2014). Estrogens may also regulate 
systemic glucose homeostasis and lowing circulating FFAs (Figure 1.2). E2 
reduces adipose tissue lipolysis in part by upregulating androgen receptors 
(ARs) and downregulating estrogen receptors (ERs). Given the marked 
changes in metabolism at the menopause it is thought that estrogen 
replacement may have beneficial on systemic insulin resistance for diabetic 
patients (Kim et al., 2014). In men, T acts via ARs by reducing lipogenesis, 
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glucose uptake and cholesterol storage in the liver and enhancing glycogen 
synthesis and insulin receptor expression (Shen and Shi, 2015). E2 modulates 
liver metabolism acting via ERs by increasing cholesterol excretion and 
lipolysis and reducing fatty acid uptake and lipogenesis in women (Shen and 
Shi, 2015). Table 1.1 shows examples of tissue-specific actions of sex hormones 
receptors in female and male KO mice (Morselli et al., 2017).  
 
Figure 1.2: Mechanisms through which estrogens regulate systemic glucose 
homeostasis; showing E2 acts via ERa to suppress adipose tissue lipolysis 
through inhibition of HSL. The result is reduced circulating FFA levels, which 
impact crucial glucose homeostasis systems including liver, skeletal muscle 
and the pancreas; (- - - -) suppression effects of E2 on lipolysis, (E2) estradiol, 
(ERα) estrogen receptor-α, (α2AR) α2-adrenergen receptor, (LPL) lipoprotein 
lipase, (HSL) hormone-sensitive lipase, (CA) catecholamines and (FFA), free 
fatty acids. 




glucose and homeostasis 
↑obesity, ↓voluntary actions, 





and ↓energy expenditure 
Lack of male sexual and 
assertive manners 
Adipose ↑adipocyte size ↑subcutaneous and visceral fat 
Muscle 
↑lipids and oxidative 
stress 
↓skeletal and perineal muscles 
in mass and strength 
Cardiovascular ↑blood pressure ↓heart size 
Table 1.1: Effects of sex hormones receptors in female and male KO mice on 
tissues. (ER) estrogen receptor-α and (AR) androgen receptor. 
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1.1.3.1 Estrogens and metabolism 
A correlation between a decrease in insulin sensitivity with reduced estrogen 
levels in female mice has led to suggestions that oral estrogen replacement 
could be used as a corrective approach for insulin resistance. Literature has 
demonstrated that estrogen replacement therapy can reduce liver steatosis 
and improve insulin sensitivity in aromatase knockout female mice (Varlamov 
et al., 2014). This suggests that estrogens alter metabolism peripherally by 
enhancing insulin sensitivity in adipose, muscle and liver tissues and possibly 
centrally by modulating receptors in central nervous system (CNS) (Varlamov 
et al., 2014). Estrogens can also exert these effects in men, controlling energy 
homeostasis even with low levels; this can be revealed in individuals with 
genetic mutation in ERα causing insulin-resistance and glucose-intolerance. 
ERα is the most abundant form of receptor in the hypothalamus. Estrogens 
reduce triglyceride production, enhance lipolysis in adipose tissue and 
decrease lipogenesis in hepatic tissue (Varlamov et al., 2014).  
1.1.3.2 Androgens and metabolism 
Metabolic conditions are linked to hyperandrogenism in females and 
hypoandrogenism in males, bringing about obesity and insulin resistance. In 
contrast T therapy enhances insulin sensitivity and decreases body fat in men. 
These relationships may be in part due to estrogen synthesis as conversion of 
T to E2 regulates energy homeostasis, and T/E2 and A4/E1 ratios correlated 
positively with amounts of visceral fat in men (Varlamov et al., 2014). AR 
knockout mice showed an increase in visceral obesity and insulin resistance. 
Furthermore, research has illustrated that humans with hypogonadism have 
higher body fat and insulin resistance, but researchers questioned if these 
results correlate directly to androgens levels or are reflective of other factors 
e.g. age and lifestyle (Varlamov et al., 2014). 
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1.1.4 Sex steroids in health and metabolic diseases 
In women, E2 is responsible for the growth of sex organs and functions (Barud 
et al., 2005). Low concentrations of E2 in females occur post-menopausally as 
do some metabolic diseases such as diabetes  (Barud et al., 2005). Research into 
aromatase knockout female mice and women with aromatase deficiency 
demonstrate reduction of insulin sensitivity and less estrogen synthesis in fat 
tissue with higher body fat and higher leptin levels (Barud et al., 2005). 
However, this is not always the case, as postmenopausal females with type 2 
diabetes can have higher concentrations of T and E2 compared to nondiabetics 
and indeed hyperandrogenism linked to obesity (Grossmann, 2014). 
Unpicking these complex relationships could be addressed by measuring 
estrogens in premenopausal and post-menopausal women and also under 
aromatase inhibitors therapy for breast cancer (Jasuja et al., 2013). 
In men, T is the major androgen responsible for the growth and protection of 
sex organs and functions (Barud et al., 2005). Aging is associated with 
reduction in endogenous sex hormone production as CVD develops (Tchernof 
et al., 1995) and it has been demonstrated that diabetic males have lower 
concentrations of endogenous blood T compare to nondiabetics whereas levels 
of A4, E1 and E2 are similar in diabetic and nondiabetic men (Selvin et al., 
2007). 
The relationship between sex hormone levels and cardiometabolic disease 
progression differ by gender. Lower risk of CVD was linked to higher blood 
E2 concentration in older men possibly due to vasculoprotective effects of 
estrogens in men (Tchernof et al., 1995). However, the data from cross-
sectional studies are not consistent and suggest sexual dimorphism but some 
concerns exist over the validity of data, particularly in the low range, due to 
the analytical methods used; often immunoassays in the older literature. 
Furthermore, a key concept to consider is the balance of androgens and 
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estrogens as opposed to changes in either hormone class in isolation needs 
explored in more depth. 
T is the pivotal hormone, positioned between estrogen synthesis and 
formation of the more active androgens, namely DHT. Therefore, the balance 
of activity of aromatase and 5α-reductases is critical in the ultimate sex 
steroids profile. For example, males with aromatase deficiency generate T 
normally, which can accumulate and drive DHT production in the absence of 
aromatase. The reverse is also true in 5α-reductase deficiency with reduced 
conversion of T to DHT resulting in sexual variation (Upreti et al., 2014). 
However, to add complexity, in this setting the excess T may be diverted to 
estrogens. 
5α-Reductase type 1 is expressed in metabolic tissues such as liver, fat, and 
muscle tissues and type 2 in prostate and skin tissues in humans and rodents, 
as well as liver in humans (Upreti et al., 2014, Russell and Wilson, 1994). 
Metabolic dysfunction is a challenge in the setting of prostate disease, where 
type 2 inhibitors are used in prostatic hyperplasia using finasteride (type 2 
selective inhibitor) and dutasteride (inhibitor of both types) (Wei et al., 2019). 
Treatment with both drugs is associated with an increased risk of developing 
type 2 diabetes in men possibly due to suppressed DHT levels in metabolic 
tissues (e.g. adipose tissue) (Upreti et al., 2014). Replacement of DHT has been 
shown to protect against development of metabolic disease in hypogonadal  
men (Wang et al., 1998). 
These outcomes of 5α-reductase deficiency are more marked in obesity and 
similar finding of insulin resistance can be seen in diet induced obesity models 
in mice, with reduced glucose tolerance, weight gain and fatty liver in both 
Srd5a1-/- mice and obese rats receiving dutasteride (Upreti et al., 2014, Upreti 
et al., 2015). Impaired glucose homeostasis with lower concentrations of 
androgens in males are linked to metabolic dysfunction in adipose and β-cells 
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(Navarro et al., 2015). Further studies of metabolic effects of 5α-reductase 
inhibitors in men and women are recommended (Mak et al., 2019). 
Insulin resistance is one of the main causes of metabolic diseases of obesity 
(Ter Horst et al., 2015). This has been studied in men and women using 
euglycemic hyperinsulinaemic clamps (Ter Horst et al., 2015). Generally, 
peripheral insulin sensitivity is higher in women than men, associated with 
patterns of body fat distribution and sex hormones concentrations in both 
genders (Ter Horst et al., 2015). Post-menopausal women showed lower 
insulin sensitivity than pre-menopausal and women under estrogen 
replacement therapy.  Insulin sensitivity is unchanged in healthy men 
compared to men with T administration, however, obese men have lower 
hepatic insulin sensitivity that could relate to a higher rate of diabetes in men 
(Ter Horst et al., 2015). 
The lipid profile is another main risk factor in CVD that is associated with sex 
hormones levels in men and women (Wang et al., 2011). Triglycerides and 
cholesterol concentrations were lower in healthy women than healthy men 
whereas, high density lipoprotein (HDL) levels are higher in pre-menopausal 
than post-menopausal and men. Studies demonstrate the impact of exogenous 
sex hormones administration (orally or parenterally) are different on lipid 
metabolism. For example, estrogens increased triglyceride levels with oral 
administration but had no effect on lipids when administered parenterally 
(Wang et al., 2011). Adipokines and insulin contribute to lipid metabolism and 
the role of sex steroids in their regulation is not fully understood (Wang et al., 
2011).  
These types of studies summarised above show the powerful effect of sex 
steroids on metabolism but emphasise the need for profiling of both 
androgens and estrogens to gain a clear picture. Precise and accurate 
measurements of low concentrations of estrogens and androgens are 
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important for the investigation of sex hormone related disorders and obesity 
in men, women and children. However, none of the commercially existing 
automatic direct methods have satisfactory sensitivity and selectivity for this 
purpose (Barud et al., 2005). Therefore, highly sensitive and specific methods 
are essential and needed for these types of clinical studies. 
1.1.5 Analysis of sex steroids 
Analysis of sex hormones is a difficult task due to their extremely low 
concentrations (f-pM) in some biological samples and especially in some 
diseases (Table 1.2) (Wang et al.; 2008). This task is made even more 
challenging because sex hormones are present across wide ranges of 
concentrations and suffer from interference from substances in the biological 
matrix such as endogenous isomers. The Endocrine Society recommended 
measurement of sex hormone concentrations using techniques with high 
accuracy and precision. This raises the importance of methods such as Gas 
chromatography mass spectrometry (GC-MS) and liquid chromatography 
mass spectrometry (LC-MS). 
In the past sex hormones were most commonly analysed by immunoassays 
because these techniques are fast and simple. In clinical practice 
immunoassays are normally used to quantify each steroid alone (albeit multi-
plexing systems may be developed). However, those techniques have some 
limitations such as lack of specificity and matrix effects (Grebe and Singh, 
2011). The next technology that appeared in the field was GC-MS which 
achieved high temporal resolution and improved specificity. However, 
because of extended sample preparation, and long analytical runs, GC-MS 
started to be replaced with LC-MS (Table 1.3). Generally, LC-MS provides high 
sensitivity and specificity, with reduced sample preparation compared to GC-
MS. However, a MS is a complex detector compared to other techniques and 
in all cases needs appropriate method validation and standardisation. This 
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chapter aims to discuss knowledge of the development, validation, and use of 
current GC-MS and LC-MS methods for sex steroid hormones profiling.  
Analyte Level (pg/mL) Human group Ref 
E1 
1.5-52 Males 1 
30-100 Pre-menopausal females 
2 
20-40 Post-menopausal females 
E2 
30-36 Males 1 
50-443 Pre-menopausal females 
2 
<50 Post-menopausal females 
T 
1800-12000 Males 1 
60-860 Pre-menopausal females 
2 
0.6-3.1 Post-menopausal females 
A4 
844 Males 1 
8-23 Pre-menopausal females 
2 
3-8 Post-menopausal females 
DHT 
300-850 Males 1 
60-330 Pre-menopausal females 2 
26-35 Post-menopausal females 3 
Table 1.2: Examples of sex hormone levels in males pre- and post-
menopausal females; estradiol (E2), estrone (E1), testosterone (T), 
androstenedione (A4) and 5α-dihydrotestosterone (DHT). (1) (Kratz and 






















376*/157* C18 LL 7 
269/145 20$ C8 PP-SPE-OL 8 
504*/171* 120 C18 LL 2 
287/171 20$ C8 PP-SPE-OL 9 
E2 
255/159 APPI+ 100$ C8 
S 
PP 1 
506*/156* ESI+ 10 Phenyl LL-SPE-OL 7 
483*/264* ESI+ 10 C18 LL 8 
271/145 ESI- 10$ C8 PP-SPE-OL 9 
506*/171* ESI+ 60 C18 LL 10 











289/97 500 C8 LL 12 
289/97 APCI+ 100 C18 PP-SPE-OL 13 







S, Bl Sp 1 
304*/112* 100 S PP-SPE-OL 3 
289/97 APCI+ 3500 S, Saliva PP-SPE-OL 5 
289/109 
ESI+ 
























PP + LLE 24 
87 PP 25 
30 SPE 16 
289/109 
72 LLE 17 













20 PP 20 
854 SPE 14 












S, Bl Sp 2 
317*/124* 100 S PP-SPE-OL 3 
287/97 10000 Bl Sp LL 4 
287/109 APCI+ 3500 S, Saliva PP-SPE-OL 5 
287/97 ESI+ 404 
- 
PP 14 






30 SPE 16 
72 LLE 17 
APCI+ 20 PP + SPE 18 
DHA 
304*/253* ESI+ 500 C18 S PP-SPE-OL 3 
394*/109* ESI+ 100 C18 Saliva SPE 6 
271/213 APPI+ 100$ C8 S PP 1 
DHEA 271/197 APCI+ 20 C18 - PP + SPE 19 
Table 1.3: Examples of LC-MS/MS methods of sex steroids analysis; (A4) 
androstenedione; (DHA) 5α-dihydroandrostanedione; (DHEA) 
dehydroepiandrosterone; (DHT) 5α-dihydrotestosterone; (E2) estradiol; (E1) 
estrone; (T) testosterone; (LOQ) limit of quantitation; (ref.) references; (*) 
derivative; ($) limit of detection; (ESI) electrospray ionisation; (APCI) 
atmospheric pressure chemical ionisation; (APPI) atmospheric pressure 
photoionisation; (-) negative mode; (+) positive mode; (S) serum, (Bl Sp) blood 
spot, (PP) protein precipitation; (LL) liquid/liquid; (SPE) solid phase 
extraction; (C18,C12,C8) octadecylsilane-bonded silica, (OL) on-line, (1) (Kratz 
and Lewandrowski, 1998), (2) (Grebe and Singh, 2011), (3) Kulle et al., 2010), 
(4) (Guillarme et al., 2010), (5) (Janzen et al., 2008), (6) (Chadwick et al., 2005), 
(7) (Wang et al., 2008), (8) (Guo et al., 2008), (9) (Corona et al., 2010), (10)  
(Courant et al., 2010), (11) (Rauh et al., 2006), (12) (Gallagher et al., 2007), (13) 
(Fanelli et al., 2011), (14) (Kushnir et al., 2010a), (15) (Bhasin et al., 2008), (16) 
(Yun et al., 2012), (17) (Santen et al., 2008), (18) (Faix, 2013), (19) (Owen and 
Keevil, 2013), (20) (Ray et al., 2015), (21) (Wu et al., 2012, Borrey et al., 2007), 
(22) (Bui et al., 2010), (23) (Fogari et al., 2005), (24) (Higashi et al., 2005b), (25) 
(Kalhorn et al., 2007), (26) (Ke et al., 2014), (27) (LAURIAN VLASE1 and 
MIKLOS2, 2016), (28) (Owen et al., 2016) and (29) (Chang et al., 2010).
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1.2 Analytical platforms for quantitation of sex steroids 
1.2.1 Historical perspective for MS – overview 
In the 1880s, the basic principles of mass spectrometry (MS) were first 
described by Sir Joseph John (J. J.) Thomson, a professor of experimental 
physics at Cambridge University and reported in 1897 to the Cambridge 
Philosophical Society (J.J. Thomson, 1897). Then, in 1898, Wilhelm Wien 
illustrated the effects of electric and magnetic fields on the trajectory of 
positive ions (Wien et al, 1898). This work inspired Eugen Goldstein in 1886 to 
discover a radiation “Kanalstrahlen” that was only formed by positively 
charged particles. In 1913, Nobel laureate, J.J Thomson, invented the first MS 
operating at under vacuum using a magnetic and an electric field to separate 
a stream of ionised neon gas into two isotopic elements (Dunn et al., 2011). 
Over the last 100 years MS has become one of the most powerful analytical 
tools in the physical and chemical sciences with five Nobel prizes being 
awarded in the field (Thomson, Aston, Paul, Fenn and Tanaka) (Dunn et al., 
2011). 
MS was initially used in stable isotope/radionucleotide studies and later, in 
the 1940s, commercially, in the oil industry market to detect organic 
substances. Biochemical applications were limited since available ionisation 
systems were unsuitable for biological specimens and compounds with 
molecular weight >~200 Daltons (Da), precluding protein analysis. GC was 
developed in 1952 and Holmes and Morrell coupled it to MS (i.e., GC-MS) in 
1957. This system was applied to analyse volatile substances with molecular 
weights <1000 Da and thermally stable substances for example fatty acids, 
steroids, and carbohydrates. In general, GC-MS ionises simple volatile 
biological mixtures that are stable in the gas phase by hard ionisation such as 
electron impact (EI). This ionisation ejects a radical ion from the electron beam 
in the gas phase. In the 1989, after John Fenn introduced electrospray 
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ionisation (ESI) (Nobel Prize 2002), a soft ionisation technique, MS became 
more widely used for large biomolecules and proteomics analysis (Fenn et al., 
1989). Throughout the 1990s, other separation techniques for example liquid 
chromatography (LC) and capillary electrophoresis (CE) were coupled with 
MS and widely applied in pharmaceutical and clinical studies. LC offers the 
advantage of a simpler laboratory workflow therefore, less cost and time. In 
conclusion, a range of MS techniques and configurations has been used in 
applications such as biochemistry, drug discovery research and even in 
studies in space. 
1.2.1.1 Instrumentation and basic principles of MS 
MS is a technique which measures the mass-charge ratio of charged particles 
(m/z). For example, a compound with a molecular weight [M] of 500 that is 
protonated (H+) will be presented as [M+H]+ (m/z 501) (Dunn et al., 2011). A 
MS instrument consists of four main units: a sample inlet system, an ionisation 
or ion source device, a mass analyser and ion detector (Figure 1.3) which are 
combined in different ways. All these components are electronically 
monitored, and data are processed by sophisticated computer units, 
particularly for newer mass spectrometer that are more complicated with great 
data handling challenges. 
1.2.1.1.1 Sample introduction 
The main function for this unit is to introduce samples to the ion source 
directly for example, direct insertion probes or separation methods known as 
“front ends” which include chromatographic units (Dunn et al., 2011). The 
advantage of using chromatographic separation is to simplify the sample as it 
enters the MS to improve individual detection for each component in a 
complex mixture with different concentrations and masses or in isomer 
analysis where molecules have same mass. Both LC and GC have been 




Figure 1.3: MS components. 
1.2.1.1.2 Ionisation source 
There are different ways in which ion scan be formed and this is dependent on 
the Ionisation Source.  Charged particles are formed in different ways for each 
analyte before passing to other MS units (Table 1.4). For example, adding a 
cation (e.g. H+) is common during Matrix-assisted laser desorption ionisation 
(MALDI) in contrast to removing an electron in EI. Soft ionisation mechanisms 
were introduced such as chemical ionisation (CI), fast atom bombardment 
(FAB), liquid secondary ion mass spectrometry (LSIMS) (Werawatgoompa et 
al., 1982), MALDI (Karas and Hillenkamp, 1988) and ESI (Fenn et al., 1989). 
Karas and Hillenkamp introduced a laser desorption method in the late 1980s 
and the early 1990s which was a key development to MS  (Hillenkamp and 
Karas, 1990). In 2002, Nobel Prize in chemistry was awarded to Koichi Tanaka 
and John Fenn, who invented MALDI and ESI respectively, offering 
significant opportunities for biology studies of glycoconjugates, proteins, and 
DNA. 
Currently a wide range of ionisation techniques are used for biological 
applications, such as ESI (Fenn et al., 1989), with new opportunities still 
evolving for example desorption electrospray ionisation (DESI) and the direct 
analysis in real time (DART) (Takáts et al., 2004) (Bunch et al., 2004) (Wiseman 
et al., 2006). ESI and APCI are the primary approaches used in this thesis as 
they are well suited to steroid ionisation. 
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1.2.1.1.2.1 Electrospray ionisation (ESI) 
ESI development began in 1960s by Dole and co-workers, in early experiments 
where they introduce a polymer as a charged molecule into the gas phase. ESI 
transfers ions from solution droplets by ion desorption. Analytes are typically 
dissolved in a polar solvent sprayed through a charged needle into the mass 
spectrometer. This technique was performed at atmospheric pressure, to avoid 
the liquid vapour overwhelming the MS vacuum. There are two proposed 
models to ions formation in ESI, namely the charged residue model (CRM) 
and the ion evaporation model (IEM). In IEM (Figure 1.4a), it is proposed that 
a Taylor Cone is generated at the end of the needle with high voltage (3–4 kV) 
where the liquid passes through and forms charged droplets (i.e., 
nebulisation). These droplets are directed into the mass spectrometer vacuum 
region, by the sampling orifice and cone, which have opposite charges. 
Droplets are propelled by a neutral gas (e.g. nitrogen) between the needle and 
ion orifice at atmospheric pressure. Droplets explode and break down to 
smaller charged ones for MS analysis after the solvent evaporates and the 
mixture reaches the Rayleigh point, where charge transfer occurs to form ions. 
In CRM (Figure 1.4b), it is proposed that the solvent is evaporated totally until 
the droplet is fragmented form to a multiply charged ions. This technique 
overcomes ionisation difficulties in large proteins analysis in comparison to 
classical MS methods  (Whitehouse et al., 1985). Highly sensitive ionisation 
(nanospray) was developed by using lower flow rates (nL/min) and a 
narrower needle to release smaller droplets (Emmett and Caprioli, 1994). This 
was initially applied in glycoconjugate analysis but is now commonly used in 
protein analysis. Nowadays, ESI-MS is commonly used in biological studies in 
conjunction with LC for qualitative and quantitative studies for small as well 
as complex biomolecules. It is a powerful analytical system which has been 
further applied to clinical analysis to detect very low concentrations of sex 
steroids (Karas and Hillenkamp, 1988, Hillenkamp and Karas, 1990).  
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1.2.1.1.2.2 Atmospheric pressure chemical ionisation (APCI) 
In APCI, the analyte is ionised in gas phase through a Corona discharge needle 
after evaporation of the mobile phase in a heated area by a nebuliser gas. Then, 
the ionised analytes in solvent proceeds to the MS via an orifice (Remane et 
al., 2010) (Figure 1.5). APCI is well suited to ionisation of compounds with 
limited polarity such as sex steroids. The ionisation technique is also shown to 
suffer less from matrix effects (Dunn et al., 2011). 
1.2.1.1.2.3 Atmospheric pressure photoionisation (APPI) 
APPI is a newer ionisation approach than APCI and ESI, which uses 
photoionisation of a dopant which to ionise non-polar compounds by proton 
charge exchange. APPI is similar to APCI in that there is a decrease in the 
impact of matrix effects. It is more selective than ESI in the range of molecules 
ionised and has been proposed as particularly useful for non-polar 
compounds like steroids (Robb et al., 2000, Hanold et al., 2004) although has 













































Very soft method 
Multiply charged 
ions 
Table 1.4: Comparison of most commonly applied MS ionisation methods. 
(EI) electron impact; (CI) chemical ionisation; (FAB) fast atom bombardment; 
(MALDI) Matrix-assisted laser desorption ionisation;(ESI) electrospray 




Figure 1.4: Positive ions generation using ESI in a) IEM and b) CRM models. This illustrates positive and negative ions are 
formed similarly. In a) IEM, a Taylor Cone is generated at the end of the needle where the liquid passes through and forms 
charged droplets (i.e., nebulisation). These droplets are directed into the mass spectrometer vacuum region propelled by 
neutral gas. Droplets explode and break down to smaller charged droplets after the solvent evaporate and the mixture reaches 





Figure 1.5: APCI ionisation process. The analyte is ionised in a Corona discharge needle after evaporation of the solvent by 
a nebuliser gas before passing into the mass spectrometer. 
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1.2.1.1.3 Mass analysers 
A mass analyser isolates ionised analytes dependent on their m/z values.  A 
number of mass analysers are used in this thesis, with their properties 
summarised below. Classical analysers separate ions by magnetic sector that 
applies a magnetic field whereas newer analysers influence ions by electrical 
field. The most popular analysers are quadrupole (Q), triple quadrupole 
(QQQ), quadrupole ion trap (QIT), time of flight (ToF), and Fourier transform 
ion cyclotron resonance (FTICR) (Table 1.5). 
These approaches will be discussed later in this chapter for quantitation of sex 
steroids and profiling. They differ in their abilities to distinguish by size and 
mass range, their sensitivity, mass resolution and capability to be interfaced 
with tandem MS analysis (MS/MS). In MS, mass resolution is the capacity to 
distinguish between ions closely related by mass and this is expressed as the 
following equation (Brown and Lennon, 1995): R = m/∆m,  where (R; the 
resolution, m; m/z and ∆m; the difference in Da). Thus, they lend themselves 
to different applications. For examples, QIT is useful for multiple reaction 
mass spectrometric analysis (MSn) and FTICR is applied in accurate mass 
analysis. A hybrid system has also been developed which is a Q coupled with 
a ToF with MS/MS (Q-ToF).  
Analyser Mass accuracy (ppm) 
Q 50-100 
 QIT 40-100 
ToF 2-50 
FTICR 0.1-2 
Table 1.5: Mass accuracies and ranges of mass analysers. Quadrupole (Q), 
quadrupole ion trap (QIT), time of flight (ToF), and Fourier transform ion 





1.2.1.1.3.1 Single quadrupole (Q) analysers 
The Q system consist of 4 identical metal rods in parallel design (Figure 1.6), 
two rods linked by radiofrequency (rf), voltage (V) and the other two with 
direct current voltage (U). Ions are directed to Q by an electrical field (5 kV) 
with opposite polarity after being generated by the ionisation source for 
example a negatively charged ion pulses to a positively charged rod. When the 
polarity is switched the ions shift and move opposite direction under a 
complex oscillation (trajectory). A narrow range of masses continue along the 
path to a detector determined by V, U, and frequency (ω) and the rest of the 
ions hold their initial trajectory then hit one of the rods. Transmission of 
several ions with different mass in the direction of the detector may occur by 
oscillating high V, U, and ω. The main advantages of Q are they are cheap, 
have a small footprint, are robust, and easy to operate. However, they have 
limited range of m/z and only unit resolving power.  
When rf only used (for example a hybrid MS) Q act as an ion focus by directing 
a wide range of ions to other part of the device. Q is a scanning technique with 
limited sensitivity in full-scan mode since not all masses reach the detector. 
This issue is minimised by longer scan times and using a single ion monitoring 
(SIM) that is more selective and sensitive by monitoring only a single mass. 
Recently, QQQ have also been operated in SIM mode in quantitation and 
clinical analysis. However, more commonly Q is linked to a second Q (e.g. 
QQQ) or a ToF to support MS/MS analysis, which is desirable in clinical 
analysis of small molecules. 
 
Figure 1.6: Schematic of a single quadrupole (Q), showing how ions are 
directed by an electrical field (5 kV). 
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1.2.1.1.3.2 Triple quadrupole (QQQ) 
Tandem MS is used to produce fragments in the gas state for identification and 
to improve selectivity and sensitivity of detection. QQQ is composed of 3 
quadrupoles Q1, Q2, and Q3 in sequence. Q1 and Q3 are operated as analysers, 
whereas Q2 is used as a collision cell that works under vacuum with an inert 
gas (helium, nitrogen, argon or xenon) in high pressure. This process is called 
Collision-induced dissociation (CID) (McLafferty, 1959). In Q2, collisions 
transmit potential energy to the ions inducing fission of covalent bonds. In 
high energy, fragmentation is influenced by ion charge whereas neutral losses 
can arise at low energy, such as fragmentation of fatty acids (Kerwin et al., 
1996). The fragmentation pattern is based on the acceleration potential and the 
type of collision gas used, and fragments of interest are selected for further 
study in Q3. 
In this technique, fragmentation proceeds individually in different spaces, 
while other system types for example (ion trap), ions fragments are generated 
and processed in same compartment with different times. QQQ can be 
performed in five modes (Figure 1.7): a) full scan, b) product ion scan, c) 
precursor ion scan, d) neutral loss scan, and e) selective reaction monitoring 
(SRM) or multiple reaction monitoring (MRM). 
In a) Full scan is performed by scanning a mass range in Q1 and Q3 without 
collision gas in Q2 to detect all ions in a sample. Full scan is used in precursor 
ion identification for a specific analyte. 
In b) product ion scanning, a single mass is selected in Q1 and passes through 
the collision gas to Q2 then all fragment masses are scanned in Q3. This 
experimentation is used in unknown samples to detect all ions and fragments 




For c) precursor ion scans, a range of masses are scanned in Q1 and those that 
fragment with collision gas in Q2 for a selected single mass in Q3 are 
identified. In addition, precursor ion scan may be applied in compound 
classification by adjusting Q1 for a mass range and Q3 for a certain ion. i.e. m/z 
which generate class-specific fragment ion as monitored in Q3. Generally, full 
scan, product ion scan and precursor ion scan are applied mainly during 
analytical development. 
In d) neutral loss scanning, a mass range is applied in Q1 and fragmented 
with collision gas in Q2 then scanning performed across a selected range 
which agrees with the predicted loss. This test is applied to identify of all 
precursor ions that have lost a specific chemical group, such as a phenyl. 
Neutral loss scan may be used for classification of common molecules such as 
fatty acids and modified peptides. 
e) SRM or MRM is the process whereby a single mass is selected in Q1, 
fragmented in Q2 then specific fragment ions selected in Q3. In SRM a single 
mass is selected in Q3 whereas MRM switches between selected and different 
masses for multiple biochemicals in Q1 and Q3. The quality of data is 
dependent on the number of ions counts, and scans required over a 
chromatographic peak and is thus influenced by the number of analytes and 
transitions. The ideal number of scans over each peak and transition over a 
given Dwell time is 12–15. The number of ions detected can be improved by 
use of scheduled SRM/MRM. SRM and MRM are highly sensitive and specific 
methods benefitting from low chemical noise in Q3 and thus lend themselves 
to quantitative analysis as explored in this thesis. Specificity of this method is 
dependent on specificity of fragment and analyte m/z and this is 
complemented by chromatographic retention time (Rt) and even now by ion 
mobility (IM). High sensitivity is achieved due to repeatedly scanning the 
same m/z for a selected time. 
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In LC-MS/MS, SRM is the method of choice for highly sensitive quantitation 
in clinical studies. SRM is achieved by MS/MS instruments that works as and  
QQQ is one of the most popularly performed and first presented in 1978. 
 
Figure 1.7: Triple quadrupole (QQQ) mechanisms, a) full scan, b) product ion 
scan, c) precursor ion scan, d) neutral loss scan, and e) selective reaction 
monitoring (SRM) or multiple reaction monitoring (MRM).  
1.2.1.1.3.3 Time of flight (ToF) 
ToF was first introduced in 1946 then applied in practice in 1995 (Brown and 
Lennon, 1995). ToF separates molecular mass by measuring flight time in a 
flight tube (1–2 m). All ions are generated by the same energy and detected in 
variable times based on their speed; smaller masses arrive faster at the detector 
than bigger ones. This is explained by the relation between molecular mass 
and time of flight (tf) as: m/z=K*tf2 (where K is calibrating factor) 
26 
 
Resolving power of ToF is based on ion kinetic energies (KE) and tube length 
of a regular ToF (Figure 1.8a). Reflectron-ToFs with different tube shapes were 
introduced in late 1970s to enhance sensitivity and accuracy of mass resolution 
(Figure 1.8b) by lengthening the flight path. Improvement of resolution was 
achieved by decreasing KE of ions of the same molecular mass. ToFs can obtain 
data across a very wide mass range and can be more sensitive than Q 
analysers. This can be useful in sex steroids analysis but this facility is not 
commonly available in quantitation labs. 
ToF combined with GC and ultra high performance liquid chromatography 
(UHPLC) is commonly used in metabolomic and proteomic studies 
particularly for complicated matrices. ToFs can be combined to MALDI and 
ESI sources in hybrid devices and used with MS/MS for macromolecules 
studies. In addition, this system is applied to determine accurate mass and 
chemical formula of small molecular metabolites or amino acid with mass 
resolutions to <5ppm. To achieve MS/MS, hybrid MS can be used with low 
CID energy for example Q-ToF. 
 




1.2.1.1.3.4 Quadrupole time of flight (Q-ToF) hybrid system 
Q-ToF instruments were introduced in the late 1990s, composed of a Q for 
scanning and a ToF providing mass resolving power (Figure 1.9). This system 
consists of two Qs connected to a ToF, the second Q being used to focus ions 
before Q1 and to cool ions in the collision sector. Q1 performs as an ion filter 
for MS/MS experiments whereas Q2 performs in rf mode with low CID. Q-
ToF can be modified for use with ESI or MALDI in MS/MS analysis. This 
device is easy to use and can be 100 times more sensitive than QQQ However, 
QQQ is preferred for quantitative analysis as it allows monitoring of a specific 
fragment. One of the quantitation and identification applications for Q-ToF is 
metabolomics and proteomics analysis by scanning all mass and product ions 
as accurate mass and fragments spectra. 
 
Figure 1.9: Quadrupole time of Flight (Q-ToF) hybrid system. 
1.2.1.1.3.5 Ion traps 
Ion traps or Q ion trap work by trapping and storing ions in a cyclic wave 
before directing the ions to a detector. Potential energy is applied to store ions 
and then move them by this energy whereas Q runs ions continually. This 
analyser is cheap and easier to use than Q and but less sensitive than ToF, 
Orbitrap, and FTICR-MS instruments although, ion traps provide capabilities 
for multiple MSn. A 3D ion trap consists of two rods opposite each other and 
isolated by a cyclic rod. All rods are connected to rf and DC voltages and ions 
are cooled by an inert gas for example helium. Ions are scanned with high 
voltages needed to release ions with high mass to the detector. 
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3D systems are restricted in mass range; therefore, an ion trap is applied to 
reduce the space-charge effect on sensitivity, allowing more ions to be 
scanned. This system is constructed with three groups of Qs that are connected 
to DC and rf voltages to separate ions. Ion traps are often used for chemical 
structure elucidation for m/z and fragments. 
1.2.1.1.3.6 Orbitrap 
The Orbitrap® MS was introduced by Alexander Makarov in 2005 (Hu et al., 
2005) and is formed with a concentric central rod covered by a cylindrical rod 
with an electrical field. Ion ejection is forced by the electric field that directs 
ions to move in circles before detection on the outer rod. Sensitivity of this 
instrument is based on the scanning time, for example higher masses require 
longer times, and that may decrease sensitivity. 
Orbitrap® MS can achieve higher resolution of ions compared with most ToF 
MS systems with improved ppm or ppb mass accuracies. Orbitrap® MS is 
applied commercially in conjunction with a linear ion trap by using a C-trap. 
This ejects ions at the analyser entrance and can be utilised as one unit or two 
separate units. The profiling mode for the Orbitrap® to analyse mass is 
achieved by ejecting ions constantly to the analyser. This instrument can be 
used in chemical structure elucidation. 
1.2.1.1.3.7 Fourier transform ion cyclotron resonance (FT-ICR) 
FT-ICR was introduced in 1998 and can detect ions following exposure to a 
cyclotron frequency in a magnetic field (Marshall et al., 1998). This analyser 
consists of two electrical plates which are connected to orbital radii with rf and 
magnetic fields applied. Cyclotron frequency is measured by the free decay 
image current on plates and then the data subject to Fourier transformation to 
characterise the m/z of the ions present. 
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FTICR is the most sensitive MS approach with the greatest mass resolution 
due to the magnetic field strength and scanning time. The best mass accuracies 
determined by FTICR are expressed in ppb and used for chemical structure 
elucidation. Electron capture dissociation and electron transfer dissociation 
are used in conjunction with the technique in proteomic analysis (Mikesh et 
al., 2006). Recently, sustained off-resonance irradiation-collision induced 
dissociation and infrared multiphoton dissociation have been developed 
(Fukui et al., 2006). 
1.2.1.1.3.8 Ion mobility (IM) 
IM mass spectrometry (IMMS) separates ions according to their size, and 
shape in conjunction with mass charge, and performs as a hybrid system in 
combination with a mass analyser (Uetrecht et al., 2010). In 1963, the initial 
combination of ToF and IMMS was established, then Q-IMMS was introduced 
in 1969. IMMS was used to improve signal to noise ratios for a wide range of 
analytes. The first IM-triple Q-ToF was available commercially in 2006. 
IMMS is available in four main forms(Politis et al., 2010): drift time IMMS 
(DTIMMS) , traveling wave IMMS , differential mobility MS , and trapped 
IMMS (TIMMS) . DTIMMS has been used for analysis of endogenous sex 
steroid isomers. IMMS has been coupled with ToF, QQQ, ion trap and 
Orbitrap, using ESI, APCI and MALDI for ionisation. Generally, IMMS 








1.2.1.2 Benefits and applications of MS 
MS is used regularly in biological studies, benefitting from high accuracy, 
mass resolution and sensitivity, fast operation and capability of coupling with 
chromatography. MS measures molecules in samples commonly as low as 
fmol for profiling of some metabolites. ToF, Orbitrap, and FTICR isolate ions 
offering advantages of high mass resolution. MS is often coupled to a 
chromatographic system and performs multi ion scans in a single sample and 
can achieve high-throughput applications in largescale studies for clinical 
research (Dunn et al., 2011, Kenny et al., 2010). However, MS suffers from high 
cost both to install but also to operate the system combined with the need for 
accurate and laborious sample preparation.  
The main applications of MS include qualitative analysis by determination of 
accurate mass, elucidation of chemical structure for ions and profiling of 
unknown samples. In addition, MS can be applied in quantitative analysis 
such as metabolites and tracers in biological samples. In conclusion, MS is 
performed in different configurations of ion sources and analysers based on 
the nature of analytes and the analytical purpose. Typically, in the quantitation 




1.2.2 Chromatography – overview 
Chromatography is an analytical tool used to isolate substances in a sample 
mixture for clinical studies such as serum or plasma (Prebihalo et al., 2018). 
The International Union of Pure and Applied Chemistry describe 
chromatography as : ‘physical method of separation in which the components 
to be separated are distributed between two phases, one of which is stationary 
(the stationary phase), while the other (the mobile phase) moves in a definite 
direction’. A mobile phase is defined as: ‘a fluid which percolates through or 
along the stationary bed in a definite direction’. Mobile phases could be liquids 
with the technique known as liquid chromatography (LC) or a gas known as 
gas chromatography (GC). GC and LC are the main chromatographic systems 
applied with MS in clinical analysis. GC-MS and LC-MS systems have been 
used for the last fifty years and first GC-MS was introduced in 1958 and used 
commercially in 1967 and the first LC-MS in 1973. Practical application is 
achieved in instruments equipped with four key parts: sample introduction 
unit (pump and injector), mobile phase, stationary phase and detection unit. 
Separation is achieved when analytes interact with both phases to different 
extents thus passing to the detector at variable times. This highlights a need to 
understand the nature of the analytes and how to modify the stationary and 
mobile phases to achieve best and bespoke separation.  
GC is applied to volatile and thermally stable compounds with a boiling point 
lower than 300°C aiming at separating them in gaseous phase (Prebihalo et al., 
2018). Analytes are passed between a gaseous mobile phase for example 
nitrogen or helium and a liquid stationary phase in a column. Separation 
depends on differences in boiling points and vapour pressure for each analyte. 
Analyte volatility can be improved by derivatisation prior to GC analysis. For 
clinical samples, liquid-liquid extraction (LLE), solid-phase extraction (SPE) 
and other sample preparation methods are commonly used prior GC analysis 
(Prebihalo et al., 2018). 
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In LC analytes are passed between a liquid mobile phase to a stationary phase 
supported on a column. Separation usually depends on differences in polarity 
for each analyte. LC is now more common than GC in clinical analysis since it 
is applicable to a greater variety of analytes for example non-volatile and polar 
compounds (Prebihalo et al., 2018). However, although fast workflows are 
desirable, with minimal sample preparation, sensitivity can still be improved 
by derivatising analytes prior LC analysis.  
Identification and quantitative analysis are performed by coupling the 
chromatographic system to different detectors and selectivity of the detector 
determines accuracy and precision of analysis. In GC, qualitative analysis 
compares retention index for unknown analytes with reference materials. LC 
used in combination with UV or fluorescence detectors offers limited 
selectivity. For both GC and LC applications, MS has higher sensitivity that 
UV and fluorescence and provides information of molecular weight and 
formula. This improved sensitivity is applicable to qualitative and quantitative 
analysis. Many variants of MS have been applied to GC and LC steroids 
analysis with single- or MS/MS filter (Q) technique being, the most widely 
used for quantitation in clinical labs. For the purpose of this thesis due to the 
practical applications, a more detailed introduction will be given about LC 
than GC. 
1.2.2.1 HPLC systems 
HPLC was the initial LC approach in the field, being performed under high 
column pressure (∼400bar) and instruments consisting of a pump, injector, 
mobile phase, stationary phase and detection unit (Figure 1.10) (Emmett and 
Caprioli, 1994). 
 




Constant flow rate of mobile phase (10μL to 2mL/min) is normally used in 
LC–MS with the exact choice being based on the HPLC column dimensions. 
For example, HPLC columns with a diameter of 4.6mm perform better at high 
flow rates, while the benefits of narrower column can be achieved at lower 
flow rate. A variety of pumping techniques are applied, and the most common 
system utilised nowadays is the reciprocating pump, offering the advantages 
of constant and pulse free flow rate of the mobile phase required to improve 
sensitivity.  
1.2.2.1.2 Injector 
Loop injection (or valve injection) is mainly used for HPLC. This approach 
contains a loop with nominal volume and introduces analytes in a liquid form 
to a liquid flow through needle. During the chromatographic run, mobile 
phase is driven with adjusted flow rate via a valve to the column. During 
injection, the flow is diverted via the loop by moving rotationally and flushing 
all contents to the column to reduce background noise. The injector 
maintenance and cleanliness are critical to the accuracy and precision in 
quantitation analysis. 
For LC-MS analysis, any air bubbles may disturb the flow therefore, causing 
errors in ionisation and detection. Precision depends on the loop volume. The 
loop should be fully filled from a larger volume reservoir in the syringe and 
the extra volume diverted to waste to avoid passing air bubbles to the system. 
For partial fill loop, an internal standard should be applied to ensure precision 
and accuracy. Under these circumstances, even if loop volume is not calibrated 
correctly, precision and accuracy will not be affected providing the same loop 




1.2.2.1.3 Mobile phase 
In HPLC, retention is characterised by the analyte interface between the 
stationary and mobile phases. The nature of this interface must be optimised 
to refine an appropriate system to use for chromatographic separation. 
Separation at this interface occurs via various mechanisms related to analyte 
properties such as polarity (Emmett and Caprioli, 1994). Analytes should 
dissolve in both the mobile and stationary phases, with the chromatographic 
separation performed mostly by reversed-phase chromatography for sex 
steroids. Separation is usually developed by manipulating different mobile 
phase components. Mobile phases composed of binary solvents are more 
commonly use than single solvent in LC analysis, but more complex solvents 
with variable polarities may be employed to develop separation systems. 
An isocratic mobile phase system uses constant proportions of solvents (one 
or more), whereas changeable proportions of solvents are utilised for a 
gradient mobile phase. The latter offers sharper, narrower peaks. Optimised 
mobile phase compositions and flow rate for analyte separation can be 
achieved by iteration which can be optimised through machine learning 
approaches (Duell and Bierman, 1990) . In addition, volatile buffers can be 
added to the mobile phase in LC analysis to improve analyte ionisation, peak 
shape and reproducibility. Degasification of the mobile phase is essential in 
LC-MS assays to avoid air bubble formation. The typical mobile phase solvents 
are HPLC grade or better MS grade to minimise MS background for optimal 
qualitative and quantitative analysis. 
1.2.2.1.4 Stationary phase 
As mentioned earlier for HPLC analysis, analytes should partition from the 
stationary phase into a mobile phase. This is achieved most commonly for 
steroids by reversed-phase chromatography. The most popular columns of 
this type are packed with a chemically modified silica stationary phase. These 
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modifications determine the column polarity and the most commonly used is 
a C18 alkyl group. Low or high mobile phase pH may lead to degradation of 
the stationary phase and increase background at the detector.  
1.2.2.3 Chromatographic properties 
Retention time (Rt) is the time that required for an analyte a specific mobile 
phase to pass through chromatographic column and reach the detector. This 
time is based on column length, mobile phase flow rate and the column 
capacity factor.  
Retention volume (Rv) is the volume of mobile phase that traverses the 
column from the point of analyte introduction to analyte detection. Rt is 
expressed as following formula: Rt=Rv/F where, (F) is the flow rate. 
Capacity factor (k) relates the Rt of an analyte to the time (t0) needed for an 
unretained substance i.e. one that elutes via the column without reacting with 
the stationary phase. These parameters are expressed as the following 
formula: k=(Rt−t0)/t0, whereas ideal (k) value is (1-10) (Figure 1.11). 
Selectivity or separation factor (α) for two analytes for example (i and ii) and 
the ratio of their capacity factors is expressed as the following formula: 
α=[k(ii)/k(i)] or α=[Rt(ii)−t0]/[Rt(i)−t0], whereas Rt(ii)>Rt(i) and α≥1. 
Resolution (R) for separation theses analytes is expressed as the following 
formula: R=[Rt(ii)–Rt(i)]/0.5*[w(i)+w(ii)], whereas w is the peak width of 
analyte regardless units as long as the same units are used (Figure 1.11). 
Peak symmetry is evaluated by the asymmetry factor (As) which is expressed 
as following formula: As=b/a where, a and b are the distances between peak 
highest and peak front and tail respectively at peak width at 10% of peak 




Figure 1.11: HPLC parameters. Retention time (Rt) of analyte (i), analyte (ii) 
and an unretained substance (t0), width at half-height (W0.5), the distances 
between peak highest and peak front and tail (a) and (b) respectively at peak 
width at 10% (W10%) of peak height. 
1.2.2.4 Column efficiency 
Efficiency of column performance is evaluated by the plate height (H) or plate 
number (N). H relates to the column efficiency per unit length and N relates 
to the number of plates for the column which is based column length (L). The 
relationships between N, Rt and w is expressed as the following formula:    
N=16*[t(i)/w(i)]2    or    N=5.54*[t(i)/w0.5]2   whereas, H=L*N. Therefore, 
reduced plate height relates to better column efficiency when more plates, or 
analyte separations, can occur over a fixed column length. These parameters 
can be applied holistically in the form of the Van Deemter equation using the 
following formula: H=A+B+u+Cu defining A (Eddy diffusion), B 
(longitudinal diffusion), Cu (the coefficient of the mass transfer) and u (the 
linear velocity of the mobile phase). 
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The relationship between these parameters are demonstrated in Figure 1.12. 
Eddy diffusion is constant and unchanged by flow rate, where longitudinal 
diffusion reflects how analyte particles pass through the stationary phase and 
greater column velocity will restrict this movement. The coefficient of the mass 
transfer is the distribution of analyte between the mobile and stationary 
phases that reduces peak efficiency with higher flow rate. Using smaller 
particle sizes improves peak efficiency and limits the impact of the flow rate.  
Column efficiency is influenced by column particle size, length, and internal 
diameter. Smaller particle size increases column efficiency with the optimal 
linear velocity at low H (Figure 1.12). Longer column will improve efficiency 
but in a longer analysis time. Bigger column diameters need higher flow rates 
and higher volumes of solvents are required as a consequence. Reducing the 
column diameter reduces the flow rate and mobile phase volumes needed to 
achieve the same optimal linear velocity and analysis time. An enhancement 
in sensitivity can be achieved by using a smaller column diameter since 
analyte will be higher concentration in the mobile phase. Smaller particle size 
increase column pressure significantly according to Darcy’s law as the 
formula: ΔP= Φ(ηLu/d2) where, (η) mobile phase viscosity, (L) column length, 
(Φ) flow resistance and (u) the linear velocity of the mobile phase. 
The typical flow rate in HPLC (0.5mL/min) is pumped with a column pressure 
up to 400bar. Column dimensions and particle size influence the loading 
capacity, sample injection volume, column pressure and the flow rates. Thus, 
development of UHPLC columns with particle size <2μm and shorter lengths 
while desirable took decades to be commercially available needing systems 
able to cope with higher column pressure up to 1200bar. Nowadays, micro and 
nano capillary columns allow separation under micro and nano flow 
(100nL/min and 50µL/min respectively) for even higher chromatographic 
resolution. These columns are packed with even smaller particles and 




Figure 1.12: The Van Deemter equation, showing the relationship between 
column flow rate and efficiency. 
1.2.2.5 Validation standards for quantitative assays 
In LC, peak heights or areas are measured to quantify amounts of an analyte 
in sample. Choice of detector is very important for a specific analysis and the 
quality achieved depends on many factors including, noise, limit of detection 
(LOD), reference standards, linearity and dynamic ranges. 
Background noise is determined by the variation in detector response without 
analyte over a time interval. Noise can come in different forms such as short-
term and drift noise, both caused by electronic parts of the system. In addition, 
chemical noise can be caused by a response of substances innate to the 
instrument or in the sample matrix other than the analyte. Signal-to-noise ratio 
(S/N) evaluates the noise by comparing analyte response to noise over certain 
time period. 
LOD is determined as the detectable response from analyte that represents a 
signal higher than the noise by a certain minimum value (Figure 1.13). Typical 
values are (2-10 X noise) based on the analysis and specifications of the 
quantitation method (Abdel-Magid et al., 1996). The linearity range is assessed 
across a range of analyte signals relative to the analyte amount. The analyte 
signal increases linearly until certain level (upper limit of quantitation; ULOQ) 
when the detector is saturated. 
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In order to achieve precise measures from samples, analyte signal must be fall 
within linear range in the calibration curve. Assessment the precision and 
accuracy are highly important for quantitative analysis. Precision is evaluated 
by determining analyte response several times within the same sample. The 
accuracy is assessed to validate analytical method by comparing the measured 
amounts to known amounts of analyte in sample, preferably in matched 
matrix. These quality control tests are used to evaluate robustness of the 
method procedure throughout routine use. 
 
Figure 1.13: Illustration of detector responses for linearity and dynamic 
ranges, showing LOD of three times noise. 
Comparison of responses from analytes in samples to those obtained from 
reference standards is used in order to quantify analytes. Standards are 
applied in a variety of methods dependent on desired analysis such as 
standard additions, external or internal standards (IS). The choice can be 




The External standard method is the easiest procedure by analysis of matrix 
samples with known amounts or concentrations of the exogenous analyte. 
Plotting these amounts or concentrations against the responses from standards 
is used to provide a calibration curve. The range of the standard 
concentrations should cover the anticipated concentrations of the analyte with 
care taken with fitting the extremes of the calibration curve. Linear regression 
is used to a ensure linear relationship between signal response and amount. 
Use of external standards avoids any effect from sample matrix that may 
suppress the analyte singles. 
Standard addition is applied to assess the effect of sample matrix. 
Quantitation is obtained by determining signal response from a sample pre- 
and post-addition of known standard amount or concentration. A response 
factor is the enhancement in signal response and expressed as the 
signal/concentration unit. Then, analyte concentration calculated by dividing 
the signal response from the sample by the response factor. In order to ensure 
precise results, two or more additions are performed used by repeating 
previous steps. These data can be plotted to calculate the analyte concentration 
in the sample by applying the linear regression (Figure 1.14). In general, 
precise quantitation may be achieved by using external standard and standard 
addition methods. However, these approaches do not consider the probability 
of loss of analyte during the analysis stages and thus are less able to result in 
accurate quantitation. 
Enhancement in accuracy and precision may be achieved by adding an 
appropriate IS to the sample in the initial analysis stage (e.g. sample 
preparation). Both responses from the analyte and IS are detected for each 
sample to determine amount of standards and unknowns. The ratio of these 
two responses is used to plot the calibration curve and to calculate the analyte 
amount for each sample. 
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Robustness of this method is improved from the assumed equal loss of the 
analyte and IS. Selection of IS is of paramount importance with criteria being:  
• No appearance in the samples prior to analysis. 
• Similar chemical and physical properties to the analyte to ensure similarity 
in losses as the analyte during analysis stages and responses in the 
instrument. Any differences in polarity for IS and analyte could result in 
differences in extraction efficiency while variable volatility could lead to 
unequal losses during analysis and storage. For derivatives, any mismatch 
in chemistry could obtain different derivatives with dissimilar behaviour 
during the analysis, and unequal yields. 
• Similar (Rt) to the analyte to detect concomitantly with the analyte. 
When using IS in MS analysis, similarity in chemical, physical and retention 
features is crucial to enhance method selectivity and specificity. Using an IS 
such as an isotopically labelled analyte with almost identical features as the 
analyte aligns behaviours. The most popular IS used contain heavy isotopes 
such as deuterium such as a deuteromethyl moiety (-CD3). The molecular 
mass of the tri-deuterium unit is thus three Daltons higher than the original 
substance and its presence can be used to confirm structure through 
fragmentation. 13C labels are also popular. 
 
Figure 1.14: A classical calibration curve for standard addition. 
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1.2.3 Chromatography and MS in sex steroids analysis 
1.2.3.1 GC-MS 
For many years, GC was applied to determine sex hormones (Table 1.6). More 
recently very sensitive techniques have been used in the field such GC-high 
resolution MS. In order to carry out GC analysis appropriate derivatisation of 
the substance is preferred to encourage formation of the gaseous form during 
the analysis. This process also enhances the separation of derivatives and the 
sensitivity of analysis. Derivatisation of hydroxyl groups of steroid nuclei has 
been achieved using many agents (Figure 1.15), for example, N-methyl-N(tert-
butyldimethylsilyfluoracetamide) (MTBSTFA), BSTFA, pentafluoro propionic 
acid anhydride. Derivatives inserting groups such as tert-butyldimethylsilyl 
(tert-BDMS) and pentafluoro propionyl are faster to form and are less sensitive 
to hydrolysis than most silyl derivatives such as trimethylsilyl (TMS). TMS 
derivatives are however more common but yield low mass fragments. Ions 
with higher masses have been formed using heptafluorobutyrate to improve 
SIM. Another derivatisation approach is the use of two substances, one for 
alkylation of phenol function (pentafluorobenzyl bromide) and one for 
silylation of the alcohol group, commonly (N, O-bis) trimethylsilyl-
trifluoroacetamide.  
GC-MS was the first commonly applied technique for sex steroid analysis 
because of the low hydrophilicity and polarity properties of the analyte. This 
system has been used to detect E2 and T in individuals under steroid therapy 
(Huhtaniemi et al., 2012). Similarity in chemical structures of sex steroids leads 
to similar fragments, therefore, chromatographic separation is needed for MS 
analysis. However, separation by this means suffers from extended analysis 
times and moreover many of sex steroids exist in glucuronide or sulphate 
forms in matrix that are not suitable for GC-MS assay due to their high polarity 
and the fact conjugates mask the group used for derivatisation. 
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E1 269 20 4860 9990 
E2 343 20 4900 10060 
T 432 5 87 202 
DHT 434 8 145 290 
DHA 432 8 145 290 
A4 430 419 86 200 
Table 1.6: Examples of GC methods of derivatised sex steroids; (A4) 
androstenedione; (E2) estradiol; (E1) estrone; (DHA) 5α-
dihydroandrostanedione; (DHT) 5α-dihydrotestosterone; (T) testosterone; 
(eV) electron volt; (LOD) limit of detection and (LOQ) limit of quantitation 
 
Figure 1.15: Derivatisation reaction of estrone, with pentafluorobenzyl 
bromide (PFBBr) and (KOH/EtOH) potassium hydroxide in ethanol 
1.2.3.2 LC-MS 
Sex steroids have been measured using a reversed-phase chromatographic 
separation starting in the era of ordinary LC pumps. UHPLC technique has 
been introduced that allow higher flows of mobile phase with higher column 
pressure and thus higher sensitivity. Faster chromatographic separation with 
narrower peaks may be achieved using narrower and shorter columns with a 
smaller particle size and consuming less solvents (Guillarme et al., 2010). To 
enhance sensitivity the with same length to particle diameter ratio must be 
increased.  
 





Estrone PFBBr PFB-estrone 
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The nature of the stationary phase that lines a chromatographic column 
influences analyte elution and retention. An octadecyl (C18) group bonded to 
silica is the most popular stationary phase applied in steroid analysis by LC. 
Non-polar steroids are retained on reversed phase Columns and subsequently 
elute by use of a gradient mobile phase. This solvent system often begins with 
a high proportion of aqueous solvent such as (90:10, aqueous:organic) and is 
then adjusted to a high proportion of organic solvents such as (20:80, 
aqueous:organic). This allows chromatographic resolution of analytes with 
similar molecular weight. Furthermore, solvent modifiers (e.g. 10mM 
ammonium acetate) can be used to enhance ionisation of the steroid. More 
recently UHPLC-MS/MS has become the method of choice in sex steroid 
analysis and therefore it will be introduced in detail.  
1.2.3.2.1 LC-MS/MS sensitivity 
Because comparatively low concentrations of sex steroids (pg/mL) exist in 
vivo, a sensitive method with low LOD and LOQ is needed. Method sensitivity 
is determined by a combination of many elements, for example 
chromatographic resolution, sample preparation efficiency and MS detector 
optimisation for best sensitivity. Sample preparation efficiency is evaluated to 
confirm efficient recovery and to reduce matrix ion suppression. 
Chromatographic resolution is developed to enhance baseline separation with 
narrow peak width. In addition, sensitive MS detector is needed to ensure 
method sensitivity.  
1.2.3.2.2 LC-MS/MS ionisation sources  
The most popular ionisation modes utilised in sex hormones analysis are ESI 
and APCI. ESI is the best choice in SRM mode to select precursor and product 
fragment i–ns – small fragments of protonated or deprotonated ions. 
However, this system generally suffers more from sample matrix ion 
suppression in comparison to others. 
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Many sex steroids, estrogens and androgens, have been analysed by LC-
MS/MS using ESI such as E1, E2, DHEA and DHT (Janzen et al., 2008, 
Chadwick et al., 2005, Wang et al., 2008, Guo et al., 2008, Corona et al., 2010, 
Courant et al., 2010). APCI has been commonly used to analyse nonpolar 
compounds for example steroids with lower sample matrix suppression. 
Recently, T and A4 were quantified by both ESI or APCI (Janzen et al., 2008,  
(Rauh et al., 2006, Kulle et al., 2010, Gallagher et al., 2007, Fanelli et al., 2011) 
and DHEA has been measured with APCI (Rauh et al., 2006). APPI is not 
commonly applied to steroids analysis due to insufficient ionisation efficiency. 
These systems are considered as soft ion sources in which protonated 
[M+H]+or deprotonated [M-H]− ions of the analyte (M) are formed. These 
fragments are either positive or negative based on the analyte polarity and the 
chromatographic conditions. Generally, sex steroids analysis is performed in 
positive mode for androgens such as T and DHT (Janzen et al., 2008, Kulle et 
al., 2010), while negative mode is used underivatised E1 and E2 (Guo et al., 
2008, Corona et al., 2010, Courant et al., 2010).  
1.2.3.2.3 LC-MS/MS method development 
For LC-MS/MS method development ion source temperature, flow curtain 
gas and the dwell time of MS should be assessed. Ion source temperature is 
used to improve analyte ionisation and reduce the aqueous proportion in the 
mobile phase. Generally, high temperatures enhance ionisation however, this 
may suppress response by losing a water molecule from the IS and the analyte. 
This will generate unpredictable precursor ions and therefore, method 






1.2.3.2.4 LC-MS/MS method validation 
LC-MS/MS is highly specific tool in sex hormone analysis with good 
performance easily achieved when hormones have different molecular 
weights. However chromatographic separation is required specially for 
steroids of the same molecular mass since these analytes may be fragmented 
similarly and generate the same mass transitions. Two mass transitions for 
each analyte and internal standard are commonly utilised to determine peak 
area proportions for each product ion. This is an important parameter used to 
validate analysis and can reveal false results through observation of variation 
in ratios between the sample to reference samples. If this is the case samples 
must be reanalysed by another method. Validation recommendations should 
be considered to validate sex hormones method before analysis with clinical 
and biological variations. 
Accuracy of MS method is assessed by comparing the method to a reference 
method by following suitable requirements or verifying calibration versus 
certified reference standards. Many reference methods and standards are 
available for steroids such as aldosterone, estriol, E1, E2, progesterone, 17-
hydroxyprogesterone, and T. The bias that should be ≤ 15% in comparison to 
real amount (Vesper et al., 2008) based on clinical variations. In addition, 
accuracy could be evaluated by assessing recovery of spiked known quantities 
of the analytes to a blank sample matrix. 
Precision should be assessed using the same sample matrix as that which will 
be analysed for example plasma, serum, tissue urine etc. All method stages 
should be assessed for precision such as sample preparation, extraction, 
derivatisation, chromatographic separation and MS. The lower limits of 




Sensitivity of MS method for sex steroids analysis is assessed by determining 
the LOD and the LLOQ meeting the recommendations of precision and bias. 
In general, androgens (e.g. T and A4) in adult males are relatively simply 
detected by MS analysis due to their relatively high-level concentrations 
(Wang et al., 2008, Rauh et al., 2006). However, more sensitive MS analysis is 
required to quantify lower levels of androgens in children, female, and 
hypogonadal male samples (Kushnir et al., 2010a, Bhasin et al., 2008). Thus, 
approaches using sensitive MS systems with intensive sample preparation 
have been required achieving LLOQ 20pg/mL to quantify androgens in 
children and females (Wang et al., 2008, Fanelli et al., 2011(Yun et al., 2012, 
Bhasin et al., 2008). Estrogens in premenopausal females are relatively simply 
detected by MS analysis with current instruments, although not those 
available at the outset of this thesis in 2011. However, higher sensitive MS 
analysis is required to quantify lower circulating levels of E2 in post-
menopausal women or those undertaking aromatase inhibitors therapy are 
challenging to detect (Guo et al., 2008, Santen et al., 2008). 
For MS method validation, possible interferences are assessed for example 
interferences from isomers of analytes that may cause incorrect measurements. 
T, DHEA and EpiT isomers are examples of analytes where interference from 
other sex steroids may arise from molecules of the same molecular weight and 
formula but with different in hydroxyl moiety position/orientation. Thus, 
these isomers should be chromatographically separated prior MS analysis or 
use different transitions. 
Extraction (offline or online) is the most common sample preparation method. 
Analyte separation from sample matrix components such as proteins, 
peptides, small molecules, salts, phospholipids is preferable to minimise ion 
suppression in LC-MS analysis. In general, sex steroids are present in low 
concentrations therefore extraction in conjunction with a highly sensitive 
technique such as LC-MS/MS is used for quantitation (Faix, 2013). 
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Popular sample extraction methods performed for sex steroids are LLE, SPE 
and liquid-solid extraction (SLE). LLE extracts analytes among two non-
miscible solvents such as aqueous and organic. SPE and SLE have benefits in 
achieving extraction but not forming emulsions unlike LLE, with analytes 
retained on a sorbent material before the extraction solvent is introduced. SPE 
works as fast LC by extracting analytes among mobile and solid phases which 
can also be automated and applied online before the chromatographic column. 
For sex hormones extraction SPE columns with reversed-phase sorbent are 
usually utilised. LLE is highly efficient method for nonpolar analytes however, 
SPE has shown higher extraction recoveries for these analytes with only one 
extra step (Owen and Keevil, 2013). In addition, using SPE decrease 
phospholipids in biological samples and that minimises matrix effects in MS 
ionisation  (Faix, 2013). SLE maintains aqueous components of the sample 
containing sex hormones using a solid support substance covered with a 
hydrophilic material. Then steroids in the sample are extracted into an organic 
solvent as with typical LLE. SLE is faster extraction method than LLE and SPE 
(Owen and Keevil, 2013). Desired sensitivity and specificity of analysis 
determine the choice sample preparation method or combined methods. 
1.2.3.2.5 Derivatisation 
Derivatisation can be necessary to improve method sensitivity by endowing 
the analyte with a chargeable or charged group for MS analysis. Derivatisation 
changes chemical and physical properties of the analyte leading to a change in 
efficiency of ionisation, fragmentation and retention. In addition, 
derivatisation achieves a higher mass of the specific product ion of the analyte 
to avoid background interference. Derivatisation reagents target functional 




Sex steroids in general are poorly ionisable by MS and detection is commonly 
enhanced by derivatisation. Derivatisation agents such as dansyl chloride, 
pentafluorobenzyl, picolinoyl, pyridyl, piperazinyl, 2-fluoro-1-
methylpyridinium-p-toluenesulfonate (FMP-TS) and 2-hydrazino-1-
methylpyridine (HMP) have been used to derivatise sex hormones (Figure 
1.16) and boost their responses.  
 
Figure 1.16: Examples of reactions of estrone and testosterone with different 
derivatisation reagents, (a) dansyl chloride (b) 2-fluoro-1-methylpyridinium-
p-toluenesulfonate (FMP-TS) (c) 2-hydrazino-1-methylpyridin (HMP), 
(NaHCO3/NaOH) sodium bicarbonate buffer and ((CH3CH2)3N) 
triethylamine. 
                 
                      
                
 
+ 
NaHCO3/NaOH, pH 10.5 




















1.3 Hypothesis and aims of the research 
1.3.1 Hypothesis 
With the benefits of better analytical approaches, understanding synthesis and 
metabolism of estrogens and androgens in the circulation will aid in the 
understanding of the role of sex steroids in determining the distribution and 
function of adipose tissue and its association with CVD. 
1.3.2 Aims and objectives 
• To establish analytical methods to quantify estrogens and androgens in 
plasma. 
• To adapt these protocols to suit analysis in samples of limited volume. 
• To investigate the role of aromatase and 5-reductases on the balance 



















2.1 Chemicals and solvents 
 T, A4, 5α-dihydroandrostanedione (DHA), DHT, EpiT, DHEA, E1,  E2, 17α-
estradiol (17αE2), formic acid (FA) ≥98%, hydrazine monohydrate, 
dichloromethane (DCM), triethylamine (TEA), trifluoroacetic acid (TFA), 
ammonium acetate, FMP-TS, methylene chloride, triacetoxyborohydride and 
sodium borohydride were from Sigma-Aldrich, (Dorset, UK). 2,3,4-13C3-T 
(13C3-T), 99%, 2,3,4-13C3-A4 (13C3-A4), ≥98%, 2,3,4-13C3-5α-DHT (13C3-DHT), 
≥97% were from IsoSciences (Philadelphia, USA). Certified solutions of T, A4 
(1mg/mL in acetonitrile) and DHT (1mg/mL in methanol) were from 
Cerilliant (Texas, USA). 3,4-[13C]2-E1 (13C2E1), 2,4,16,16-[2H]4-E1 (95-97%) 
(d4E1), 3,4-[13C]2-E2 (13C2E2) and 2,4,16,16-[2H]4-E2 (d4E2) were from 
Cambridge Isotope laboratories Inc. (Andover, USA). HPLC grade glass 
distilled solvents were used (methanol, acetonitrile, acetone, n-hexane, DCM 
and water) and LC-MS grade solvents (methanol, acetonitrile and water) for 
mobile phases were from Fisher Scientific UK Limited (Leicestershire, UK). 
2.2 Standard solutions 
Androgens (T, A4, DHT, DHA, DHEA and EpiT) and internal standards (13C3-
T, 13C3-A4 and 13C3-DHT) (IS, 1mg) were individually dissolved in methanol 
(1mL). Estrogens (E1, E2 and 17αE2) and internal standards (13C2E1, d4E1, 
13C2E2 and d4E2) (IS; 5mg) were dissolved in acetone (5mL). All solutions 
stored at -20°C and working solutions (100µg/mL to 1pg/mL) were prepared 







2.3 Plasma and serum samples 
Pooled post-menopausal female human serum, male and female human 
plasma and stripped (using activated charcoal to remove free and protein 
bound hormones) and unstripped serum used in method development and 
validation were from TCS Biosciences (Buckingham, UK), stored at -20°C. All 
human blood was obtained from healthy donor in approved blood collection 
centres. Plasma was prepared by TCS Biosciences from whole blood which 
was collected into anticoagulant (citrate phosphate dextrose adenine, CPDA-
1), whereas serum was collected without anticoagulant and allowed to clot 
naturally. In addition, UK samples from the National External Quality 
Assessment Scheme (NEQAS) for steroid hormones were used in method 
comparison. These samples were obtained from Birmingham Quality which is 
part of the National Health Service (NHS) and University Hospitals 
Birmingham NHS Foundation Trust (Birmingham, UK), stored at -20°C.  
For method application, serum was collected from 33 pre-menopausal women 
undergoing investigations for menstrual disorders (24-54years); these patient 
samples were anonymised prior to analysis and ethical approval was thus not 
required. For pre-menopausal female samples, E2 had been previously 
measured using an automated immunoassay on an Architect i2000 analyser 
(Abbott Laboratories Ltd, Maidenhead, Surrey). Further plasma samples were 
obtained from subjects participating in experimental medicine studies for 
which local ethical approval had been obtained; 20 post-menopausal women 
(58-60years old) and 46 men (21-85years old) men (Gibb et al., 2016, Gibb et al., 
2019a, Gibb et al., 2019b, Upreti et al., 2014, Upreti et al., 2015) .  
For animal models, samples were collected from male and female mice (aged 
12weeks) (Livingstone et al., 2017). The animals were bred from an inhouse 
colony derived from the line of Mahendroo et al. and under the auspices of 
Home Office guidance. To compare methodology for analysis of T, data from 
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the LC-MS/MS method was compared to data from an immunoassay method 
using plasma from 14 male wild-type mice of mixed C57Bl6/SvEv/129 
background (12weeks) (Livingstone et al., 2017). Plasma was also collected 
from castrated wild-type mice and compared with sham-operated animals 
(n=6). These were further compared to male mice with genetic disruption of 
Srd5a1-/- (5αR1 KO n=6) and female wild type (n=6) and Srd5a1 -/- mice (n=6) 
were studied (Upreti et al., 2014, Upreti et al., 2015).  
2.4 Instrumentation 
Initial work (Ch3) was performed using HPLC ultraviolet (HPLC-UV, Dionex 
ASI-100, Thermofinnigan, Waltham, USA), operated using Chromeleon™ 6.8 
Chromatography Data System (CDS) Software (Thermofinnigan, Waltham, 
USA) to establish chromatographic conditions and to develop an extraction 
method underivatised androgens and estrogens. In order to develop the 
approach further to be suitable for interfacing with MS, the HPLC method was 
transferred to UHPLC using an ultra-high-performance liquid 
chromatography with ultraviolet detection (UHPLC-UV, UltiMate 3000 
UHPLC, Thermofinnigan, Waltham, USA) operated using Chromeleon™ 7.2 
Chromatography Data System (CDS) Software Thermofinnigan, Waltham, 
USA). 
Initial structural elucidation of estrogen derivatives was performed on a LC 
QQQ MS, a TSQ Quantum Discovery MS coupled to a Surveyor autosampler, 
with a Surveyor MS pump (Thermofinnigan, Waltham, USA) and operated 
using Xcalibur software version 2.0. High-sensitivity quantification for all 
derivatives were performed on a QTrap 5500 QQQ MS (Sciex, Warrington, 
UK) coupled to an Acquity™ Classic Ultra Performance LC (Waters 
Corporation, Milford, USA), operated using Analyst software version 1.5.1 




Confirmation of accurate mass of HMP was performed by direct infusion into 
a 12 T SolariX dual source FT-ICR MS (Bruker Daltonics, MA, US), operated 
with SolariX control v1.5.0 (build 42.8) software. Structural elucidation and 
accurate mass for HMP fragment ions were confirmed by infusing into a high-
resolution MS (Synapt G2-Si MS, Waters Corporation, Milford, USA) with an 
ESI ion source in positive mode and operated with MassLynx v4.2 software.  
2.5 Statistical analysis 
Statistical analysis was performed using SPSS for Windows, version 24 (IBM, 
UK). Absolute values and % differences between methods were compared by 
Bland-Altman analysis (Moal et al., 2007). 
2.6 Validation method requirements 
Method accuracy was assessed where the bias should be compared to the real 
amount. Bias was calculated as the Relative mean error:  
 (RME) = Mean error/actual measurement X 100 
Method precision was assessed for all method stages at the upper and lower 
limits of quantitation (LLOQ) and using matrix samples. Precision was 
calculated as the Relative Standard Deviation: 
(RSD) = Standard Deviation/Mean X 100 
General precision and accuracy requirements were approved when the RSD 
and RME respectively should be ≤15% at all points except at the LLOQ where 
≤20% and ≤25% were permitted in standards and to endogenous biomarkers 
in matrix respectively (Vesper et al., 2008, Kruve et al., 2015). 
Linearity was assessed by fitting regression lines to the calibration data, with 
comparison of accuracy using weightings of 1, 1/X and 1/X2 and seeking 












In men, T is the major androgen which responsible for the growth and 
protection of sex organs and functions (Miller and Auchus, 2011). Aging is 
associated with a reduction in production of endogenous androgens as well as 
increased risk of CVD (Tchernof et al., 1995) and the two may be linked. 
Diabetic males have lower concentrations (~25%) of circulating T compared to 
nondiabetics and suffer a higher incidence of hypogonadism (Varlamov et al., 
2014). Researchers have also found low concentrations of T (0.17–0.31nmol/L) 
in obese males compared to lean counterparts (4.5–21nmol/L) (Karas and 
Hillenkamp, 1988, Hillenkamp and Karas, 1990, Kushnir et al., 2010a). 
Metabolism of T by 5α-reductase activity may be increased in obesity and T 
concentrations decreased, however, circulating concentrations of DHT appear 
stable or slightly reduced, as are those of A4 (Krone et al., 2007, Kushnir et al., 
2010a). The concentrations of androgens (T and A4) in women are lower than 
men, even lower in diabetic females compared to non-diabetic females 
(Barrett-Connor et al., 1990, Bray, 2003, Gambineri and Pelusi, 2019). 
Furthermore, a number of lifestyle factors or therapies are associated with low 
androgens. For example, A4 levels are also even lower in smoker post-
menopausal women compared to non-smokers (Law et al., 1997) and women 
under estrogen therapy (Samaras et al., 1999). However, many reports of these 
steroid levels in metabolic disease have relied on immunoassays, now subject 
to criticism.  
In the past immunoassay s were used to measure androgens since these 
techniques are fast and simple. However, immunoassays have some 
limitations such as lack of specificity and matrix interference and generally the 
commercially existing automatic direct immunoassay methods do not have 
satisfactory sensitivity and selectivity for clinical purposes in metabolic 
disease or research (Bhasin et al., 2008). A range of circulating concentrations 
of (T); 0.1-37.1nmol/L and (A4); 0.2-8.8nmol/L (Kratz and Lewandrowski, 
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1998)  are reported, but analytical specificity at low concentrations 
(<1.7nmol/L) is poor due to interference from endogenous isomers and other 
steroids in the biological matrix such as EpiT and DHEA (Tamae et al., 2013). 
This presents a particular problem when measuring low abundance bioactive 
5α-reduced androgens, DHA and DHT, the latter with plasma concentrations 
of 0.1-1.9nmol/L in men and 0.1-1.2nmol/L in women (Tamae et al., 2013). 
These difficulties mean that immunoassays cannot be used reliably in a variety 
of settings e.g. in males with anti-androgen  therapy, and in children and 
women (Liu et al., 2009), but importantly for this thesis, in metabolic disease 
and calls into question some of the earlier literature in the field around the 
start of this thesis in 2011. 
The Endocrine Society published recommendations regarding measuring T 
accurately and precisely in clinical samples (Liu et al., 2009). Generally, LC-
MS/MS provides high sensitivity and specificity, with less sample preparation 
compared to GC-MS (Santen et al., 2007). However, a MS is complex detector 
compared to other techniques which needs an appropriate expertise, method 
validation and standardisation. Accordingly, LC-MS/MS is already replacing 
immunoassay in the analysis of T in clinical practice but only in specialist labs 
(Borrey et al., 2007). 
At the outset of this thesis (around med-2011), we aimed to establish an 
analytical approach to quantify androgens in human and murine biological 
fluids by MS/MS for use to address hypotheses in metabolic research, and in 
particular, to evaluate if the approach could quantify circulating steroids in 
small volume samples, in post-menopausal females and in pre-clinical 
samples. We further evaluated if the same sample aliquot could be used for 
concomitantly estrogen analysis to maximise outputs/sample. A sensitive 
method was validated using solid phase extraction, in conjunction with LC–
MS/MS and its benefits and limitations assessed. These studies were 
conducted between 2011-3. 
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3.2 Materials and methods 
An overview of the method development approach is given in Figure 3.1. 
 
Figure 3.1: Proposed workflow for development of liquid chromatography 
tandem mass spectrometry (LC-MS/MS) method for sex steroids profiling 
in plasma and serum. 
3.2.1 HPLC-UV 
Initial development work was performed using HPLC with UV detection 
(Dionex ASI-100) to establish chromatographic conditions. This simpler 
analytical approach was used to evaluate a preliminary extraction method for 
androgens. In addition, a combined extraction method was proposed to 
extract androgens and estrogens in two separate fractions using the same 
sample (Figure 3.1). 
3.2.1.1 HPLC-UV chromatographic conditions  
HPLC analysis was carried out utilising a C18 column (Sunfire C18, 4.6mm x 
150mm) with the column temperature, 25°C and the injection volume, 100µL. 
Elution was performed using an isocratic solvent system of 
water:acetonitrile:methanol (45:35:20) with the optimal flow rate of 
1.5mL/min for 15min. UV detector wavelengths were λ= 195nm for (DHT and 
DHA) and 245nm for (T, A4, EpiT).  
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3.2.1.1.1 Reproducibility test of HPLC-UV method 
A 100µL aliquot of each of (10 and 100µg/mL) solution of androgens in mobile 
phase solvent system of water:acetonitrile:methanol was injected six times on 
two occasions to assess the robustness of the system. Standard deviations (SD) 
and RSDs were calculated from peak areas and retention times of the mean six 
samples.  
3.2.1.2 Extraction method 
SPE using Oasis HLB (1CC/10mg) extraction cartridges was performed 
under gravity as detailed in Table 3.1. This method was developed from 
suggested extraction method for steroids by Waters Corporation (Milford, 
USA). This was applied to aqueous solutions and stripped, post-spiked serum 
samples. Eluants were reduced to dryness under nitrogen at 40°C and then 
residues were reconstituted in (50µL) mobile phase for HPLC-UV analysis 




Loading 1mL sample 
Washing  1mL of 5% methanol in water 
Elution  1mL methylene chloride: methanol (50:50) 
Table 3.1: Initial method for extraction of androgens with Oasis HLB® 
columns (Waters corporation, Milford, USA). 
3.2.1.2.1 Recovery of androgens following extraction 
Recoveries of IS from water and plasma were assessed by comparison of signal 
intensities, following extraction from samples pre- and post-spiked with IS 
(1µg; n=6). Mean peak areas of androgens following extraction in pre-spiked 
samples were divided by those in post-spiked samples and expressed as a 
percentage. In addition, RSDs of the extraction percentages were calculated 
aiming to achieve greater than 90%.  
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3.2.1.2.2 Calibration curves of extraction method 
Blank samples (0µg) and aliquots containing (0.1, 0.25, 0.5, 1, 2.5, 5 and 10)µg 
and (1, 2.5, 5, 10, 25, 50 and 100)µg were prepared from the stock solutions of 
(T and A4) and (DHT and DHA) respectively. These solutions were used to 
obtain the calibration curves to assess the linearity of the extraction method, 
albeit the concentration range needed for UV detection was higher than the 
anticipated final method. The calibration curves were produced by plotting 
the peak areas produced from each solution against the amount of androgen 
added. 
3.2.2 UHPLC-UV 
In order to develop the approach further to be suitable for interfacing with MS, 
the HPLC method was transferred to UHPLC. 
3.2.2.1 UHPLC-UV chromatographic conditions 
UHPLC was carried out utilising a C18 UPLC column (Acquity UPLC BEH C18, 
2.1mm x 50mm, 1.7µm) with the column temperature, 25°C and the injection 
volume, 10µL. An isocratic solvent system of in water: acetonitrile: methanol 
all containing formic acid (0.1% (v/v) (55:25:20) was used initially for 7min 
run with flow rate of 0.25mL/min. As previously, UV detector wavelengths 
were λ=195nm for (DHT and DHA) and 245nm for (T, A4, EpiT). 
3.2.3 MS 
Once an initial UHPLC method was in place, standards were infused into the 
MS mobile phase to assess ion transitions. At the outset of this work (2012) the 
laboratory was equipped with a TSQ Quantum Discovery MS and at a later 
stage a QTrap 5500 was installed offering improved sensitivity.  
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3.2.3.1 Fragmentation analysis of androgens 
For product ion characterisation by a TSQ Quantum Discovery MS at nominal 
mass, molecular ions of androgens were isolated by Q1. Q3 was operated in 
the scanning mode (m/z 50-100) above and below the mass of the anticipated 
molecular ion under analysis. Conditions for MRM were optimised by 
autotuning, performed by manual infusion of representative androgen 
solution (1µg/mL).  
3.2.3.2 Tuning androgens on the Q trap MS 
To allow analysis with higher sensitivity, androgens were retuned on the 
Qtrap 5500 QQQ MS in MS/MS mode. Androgen solutions (1µg/mL) in 
mobile phase (water: methanol both with 0.1%(v/v) formic acid (45:55)) were 
used. ESI and APCI ion sources were assessed in positive mode. 
3.2.3.3 Optimising ion source conditions 
Androgen solutions (100ng/mL) in mobile phase were used to optimise ion 
source conditions. Methods were carried out for 1min without a column 
present and the injection volume was 10µL. Androgen mixtures were analysed 
with flow rate of 0.25mL/min. An isocratic solvent system of water: methanol 
both with 0.1%(v/v) formic acid (45:55) was used. Parameters optimised for 
ESI including curtain gas, collision gas, ion spray, temperature, ion gas 1 and 
2. For APCI, curtain gas, collision gas, temperature, ion gas 1 and nebulizer 
current were optimised. Values were screened for each parameter as 
following: curtain gas, ion source gas 1 and 2 (20, 25, 30, 35, 40, 45, 50 and 
55mTorr), collision gas (low, medium and high), ion spray (1500, 2000, 2500, 
3000, 3500, 4000, 4500, 5000 and 5500V), temperature (300, 350, 400, 450, 500°C), 




3.2.4 UPLC-MS/MS chromatographic conditions  
Analysis was performed on a C18 UPLC column (Acquity UPLC BEH C18, 
2.1mm x 50mm, 1.7µm) with the column temperature, 25°C and the injection 
volume, 10µL. Analytes were initially eluted using an isocratic solvent system 
of water: methanol both with 0.1%(v/v) formic acid (45:55) for 10min run with 
flow rate of 0.25mL/min. ESI  in positive mode optimised to the following 
conditions: curtain gas (20mTorr), collision gas (medium), ion spray (5500V), 
temperature (500°C), ion gas 1 and 2 (40,35mTorr). In addition, APCI in 
positive mode optimised to the following conditions: curtain gas (25mTorr), 
collision gas (medium), temperature (450°C), nebulizer current (3.5A) and ion 














T 289 97 25 44 111 10 
EpiT 289 97 25 46 201 10 
A4 287 97 25 48 131 10 
DHT 291 255 17 32 76 10 
DHA 289 271 17 34 66 10 
13C3-T 292 100 27 6 61 10 
13C3-A4 290 100 27 44 11 10 
13C3-DHT 294 258 27 26 136 10 
Table 3.2: MS/MS conditions for androgens analysis. (CE) collision energy; 
(CXP) collision cell exit potential; (DP) declustering potential; (EP) entrance 
potential; (m/z) mass-to-charge ratio; testosterone (T); androstenedione (A4); 
5α-dihydrotestosterone (DHT); 5α-dihydroandrostanedione (DHA); 
epitestosterone (EpiT); 2,3,4-13C3-Testosterone (13C3-T); 2,3,4-13C3-






3.2.4.1 Sensitivity of UPLC-MS/MS androgens method 
3.2.4.1.1 Limit of detection (LOD)  
Aliquots (100, 10, 1ng and 100, 10, 1pg/ml) of androgens were prepared from 
the stock solutions. In order to evaluate the sensitivity, LOD was calculated 
using the signal-to-noise ratio (S/N=3) as described in section 2.6, by 
integrating an adjacent area of baseline over the time window equivalent to 
the peak width. 
3.2.4.1.2 Limit of quantitation (LOQ)  
Aliquots (100, 10, 1ng and 100, 10, 1pg/mL) of androgens were prepared from 
the stock solutions. In order to estimate the sensitivity, LOQ was calculated 
assessing a series of solutions in the range of signal-to-noise ratio (S/N=5-10) 
as described in section 2.6, subsequently refining the amount associated with 
precision and accuracy ≤20%, for n=6 replicates. 
3.2.4.1.3 Ion Suppression test 
Ion suppression was evaluated ESI and APCI in positive mode for androgens. 
This test was applied for aqueous solutions and stripped post-spiked plasma 
samples following extraction. Integrated mean peak areas of androgens in the 
stripped post-spiked plasma samples extracted using Oasis HLB cartridges 
were compared to mean peak areas of aqueous samples without an extraction 
step (n=6/group). 
3.2.4.1.4 Accuracy and precision 
Injector reproducibility was tested by re-injecting the same samples of 
standards (1, 50, 400pg) as well as extracted 6 times on the same day to assess 
precision. Aliquots of male and female plasma (1mL) extracted 6 times on the 
same day to assess precision. 
65 
 
Furthermore, the intra- and inter-assay precision and accuracy were assessed 
using 6 standard samples (1, 50 and 400pg) extracted from water and prepared 
on the same and different days respectively, alongside a standard curve 
(n=6).Precision and accuracy were calculated as described in section 2.5. The 
bias (average inter-assay concentration - certified standard concentration X 
100) of the calibrators was assessed against certified standards for T, A4 and 
DHT (Vesper et al., 2008, Kruve et al., 2015). 
3.2.4.1.5 Stability 
Stability following storage in the auto-sampler (10°C) was evaluated by 
reinjection of a calibration curve and plasma samples after 24 hours.  
3.2.4.2 Method Application 
T and A4 were quantified in human serum from pre- and plasma from post-
menopausal females and males using the validated approach. T was 
quantified in plasma from an animal model (male and female mice). 
3.2.4.2.1 Plasma and serum samples 
Human and animal samples were collected as describe in section 2.3. 
3.2.4.2.2 Data analysis and method validation 
Data analysis and method validation were performed as described in section 
2.5 and 2.6.  
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3.3 Results and discussion 
3.3.1 HPLC-UV 
HPLC-UV was used as an analytical method to detect individual androgens, 
to permit initial testing of extraction efficiency. Figure 3.2 shows baseline 
resolution between androgens in reasonable retention times (5.7min T, 6.9min 
A4, 9.7min DHT and 11.9min DHA). Androgens peaks were symmetrical, and 
the highest intensity of detection was at wavelength 245nm for T and A4 from 
absorbance by the conjugated chromophore in A ring, whereas, DHT and 
DHA were observed at 195nm from ketone in A ring. 
 
Figure 3.2: Chromatogram at wavelengths (a) 245nm and (b) 195nm recorded 
by HPLC-UV, showing peaks obtained for testosterone (T), androstenedione 
(A4), 5α-dihydrotestosterone (DHT) and 5α-dihydroandrostanedione (DHA). 






3.3.1.1 Reproducibility for androgens standards 
Standard solutions were injected to assess the robustness of analysis by HPLC-
UV. This method was deemed reproducible since %RSD values of retention 
times and peak areas were less than the defined cut off 15 % (0.3–1.4) (Table 
3.3). This method was then used to develop extraction method. 
Androgens 
Retention time Rt (min) Peak area (mAU) 
T A4 DHT DHA T A4 DHT DHA 
Mean 5.7 6.9 9.7 11.8 164.2 166.6 141.3 138.8 
SD 0.1 9.7 0.04 0.04 1.3 1.4 1.3 1.1 
% RSD 0.8 1.4 0.4 0.3 0.8 0.4 0.9 0.3 
Table 3.3: Reproducibility test for androgen standards. (T) testosterone; (A4) 
androstenedione; (DHT) 5α-dihydrotestosterone; (DHA) 5α-
dihydroandrostanedione; Rt = retention time; mAU = milli-absorbance unit; 














3.3.1.2 Extraction method 
Development of an extraction method was performed initially using HPLC-
UV. The lipophilic polymeric adsorbent, Oasis®, was ultimately selected for 
solid phase extraction and using HLB (1CC/10mg) extraction cartridges 
assessed under gravity. Various proportions of elution solvent (methylene 
chloride and methanol) were used to establish conditions permitting best 
extraction recoveries and the method was applied initially to aqueous 
solutions and subsequently stripped post-spiked serum samples. 
Combined extraction methods for androgens and estrogens were assessed 
using different solvent compositions with different proportions for 
conditioning, washing and elution. These solvents included water and 
methanol for conditioning and washing with proportions of (5-95%) applied. 
For elution, methylene chloride, methanol and water with proportions of (5- 
95%) were assessed for both solvents and maximum recovery of androgens 
was achieved by using methylene chloride:methanol (50:50). All sex steroids 
were eluted similarly for each extraction method therefore, subsequently 
separate methods were developed for androgens and estrogens (Chapter 5). 
3.3.1.2.1 Extraction recovery from aqueous solution 
Unextracted and extracted samples were compared initially from water to 
assess recovery. Excellent extraction recoveries were demonstrated (mean 
±RSD; T 96±2%, A4 97±6%, DHT 93±1%, DHA 94±4%).  
3.3.1.2.2 Extraction recovery from serum 
Pre-spiked and post-spiked stripped serum were extracted to assess recovery. 
The Oasis HLB columns showed excellent retention of analytes and 
generated a clean extract from the biological matrix with reproducibly high 
recovery (Table 3.4). 
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3.3.1.2.3 Matrix interference from serum 
Unextracted, extracted and post-spiked samples from serum were compared 
to assess matrix interference. (Table 3.4). There were no significant differences 
between the groups. Therefore, the extract did not interfere with the signal 
when analysing with UV, but this would not necessarily translate to MS 
detection or in lower amounts. 
3.3.1.2.4 Calibration curves for extraction method 
A series of standard solutions were used to prepare calibration curves to assess 
the linearity of the extraction method. The method was linear with R values 








Analyte T A4 DHT DHA T A4 DHT DHA T A4 DHT DHA 
Mean 90 97 93 92 97 96 102 99 91 90 91 93 
SD 3 3 5 3 1 1 1 1 4 3 5 3 
% RSD 4 3 6 4 1 1 1 1 4 3 5 4 
Table 3.4: Extraction percentages (% Ex) for androgens unextracted, 
extracted and post-spiked samples from serum. (T) testosterone; (A4) 
androstenedione; (DHT) 5α-dihydrotestosterone; (DHA) 5α-









3.3.2 Method transfer to UHPLC-UV  
The HPLC-UV method was transferred to UHPLC-UV in order to combine 
better with the MS. The use of a UHPLC column with different dimensions 
and particle size from HPLC column led different elution order, shorter 
retention times and more sensitive signals. Epi-T, an isomeric, inert 
endogenous steroid which may interfere with bioanalysis was included in the 
method and elution conditions were optimised. 
The column used for UHPLC analysis was an Acquity UPLC BEH® C18 column 
(50  2.1mm, 1.7µm). This column consists of a silica stationary phase with 
particles less than 2μm with low backpressure. This allows for UHPLC type 
separation but using a conventional HPLC pump with a maximum 400bar 
pressure. This was the only available local option at the start of this PhD, 
although other options became available later. This column conformation gave 
far better Eddy diffusion than could be achieved on 3 or 5µm standard HPLC 
columns. 
Baseline separation was achieved by adopting an isocratic solvent system of 
water: acetonitrile: methanol all containing formic acid (0.1%(v/v)) from 
(45:35:20) to (55:25:20). Figure 3.3 shows that separation among androgens was 
achieved with short retention times and symmetrical peaks 2.5 (T), 3.2 (A4), 
4.2 (DHT), 5.4 (DHA) and 4.8min (EpiT). The highest intensity of detection was 
still obtained at the same wavelengths with the modified mobile phase; 
wavelength 245nm for T, A4 and EpiT and, 195nm for DHT and DHA. 




Figure 3.3: Chromatogram at wavelengths (a) 245nm and (b) 195nm recorded 
by UHPLC-UV, showing peaks obtained for testosterone (T), androstenedione 
(A4), 5α-dihydrotestosterone (DHT), 5α-dihydroandrostanedione (DHA) and 












3.3.3 Method transfer to mass spectrometer  
The UHPLC-UV method was subsequently interfaced with MS in order to 
develop an analytical method of sufficient sensitivity to detect steroids in 
biological fluids. ESI and APCI ionisation were compared in positive modes, 
in conjunction with UHPLC. QQQ was selected, as it is ideal for quantitation, 
with rapid switching and a wide dynamic range of detection.  
3.3.3.1 UPLC-MS/MS method for androgens standards 
Tuning androgens in positive mode showed that ESI and APCI registered the 
same precursor and product ions for androgens using both instruments (Table 
3.2). Figure 3.4 showed mass chromatograms with baseline resolution between 
androgens in reasonable time, 3.5 (A4), 5.0 (T), 6.0 (DHA), 7.1 (EpiT) and 
7.9min (DHT), with more intense ions in ESI than APCI. For both modes, more 
intense peaks were recorded for A4, T and EpiT, whereas lower signals were 
obtained for DHA and DHT, due to their lower propensity to ionise. 
The precursor ions were the expected quasi-molecular ions, m/z 289 (T), m/z 
287 (A4), m/z 291 (DHT), m/z 289 (DHA) and m/z 289 (EpiT) (Table 3.5). 
Fragmentation of the precursor ions generated two product ions of significant 
abundance (Joly et al., 2005). Stable-isotopically labelled androgens were used 
to elucidate potential fragmentation pathways. For example, 13C3T, 13C3A4 and 
13C3DHT fragmented similarly with product ions with m/z+3 of T, A4 and DHT 










Figure 3.4: Mass chromatograms obtained by UHPLC-MS/MS system using 
positive mode with two different ion sources (a) ESI and (b) APCI, showing 
higher ionisation intensities in ESI than APCI registering the same precursor 
and product ions and baseline separation of peaks obtained for testosterone 
(T, m/z 289-97), androstenedione (A4, m/z 287-97), 5αdihydrotestosterone 
(DHT, m/z 291-255), 5α-dihydroandrostanedione (DHA, m/z 289-271) 
epitestosterone (EpiT, m/z 289-97). (ESI) electrospray ionisation, (APCI) 
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Androgens and their internal standards were analysed individually to test for 
background interference with other ions. Table 3.6 showed only slightly lower 
background interferences in ESI than APCI. Having established specific 
transitions, interferences between analytes were assessed since mass 
differences of two allow cross-signal from natural 13C2 or 13C2H isotopes, 
indistinguishable at nominal mass. Some interferences were observed 
between ions relating to T, A4 and DHA due to naturally occurring 
isotopologues. For example, T has a mass equivalent to 13C2A4, likewise DHT 
has a mass equivalent to 13C2T. 
Table 3.6 and Figure 3.4 summarise the interferences between the androgens, 
emphasising the importance of ensuring they eluted at different times. These 
interferences were linked to the similarities in the chemical structures, 
especially for the isomers T and EpiT. For example, T may interfere with EpiT 
and DHA because they have the same precursor ion at m/z 289. Furthermore, 
table 3.5 shows same product ion for T, A4 and EpiT at m/z 97 because they 
fragmented similarly. In addition, these interferences will be more of an issue 
when they originate from the more abundant steroids such as T and A4. 













Analyte T EpiT A4 DHT DHA T EpiT A4 DHT DHA 
T - - 1.1 0.2 12.2 - - 1.9 2.5 12.8 
EpiT - - 0 0.1 24.0 - - 1.0 0.7 24.3 
A4 1.1 1.1 - 0 0 1.9 2.0 - 0.2 0.2 
DHT 0.2 0.2 0 - - 2.5 0.7 0.2 - - 
DHA 10.2 24.0 0 - - 10.8 24.3 0.2 - - 
Table 3.6: Percentage of interference between androgens using ESI and 
APCI in positive mode; showing lower background interferences in ESI than 
APCI. The area of peak in the expected ion was expressed as 100 % and then 
the amount of signal at the same retention time in alternative ions expressed 
related to this. Testosterone (T); androstenedione (A4); 5α-
dihydrotestosterone (DHT); 5α-dihydroandrostanedione (DHA) and 
epitestosterone (EpiT), (ESI) electrospray ionisation and (APCI) atmospheric 














3.3.3.2 Sensitivity of detection by UHPLC-MS/MS 
3.3.3.2.1 LOD and LOQ 
In general, the analysis of biological samples needs very low LOD and LOQ 
values because of the f-pM concentration of analytes of interest in these fluids. 
LOD was calculated and LOQ estimated using indicative S/N ratios of 3 and 
5 respectively. In standard solutions, ESI had yielded higher signals than APCI 
from aqueous standard samples (Figure 3.4).  
To address if that was still the case when applied to biological samples where 
ion suppression was present, the sensitivity (LOD, LOQ and ion suppression) 
of signal obtained ESI and APCI modes was compared using surrogate 
biological matrix (stripped post-spiked plasma) and LODs and LOQs for both 
modes are shown Table 3.7. In general, lower LODs and LOQs were also 




Analyte T A4 DHT DHA EpiT T A4 DHT DHA EpiT 
LOD 
(pg) 
0.5 0.5 50 50 5 1 1 100 50 5 
LOQ 
(pg) 
1 5 100 100 10 2 10 100 100 10 
SD 0.1 2.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
% RSD 3.4 1.7 2.3 3.4 0.8 4.4 3.2 2.0 3.7 4.4 
Table 3.7: Limit of detection (LOD) and Limit of quantitation (LOQ) on 
column of androgens from stripped post-spiked plasma, using UPLC-
MS/MS in both ESI and APCI positive mode (N=6). testosterone (T); 
androstenedione (A4); 5α-dihydrotestosterone (DHT); 5α-
dihydroandrostanedione (DHA); epitestosterone (EpiT); standard deviations 




3.3.3.2.2 Ion suppression  
Ion suppression was evaluated in ESI and APCI positive modes. Table 3.8 
shows RSD values of peak areas less than the defined cut off 15 %–(–.5 - 13.1) 
for ESI and (9.7- 12.9) for APCI. There were no significant differences between 
signal intensity in unextracted water solutions and stripped post-spiked 
plasma samples in both ESI and APCI. Therefore, minimal ion suppression 
was observed due to matrix.  
Ion source ESI APCI 
Analyte T A4 DHT DHA EpiT T A4 DHT DHA EpiT 
%Mean 92 94 91 93 94 93 95 92 92 93 
SD 11.1 12.3 10.7 9.4 12.3 11.4 11.2 10.4 9.0 11.2 
%RSD 11.7 13.0 10.5 9.5 13.1 12.9 12.0 10.9 9.7 11.9 
Table 3.8: Standard deviations (SD) and relative standard deviations (RSD) 
of peak areas of extracted stripped post-spiked plasma to unextracted water 
samples, using UPLC-MS/MS on ESI and APCI (N=6). testosterone (T); 
androstenedione (A4); 5α-dihydrotestosterone (DHT); 5α-
dihydroandrostanedione (DHA) and epitestosterone (EpiT). 
3.3.3.2.3 Linearity  
13C3 labeled androgens were selected as internal standards to avoid isotopic 
interference of mass+2. Linear standard curves were generated with a mean r 
value of 0.996. Weighting of 1/x2 was ultimately applied to improve accuracy 
at the low amounts, yielding a mean intercept of 0.0032 within the quantitation 







3.3.3.2.4 Precision and accuracy 
The values of intra- and inter-assay precision and accuracy of analysis of 
standards were acceptable (<20% RSD for precision and <±20% accuracy) at 
the LOQ and <15% above this value for extracts from water, male and female 
plasma (Table 3.9). Acceptable reproducibility upon repeat injection of the 
same sample was demonstrated with RSD; T (3%), A4 (5%) in male and T (8%) 
and A4 (3%) in female plasma. 
Standard 
solutions 
Low (1pg) Middle (50pg) High (400pg) 
Analyte T A4 DHT T A4 DHT T A4 DHT 
Precision (%RSD) (n=6) 
Intra-assay 5 3 4 5 9 8 11 12 12 
Inter-assay 8 5 6 8 11 11 13 14 15 
Accuracy (%RME) (n=6) 
Intra-assay 1 1 12 2 1 14 14 10 17 
Inter-assay 2 7 10 14 10 10 11 18 19 
Precision (%RSD) (n=6) 
Plasma Male Female 
Analyte T A4 DHT T A4 DHT 
Intra-assay 2 1 2 2 2 3 
Inter-assay 6 5 7 7 6 8 
Table 3.9: Precision and accuracy of analysis of androgens. Testosterone (T), 
androstenedione (A4), 5α-dihydrotestosterone (DHT), Relative Standard 
Deviation (RSD) and Relative Mean Error (RME) 
3.3.3.2.5 Stability 
Samples demonstrated suitable stability upon storage in an auto-sampler 
(10°C) over 24h, with limited degradation measured for T (12%, 5%) and A4 




3.3.3.3 Method application 
The method was applied to samples from pre- and post-menopausal females 
and males and compared to reported biological concentrations (Table 3.10) 
(Kratz and Lewandrowski, 1998) and amounts obtained fell within the 
anticipated reference ranges. In clinical practice immunoassays are used to 
quantify T or A4 alone, but not in combination; the LC-MS/MS approach 
allowed concomitant analysis of T and A4 across a wider age range and may 
be extended to further metabolites. In pre- and post-menopausal female serum 
200µL of serum was required to ensure reliable detection for T and A4. T and 
A4 concentrations were quantified using 20µL male plasma however, DHT 
and DHA could not be detected in either males or females even using 200µL. 
These volumes were compared with those in the previous literature (100-
500µL) to measure T and A4 using immunoassay, radioimmunoassay and MS 
methods (Pazzagli et al., 1975, Moal et al., 2007) 
The concentrations of T and A4 were compared to data previously collated by 
NEQAS for male and female samples using LC-MS/MS, but with a simple 
protein precipitation clean-up (Figure 3.5). Bland Altman plots (Figure 3.5C) 
shows the percentage difference (D%) between the in-house LC-MS/MS 
method and NEQAS measurements, and most data points fell within ±1.96 SD 
of D%. The correlation coefficients between concentrations measured by 
NEQAS and LC-MS/MS was 0.9853 for T. T concentrations measured with in-
house LC-MS/MS were generally lower than the previous NEQAS data (Table 
3.10). The bias increased as the measurements mean of T decreased. While a 
correlation was observed between the A4 data, this was less good, r=0.8866. A 
positive bias with greater variation from the NEQAS measurements was 
observed, again more marked in low concentrations. The differences between 
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methods may relate to different ion suppression between the more efficient 








T A4 T A4 
Males 48 21-85 4.6-17 1.5-4.7 4.6-24 0.8-4.7  
Pre-menopausal 
females 
6 37-54 0.3-1.3 1.6-6.6 0.2-1.9 0.5-7.5 
Post-menopausal 
females 
20 58-60 0.4-1.1 0.5-2.3 0.2-1.1 0.5-2.9 
Table 3.10: Concentrations of androgens in males, pre- and post-
menopausal females, (1) (Kratz and Lewandrowski, 1998), (2) (Grebe and 




Figure 3.5: Correlation and (──) regression lines (A, B) and Bland Altman plots (C,D) of concentrations of testosterone (T) 
and androstenedione (A4) in plasma measured by in-house LC-MS/MS and national quality control scheme (NEQAS). 
The percentage difference between values of two measurements ((in-house LC-MS/MS- NEQAS)/NEQAS x 100) (D%); the 
horizontal lines are mean of D%; +1.96 standard deviation (+1.96 SD) and –1.96 standard deviation (-1.96 SD). 
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For mice, T could be detected in 50µL and 30µL in blood from females and 
males respectively (Table 3.11) within the quantitation limits of the assay of (1-
100pg) and agreed with the anticipated reference range. DHT and DHA could 
not be detected in plasma from males and females in these volumes. The 
concentrations of T were compared with data previously collated by 
immunoassay (Figure 3.6). Generally, measurements showed poor agreement 
between LC-MS/MS and IA, but this was to be expected since immunoassays 
are known to be unreliable (Bhasin et al., 2008). The correlation between T 
concentrations measured by IA and LC-MS/MS was only 0.8722. Bland 
Altman plot (Figure 3.6 A,B) shows the percentage difference (D%) between 
the LC-MS/MS and immunoassay measurements. T concentrations were 
higher with LC-MS/MS than immunoassay which was not anticipated as 
usually interference with IA introduces a positive bias: e.g. measurements 
mean were (SD) 1.2 (0.47) and 0.78 (0.68)ng/mL by LC-MS/MS and IA 
respectively. The positive bias increased as the measurements mean of T 
decreased with better agreement in high concentrations than in low 
concentrations. These data highlight the concerns over sex steroid measures in 
preclinical studies. 
In addition, T levels were assessed in male mice plasma (n=6) collected from 
castrated wild-type, sham-operated and with genetic disruption of Srd5a1-/- 
(5αR1 KO). Figure 3.7A shows that T could not be detected following 
castration. In addition, T levels were higher in mice with genetic disruption of 
Srd5a1-/- (5αR1 KO) compared with wild-type male (sham-operated). Further 
comparison of T levels in female mice also showed that those with genetic 
disruption of Srd5a1 -/- mice had higher levels of T levels than wild-type 
controls. This fits with lack of metabolism by 5α-reductases. 
Group N T (nmol/L) Reference range T (ng/mL) [1] 
Male mice 20 0.9-3.1 1.3-6.9 
Female mice 6 0.1-0.3 0.05-1.6 




Figure 3.6: Correlation plot (A) and Bland Altman plot (B) of testosterone (T) 
for LC-MS/MS and IA. The percentage difference between values of two 
measurements ((LC-–S–MS - IA)/IA x 100) (D %); the horizontal lines are mean 
of D% and +1.96 stranded deviation (+1.96 SD) and – 1.96 standard deviation 








Figure 3.7: Histograms for T levels in male and female mice plasma (n=6), 
(A) showing lack of steroid in castrated wild-type (WTGDX). Levels of T were 
significantly higher (p=0.004) in male mice with genetic disruption of Srd5a1-
/- (KOSHAM) sham-operated compared with wild-type animals (WTSHAM) 
and likewise, (B) showing a significant increase (p=0.003) in female mice with 
genetic disruption of Srd5a1-/- (KO) than female wild type and Srd5a1 -/- 
mice (WT). Data are mean +/- SEM, (T) testosterone and (* p<0.01 vs wild-





In summary this approach allows robust measurement for T and A4 across 
typical physiological ranges found in pre- and post-menopausal women and 
men, contrasting with immunoassays and LC-MS/MS in humans, for which 
inaccurate measurements are often recorded in the lower physiological range 
of concentrations. This method could be extended for animal models to 
quantify T in small volumes (30-50µL). However, this method requires large 
volume (>0.5mL) for analysis of DHT. While further assessment of the 
validation criteria versus certified materials needed refined. Additional 
assessment of recovery and ion suppression using normal matrix as opposed 
to stripped matrix was introduced going forward to assess if this could 









Chapter 4: Derivatisation of androgens for 












Using UHPLC (Weng et al., 2010) and coupled with other technical 
innovations such as UHPLC-Q-Orbitrap (Ke et al., 2014), values for DHT 
concentrations are often below the LOD of analysis in human plasma and 
serum (Higashi et al., 2007a, Santa et al., 2007, Kalhorn et al., 2007, Tamae et 
al., 2013, Higashi, 2006). Thus, large plasma volumes (>500µL) are required for 
detection, undesirable clinically and unsuitable for animals. 
Derivatisation of the ketone or the hydroxyl group within the androgen (Santa, 
2011) may improve sensitivity by endowing the analyte with a chargeable or 
permanently charged group for analysis by MS, changing efficiency of 
ionisation, fragmentation and retention (Weng et al., 2010). LC-MS/MS 
methods using derivatisation often demonstrate improved LOQs: for example 
LOQs of derivatised steroids (T; 1, A4; 52, DHT; 2pg/mL) (Higashi et al., 
2005b, Shibayama et al., 2009, Regal et al., 2009) versus those of underivatised 
steroids (T; 10-50, A4; 100, DHT; 40pg/mL) (Higashi et al., 2007b, Higashi et 
al., 2005a, Faqehi et al., 2016). 
Previous derivatisation reagents employed for androgen analysis include 
picolinic acid, fusaric acid, isonicotinoyl azide, dansyl chloride, 
hydroxylamine, methoxylamine (Santa, 2011), FMP-TS (Santa, 2011, Faqehi et 
al., 2016). In addition, typical hydrazine-based reagents: 1-(carboxymethyl) 
pyridinium chloride hydrazide (Girard T), carboxymethyl 
trimethylammonium chloride hydrazide (Girard P) (Santa, 2011) and 2-
hydrazinopyridine have been used to increase sensitivity (Shibayama et al., 
2009, Regal et al., 2009).  Recently, further reagents were applied, namely HMP 
(Santa, 2011, Shibayama et al., 2009, Santa, 2013), and 2-hydrazino-4-
(trifluoromethyl)-pyrimidine (HTP) (Weng et al., 2010, Santa, 2011), but 
methods have not been fully validated or applied to biological samples. 
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HMP has a permanently charged moiety (quaternary ammonium) and its 
reaction with the oxo-steroids (e.g. T, DHT and DHEA) was used in LC-
MS/MS analysis from human prostatic tissue, rat serum and saliva (Santa, 
2011, Wei et al., 2019). However, HMP derivatives form several isomers, in 
some cases 4, and previous chromatographic methods have found difficulty in 
achieving resolution of all isomers from potential isobaric interferences. 
Specifically, the heavy isotope enriched isomers of T interfered with DHT 
analysis – a particular problem given the levels of T greatly exceed those of 
DHT, at least in plasma. Weng et al (Weng et al., 2010) proposed the use of 
HTP derivatives as an alternative since the isomers, while still forming, co-
elute and hence cause less chromatographic complexity.  
In this Chapter the hypothesis that derivatisation could be applied to improve 
assay sensitivity of androgens was explored. The particular aim was to 
overcome the chromatographic problems faced with the hydrazine derivatives 
and validate an analytical approach to detect low abundance DHT by 
derivatisation in plasma from men and post-menopausal women.  Validation 
was extended to further improve performance. 
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4.2 Materials and methods 
4.2.1 Standards and solvents 
4.2.1.1 Commercial sources 
Reagents were as listed in section 2.1. 
4.2.1.2 Synthesis of 2-hydrazino-1-methylpyridine (HMP) 
HMP is not commercially available and therefore was synthesised from FMP-
TS, using a method adapted from (Santa, 2011). Methanol (100mL) was placed 
in a flask (~0°C) and hydrazine monohydrate (65%w/v, 660µL) added, 
producing a colourless solution. FMP-TS (1.5g) was dissolved in methanol 
(30mL) and added dropwise, resulting in a yellow solution. The resultant 
solution was stirred (0°C, 15min), and then at room temperature (18-22°C, 
60min). The solution was concentrated under vacuum, generating an orange 
residue. The residue was re-dissolved in hot (DCM; 100mL) and heated (60°C) 
with dropwise addition of n-hexane (10mL) to produce a cloudy solution. This 
was clarified by heating the flask and then stored overnight (4°C, 48h). The 
product was filtered and crystallised twice as described above yielding needle-
like, colourless crystals which were stored at -20°C.  
4.2.2 Sources of biological samples 







High-sensitivity quantification were performed on a QTrap 5500 QQQ MS 
coupled to an Acquity™ Classic Ultra Performance LC, operated using 
Analyst software. Confirmation of accurate mass of HMP was performed by 
direct infusion into a 12 T SolariX dual source FT-ICR MS, operated with 
SolariX software. 
Structural elucidation and accurate mass for HMP fragment ions were 
confirmed by infusing into a high resolution MS (Synapt G2-Si MS), with an 
ESI ion source in positive mode. For structural elucidation by FTICR-MS, ions 
of accurate mass of HMP were confirmed in full scan (m/z 50-1200), 
electrospray (ESI) positive mode, with capillary voltage (4500V), nebuliser 
pressure (1.2bar) and source temperature (200°C). 
4.2.4 Standard solutions 
For the chromatographic assessment androgens (T, A4, DHT, DHA, DHEA 
and EpiT) and internal standards (IS; 13C3-T, 13C3-A4 and 13C3-DHT, 1mg) were 
individually dissolved in methanol (1mL) and stored at -20°C. Working 
solutions (100µg/mL-1pg/mL) were prepared by serial dilution on the day of 
use. Data were validated against certified solutions, when available. 
4.2.5 Generation of derivatives 
Reaction conditions for both derivatives were optimised to give those 
described below using solutions of androgen standards. Incubation 
temperature (25-80°C), time (5-120min) and reaction volume (100-1000µL) 
were evaluated for both derivatives. Formation of HMP and HTP derivatives 
was assessed following use of a range of reagent concentrations (0.1-2 and 




4.2.5.1 HMP derivatives 
HMP (100µL; 0.5mg/mL in methanol, containing FA (1% v/v)) was freshly 
prepared prior to reaction and added to standards (1ng)/sample extract and 
then vortexed (10s). Incubation was performed with HMP (60°C, 15min) and 
then solvents were evaporated under oxygen-free N2 (OFN; 60°C) before 
mobile phase (50µL) was added to quench the reaction (Santa, 2011).  
4.2.5.2 HTP derivatives 
HTP (100µL; 0.1mg/mL in acetonitrile, containing TFA (0.05%v/v)) was 
freshly prepared prior to reaction and added to standards (1ng)/sample 
extract and then vortexed (10s). Incubation was performed (60°C, 30min) and 
then the mixture cooled (ice bath, 5min). Solvents were evaporated under OFN 
(60°C) and HTP derivatives were reconstituted in mobile phase (50µL). 
4.2.6 MS tuning of derivatives for quantitation 
The precursor and product ions to be used for quantitative analysis of HMP 
and HTP derivatives of androgens were identified by tuning by direct infusion 
individually into a QTrap 5500 QQQ MS, operated in positive ion ESI mode 
with entrance potential (10V). Androgen derivatives (1µg/mL) were diluted 
1:10 in mobile phases as above (2.6). Precursor ions for HMP derivatives were 
selected as follows; analytes m/z 394 (T, DHA), m/z 392 (A4), m/z 396 (DHT), 
naturally occurring isomers m/z 394 (EpiT, DHEA) and internal standards, m/z 
397 (3C3-T), m/z 395 (13C3 -A4) and m/z 399 (13C3-DHT).  Precursor ions for HTP 
derivatives were selected as follows; analytes m/z 449 (T, DHA), m/z 447 (A4), 
m/z 451 (DHT), naturally occurring isomers m/z 449 (EpiT, DHEA) and internal 




Positive ESI source conditions were optimised to generate transitions with 
highest sensitivity of qualifier and quantifier ions. Optimised conditions are 
shown in Tables 4.1 and 4.2, established in conjunction with curtain gas (20, 
25mTorr), ion gas 1 (40, 45mTorr) and gas 2 (25, 20mTorr), collision gas 
(medium, high), ion spray (4500, 4000V) and temperature (650, 600°C) for 
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Table 4.1: Optimised tuning conditions for analysis of HMP derivatives of 
androgens. Voltage (V); testosterone (T), androstenedione (A4), 5α-
dihydrotestosterone (DHT), 5α-dihydroandrostanedione (DHA), 
epitestosterone (EpiT), dehydroepiandrosterone (DHEA), 2,3,4-13C3-
testosterone (13C3-T), 2,3,4-13C3-androstenedione (13C3-A4), 2,3,4-13C3-5α-
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Table 4.2: Optimised tuning conditions for analysis of HTP derivatives of 
androgens. Voltage (V); testosterone (T), androstenedione (A4), 5α-
dihydrotestosterone (DHT), 5α-dihydroandrostanedione (DHA), 
epitestosterone (EpiT), dehydroepiandrosterone (DHEA), 2,3,4-13C3-
testosterone (13C3-T), 2,3,4-13C3-androstenedione (13C3-A4), 2,3,4-13C3-5α-









4.2.6.1 Reduction of the HMP derivatives 
Reduction of HMP imines to restrict the number of chromatographic peaks 
was assessed using sodium triacetoxyborohydride and sodium borohydride. 
Reducing reagents (5µL; 4mg/mL in methanol) were freshly prepared and 
added to the HMP residues (10µg steroid equivalent). The mixture was 
vortexed (10s) then incubated (60°C, 15min). Solvent was evaporated (OFN, 
60°C) and the residue reconstituted in mobile phase (50µL) as above (4.2.6). 
Reducing conditions were evaluated including incubation temperature (25-
80°C), time (5-60min), reaction volume (5-200µL) and injection volume (1-
20µL). Potential reduced HMP derivatives were injected into the UHPLC-MS 
system and compared with unreduced derivatives. Molecular ions of reduced 
derivatives with a mass increment of 2 were monitored, predicted to elute as 
single peaks. 
4.2.7 Fragmentation analysis of derivatives of androgens 
For product ion characterisation by MS/MS at nominal mass, molecular ions 
of derivatives were isolated in Q1. Q3 was operated in the scanning mode m/z 
50 below and above the mass of the molecular ion under analysis. Conditions 
for MRM were optimised by autotuning, performed by infusion of 
representative androgen derivative solutions (100ng/mL).  
The identity of HMP derivatives was confirmed by accurate mass 
measurements using a Synapt G2-Si QTOF MS in resolution mode. Ions were 
isolated in full scan (m/z 50-1200) and ESI positive mode. Positive ESI source 
conditions were curtain gas (35mTorr), collision gas (40V), ion spray (3000V) 




4.2.8 Chromatographic conditions for resolution of androgen derivatives 
4.2.8.1 HMP derivatives 
The optimised chromatographic analysis over 10min for HMP derivatives 
separation was carried out on an Acquity UPLC® BEH C18 column (50  
2.1mm, 1.7µm, Waters Corporation, Milford, USA). The aqueous phase was 
ammonium acetate (5mM) and the organic phase (methanol:acetonitrile, 
50:50). Flow (0.5mL/min) was diverted to waste between 0-2 and 8-10min. The 
final method began with an initial highly aqueous solvent system (90 
aqueous:10 organic), sustained for 1min followed by a rapid gradient over 
1min to achieve 50:50 conditions. Then, a slower gradient was performed for 
5min to 45:55, followed by a rapid gradient to achieve 10:90, over 1min and 
sustained for 2min. The column and autosampler temperatures were 50°C and 
10°C respectively. Injection volume was 20µL in partial loop needle overfill 
mode. 
4.2.8.2 HTP derivatives 
Separation of HTP derivatives was performed on an Acquity UPLC® BEH C18 
column (150  2.1mm, 1.7µm, Waters Corporation, Milford, USA) with a total 
run time of 20min. Mobile phase comprised aqueous (ammonium acetate 
(5mM)) and organic (methanol:acetonitrile, 35:65). Flow (0.3mL/min) was 
diverted to waste between 0-10 and 18-20min. A highly aqueous solvent 
system (90 aqueous:10 organic) was sustained for 1min followed by a rapid 
gradient over 1min to achieve 40:60. Conditions were maintained for 10min, 
followed by a slow gradient for 5min to achieve a high organic phase 10:90, 




4.2.9 Extraction method  
Aliquots of male (100µL) and post-menopausal female plasma (200µL) were 
subject to centrifugation (8000g, 4°C, 20min). The volumes of the sample were 
adjusted with water to 1mL and enriched with internal standards (100pg). SPE 
using Oasis HLB (1CC/10mg, Waters) cartridges was performed under 
gravity. The cartridges were conditioned with methanol (1 mL) followed by 
water (1mL) before loading the IS enriched samples (1 mL). The cartridges 
were washed with methanol/water (5:95; v/v) methanol (1 mL) and steroids 
were eluted in methanol (1mL). Extracts were reduced to dryness under OFN 
(60°C) and the residues were derivatised as above (4.2.6). 
4.2.10 Assay validation of HMP derivatives 
4.2.10.1 Extraction efficiency  
Recoveries of IS from water and plasma were assessed by comparison of signal 
intensities, following extraction from samples pre- and post-spiked with IS 
(100pg; n=6) prior to derivatisation. Mean peak areas of derivatives following 
extraction in pre-spiked samples were divided by those in post-spiked 
samples and expressed as a percentage. 
4.2.10.2 Assessment of ion suppression  
Ion suppression of signals of derivatives in the presence of extracts of plasma 
was evaluated by comparing signal intensity of IS (100pg) post-spiked into 
extracted plasma with that of aqueous IS solutions of the same concentration 
(n=6). Mean peak areas of derivatives following extraction of steroids from 
post-spiked plasma were divided by mean peak areas of unextracted 
standards and expressed as a percentage. 
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4.2.10.3 Specificity  
MRM chromatograms were inspected close to the retention times of HMP 
derivatives for expanding the panel of possible interferences by other 
endogenous compounds in plasma such as DHEA and EpiT. The ratio of 
quantifier to qualifier ions of each HMP derivatives of IS was measured in 
extracts from plasma and compared with those of standards and accepted if 
within 20%. 
4.2.10.4 LODs and LOQs 
LODs and LOQs were assessed using extracts from aqueous standard 
solutions. Derivatives of androgens (10, 1ng and 100, 10, 1, 0.1pg) were 
analysed by LC-MS/MS and the Signal/Noise (SNR) calculated from peak 
areas of steroids and adjacent background noise, with matched time intervals. 
The LOD of standards was assigned as a SNR ~3. Replicate aliquots (10, 1 and 
0.1pg; n=6) of androgens and internal standards were subsequently prepared 
as above and the LOQ calculated as the concentration affording precision and 
accuracy of 20% or less.  
4.2.10.5 Linearity of response  
Extracts of blank samples (IS only) and aqueous aliquots containing androgens 
(1, 2.5, 5, 10, 25, 50, 100, 200pg) and internal standards (100pg) were analysed 
by LC-MS/MS. Calibration curves were plotted as the peak area ratio 
(standard/IS) versus amount of androgen. Calibration lines of best fit were 
acceptable if the regression coefficient, r, was >0.99. Weightings of 1, 1/x and 




4.2.10.6 Accuracy and precision of HMP derivatives 
Injector reproducibility was tested by re-injecting the same samples of 
standards (1, 50 and 200pg on column). The intra- and inter-assay precision 
and accuracy were assessed using 6 standard aliquots (1, 50 and 200pg) 
extracted from water and prepared on the same and different days 
respectively, alongside a standard curve (n=6). Aliquots of male (100µL) and 
post-menopausal female plasma (200µL) were extracted 6 times on the same 
day to assess precision. In addition, aliquots of male (100µL) and female 
plasma (200µL) from the NEQAS scheme for steroid hormones were also used 
in method validation. The data relating to T and A4 concentrations in these 
sample were compared by Bland-Altman analysis. Precision and accuracy 
were calculated as described in section 2.5. The bias (average inter-assay 
concentration - certified standard concentration X 100) of the calibrators was 
assessed against certified standards for T, A4 and DHT (Vesper et al., 2008, 
Kruve et al., 2015). 
4.2.10.7 Stability of HMP derivatives 
Stability following storage in the auto-sampler (10°C) was evaluated by 
reinjection of a calibration curve and plasma sample after 24 hours. Short-term 
storage in the freezer (-20 and -80°C) were assessed by injection after 24 hours, 
7 and 30 days storage. 
4.2.10.8 Method application for HMP derivatives 
T, A4  and DHT  were quantified in replicates (n=6) of human plasma from 
post-menopausal females and males using the validated approach. 
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4.3 Results and discussion 
4.3.1 Method development 
4.3.1.1 Synthesis of HMP 
HMP was synthesised successfully with a 65% (3.9 g) yield, using the adapted 
method. FTICR-MS analysis confirmed the presence of HMP product with 
m/z 124.0869, and a ppm of 2.4 from the theoretical mass (124.0872 amu; 
C6H10N3) (Figures 4.1A and B). 
 
Figure 4.1: (A) Synthetic reaction of HMP from FMP-TS; 2-fluoro-1-
methylpyridinium p-toluene sulfonate (FMP-TS) and 2-hydrazino-1-
methylpyridine (HMP) (B) Exact mass of HMP was confirmed by FTICR-MS 
analysis, HMP structural formula of C6H10N3 and the theoretical mass (i) m/z 




4.3.1.2 Development of derivatisation approach for HMP and HTP 
derivatives 
The anticipated reactions with HMP and HTP are shown in Figures 4.2 and 4.3 
respectively, yielding positively charged derivatives. APCI is often the 
method of choice for underivatised steroids, due to their low proton/electron 
capture (Grebe and Singh, 2011). However as in previous studies, more intense 
signals from ions of the derivatives were recorded with ESI compared with 
APCI (Santa, 2011), typical of species with pre-existing charge. 
4.3.1.2.1 Fragmentation of HMP derivatives 
The precursor ions of HMP derivatives were the expected molecular ions, m/z 
394 (T, EpiT, DHEA and DHA), m/z 392 (A4) and m/z 396 (DHT) (Figure 4.2) 
(Weng et al., 2010,  Santa, 2011, Shibayama et al., 2009). Fragmentation of the 
precursor ions generated two product ions of significant abundance resulting 
from 1-methylpyridinoamino moiety at m/z 109 [N-methylpyridine+NH2]+, 
(C6H9N2) for DHEA (with derivative formation on the D-Ring) and m/z 108 [N-
methylpyridine+NH]+, (C6H8N2) for all other A-ring derivatives (Table 4.1) 
(Shibayama et al., 2009). These ions were generated from the cleavage of the 
N-N bond of the hydrazone (Figure 4.2). HMP derivatisation for di-oxosteroids 
(A4 and DHA) was not as efficient as mono-oxosteroids (T, DHT, EpiT and 
DHEA) (Shibayama et al., 2009) due to formation of multiple products as 
opposed to just the bis-HMP derivative (Santa, 2011). Ultimately mono-HMP 
derivatives were selected and the nature of the product ions confirmed using 




Figure 4.2: Example of formation of steroid-HMP derivative, showing 
examples of derivatisation of DHT (A ring) and DHEA (D Ring) and putative 
fragmentation with product ions scans and confirmation using accurate mass 
data; difference (), 5α-dihydrotestosterone (DHT), dehydroepiandrosterone 





4.3.1.2.1 Fragmentation of HTP derivatives 
The precursor ions of HTP derivatives were the expected molecular ions, m/z 
449 (T, EpiT, DHEA and DHA), m/z 447 (A4) and m/z 451 (DHT) (Table 4.2) 
(Weng et al., 2010, Santa, 2011) . Fragmentation of the precursor ions generated 
two product ions of significant abundance at m/z 257 (C11H12N4F3) and m/z 269 
(C12H12N4F3) for T, A4 and EpiT resulting from the cleavage of the steroid A 
and B ring (Figure 4.3) (Weng et al., 2010). Product ions for DHT were 
monitored at m/z 288 (C19H30ON) and m/z 164 (C5H5N3F3) (Weng et al., 2010), 
whereas, m/z 286 (C19H28ON) and m/z 164 (C5H5N3F3) were selected for DHA 
and DHEA respectively. Heterolytic cleavage of hydrazine N-N bond of 
derivative may form ions at m/z 288 and m/z 286, and m/z 164 characterises the 
protonated trifluoromethyl-pyrimidine moiety (Weng et al., 2010). 
Stable-isotopically labelled for T, A4 and DHT corroborated potential 
fragmentation pathways (Figure 4.3). Importantly these product ions often 
included the section of the steroid which carried the labels in the IS, offering 
increased specificity in comparison to derivatives which fragment to yield a 
common (reagent derived) product ion. 
4.3.1.3 Optimisation of derivatisation conditions for HMP and HTP 
derivatives 
Reaction conditions to generate HMP and HTP derivatives were optimised as 
described (2.12.1). The efficiency of reaction was improved by increasing 
temperature from 25 to 60°C for both derivatives and reaction time to 15min 
(HMP) and 30min (HTP), but further improvement was not seen at higher 
temperatures or with longer incubations. Intensity of response was improved 
by decreasing the reaction volumes from 500 to 100µL for both reagents and 






Figure 4.3: Putative Fragmentation of HTP derivatives; testosterone (T), 
androstenedione (A4), 5α-dihydrotestosterone (DHT), 5α-
dihydroandrostanedione (DHA), epitestosterone (EpiT), 
dehydroepiandrosterone (DHEA), 2,3,4-13C3-testosterone (13C3-T), 2,3,4-13C3-




4.3.2 Chromatographic conditions 
4.3.2.1 HMP derivatives 
HMP derivatisation forms two E and Z isomers which elute as double peaks 
for each androgen (Santa, 2011), creating chromatographic complexity. In this 
study, the challenge was to separate ten peaks or more for HMP derivatives 
(androgens and endogenous isomers) by chromatography. To overcome 
chromatographic complexity, initially reduction of the imines using sodium 
triacetoxyborohydride and sodium borohydride was assessed. The principle 
of this approach was to generate a single chromatographic peak but proved 
unsuccessful. While this concept still has potential, chromatographic 
separation of isomers was pursued, aiming to quantify using the more intense 
isomeric peak for each analyte. 
Chromatographic analyses were developed using several C18 columns with 
modified stationary phases, particle sizes and dimensions, following 
significant efforts in method development. SunFire® C18 (2.1mm x 150mm, 
3.5μm), ACE® Excel PFP-C18 (2.1mm x 100mm, 3.5μm), ACE® UltraCore 2.5 
SuperC18 (2.1mm x 150mm, 2.5μm), ACE® Excel super C18 (2.1mm x 150mm, 
2μm), Acquity UPLC® BEH C18 (2.1mm x 150mm, 1.7μm) and Acquity UPLC® 
BEH C18 (2.1mm x 50mm, 1.7μm) were evaluated aiming to achieve baseline 
resolution of isomers and isotopologues within reasonable analytical times. 
HPLC methodology was transferred to a UHPLC column to reduce method 
time. Optimal results were achieved with a gradient programme and flow 
rates of 0.5mL/min and temperatures of 50°C and binary organic solvents 





Chromatographic separation of most analytes was achieved in a short time 
frame (10min) using a UPLC® BEH C18 (2.1mm x 50mm, 1.7μm) column 
however, DHT and T peaks continued to have co-eluting peaks, although one 
peak of each was distinct, allowing selective quantification. A beneficial effect 
of adjusting acetonitrile/methanol proportion on peak separation was 
observed and may be due to acetonitrile influencing -  and/or dipole-dipole 
interactions between the analyte and the column stationary phase (Yang et al., 
2005, Croes et al., 2005). 
Ultimately rapid chromatographic separation was achieved between 
individual isomers of HMP derivatives of each androgen and its endogenous 
isomers allowing total run times of only 10min (Figure 4.4A). At least one of 
the analyte’s isomeric peaks could be used for quantitation without 
interference from isobaric interferents. It is important to note, this approach 
therefore relies on equity in the proportions of the isomers with every reaction 
and between standards and biological samples. 
Figure 4.5 i, ii and iii show the peaks selected for quantitation, where notably 
the earlier peak for T-HMP was distinct from the later peak DHT-HMP. A4-
HMP isotopologues had potential to interfere with T analysis but again were 
carefully chromatographically resolved. At early and late time points the flow 
was diverted to waste and a rapid increasing organic gradient was employed 
latterly; both strategies employed aimed to minimise build-up of 
derivatisation reagent on the column and in the source, required for 







4.3.2.2 HTP derivatives 
Single peaks were observed for each HTP-analyte as reported previously 
(Weng et al., 2010, Santa, 2011), offering a simpler chromatographic challenge 
than HMP. Baseline resolution between HTP derivatives of androgens and 
their endogenous isomers was most readily achieved using a C18 UPLC 
column (2.1mm x 150mm, 1.7μm) and gradient solvent method. Typical 
retention times for HTP derivatives of T, DHT, and A4 were 13.1, 13.5 and 
14.8min respectively (Figure 4.4B) and so the run-time was somewhat longer 
than for HMP derivatives. Similar cleaning strategies were employed to the 
HMP method. While run time might be reduced further, the LOQs of each 
derivative were first compared to identify the superior approach for 
development. 
4.3.3 Comparison of LOD and LOQ of derivatives 
LODs for HMP derivatives were 0.2, 0.4 and 0.2pg and the LOQs were 0.4, 0.8 
and 0.5pg on column for DHT, T and A4 respectively. Thus, LOQs were 
improved ~250-fold, ~10-fold and ~1.5-fold for HMP-DHT, HMP-T and HMP-
A4 respectively in comparison to an LC-MS/MS method for underivatised 
androgens which was developed in Chapter 3 (Table 3.7) and better than other 
methods reported previously. Using this method, similar sensitivity was 
achieved however for HMP-A4 as that seen without derivatisation. Higher 
LODs were determined for HTP derivatives (40, 21 and 52pg on column) and 
LOQs were 96, 54 and 83pg on column for DHT, T and A4 respectively. 
Therefore, owing to the higher sensitivity, the HMP derivative method was 
selected for validation and application, despite the more challenging 





4.3.3 Extraction of androgens and assessment of ion suppression 
The lipophilic polymeric adsorbent, Oasis®, was selected again for extraction 
of androgens (Shibayama et al., 2009). Here, rather than in Chapter 3 the 
labelled steroids were used as surrogates in combination with matrix as 
opposed to analytes and stripped matrix, in an attempt to better assess 
extraction. There is no perfect approach due to a lack of steroid-free matrix. As 
in Chapter 3, indices of recovery, using the adjusted sample volumes and with 
the revised methods, met high standards; excellent recoveries were 
demonstrated (>90%), assessing recovery from water initially (mean ±RSD; T 
97±4%, A4 96±8%, DHT 96±7%, 13C3T 97±9%, 13C3T 99±1% and 13C2DHT 
98±5%). Ion suppression in the plasma extracts was minimal and high 
recoveries from matrix were sustained (mean ±RSD; 13C3T 87±2%, 13C3T 89±2% 




Figure 4.4: Mass chromatograms of quantifier mass transitions of HMP and HTP derivatives; A) HMP (DHT-HMP m/z 
396→108; T-HMP m/z 394→108; A4-HMP m/z 392→108; DHA-HMP m/z 394→108; EpiT-HMP m/z 394→108; DHEA-HMP m/z 
394→109) and B) HTP (DHT-HTP m/z 451→288; T-HTP m/z 449→257; A4-HTP m/z 447→269; DHA-HTP m/z 449→286; EpiT-
HTP m/z 449→257; DHEA-HTP m/z 449→286), testosterone (T), androstenedione (A4), 5α-dihydrotestosterone (DHT), 5α-
dihydroandrostanedione (DHA), epitestosterone (EpiT), dehydroepiandrosterone (DHEA), 2-hydrazino-1-methylpyridine 





Figure 4.5: Retention times of quantifier mass transitions of HMP 
derivatives; i) DHT-HMP (4.9min), ii) T-HMP (4.6min) and iii) A4-HMP 
(5.1min), testosterone (T), androstenedione (A4), 5α-dihydrotestosterone 










4.3.4 Assay validation 
4.3.4.2 Linearity of HMP derivatives 
13C3 labeled androgens were selected as internal standards, since loss of 
deuterium may happen during derivatisation, particularly from the A-ring. 
Standard curves of androgen HMP derivatives from aqueous standards were 
generated in the range 1-200pg with acceptable linearity and a mean r value of 
0.9953. Best fit using weighting of 1/x was applied, minimizing bias at low 
concentrations and yielding a mean intercept of 0.0017. In order to increase 
confidence in the accuracy of the data, given some variation against NEQAS 
data in Chapter 3, accuracy of calibration data was compared with certified 
reference material for T, A4 and DHT. The bias was greater at low 
concentrations than high concentrations on the calibration curves, particularly 
with T, but acceptable within the predicted reference range (Table 4.3). 
Amount (pg) 
Bias (%) 
T A4 DHT 
5 36 10 18 
10 21 15 8 
20 11 5 16 
40 14 5 2 
50 14 11 6 
100 5 3 8 
200 2 4 3 
Table 4.3: Bias of the calibrators against certified standards for T, A4 and 








4.3.4.3 Specificity of HMP derivatives 
The ratio of peak areas of quantifier to qualifier mass transitions for HMP 
derivatives was monitored in plasma and standards to ensure specificity. The 
ratios in standards (T 2.1, A4 1.9, DHT 2.0, 13C3T 1.7, 13C3A4 1.8, and 13C3DHT 
2.7), were comparable to those in plasma, showing differences less than 20% 
(T 11%, A4 13%, DHT 14%, 13C3T 16%, 13C3 A4 18%, and 13C3 DHT 17%). 
Chromatographic separation for DHT-HMP derivatives and their endogenous 
isomers was achieved thus achieving the goal of eliminating known analytical 




Figure 4.6: Mass chromatograms of quantifier mass transitions of DHT-HMP and internal standard 13C3-DHT-HMP 
derivatives in males (A and B) and post-menopausal females (C and D); (DHT-HMP m/z 396→108), (13C3-DHT-HMP m/z 
399→108); 5α-dihydrotestosterone (DHT), 2,3,4-13C3-5α-dihydrotestosterone (13C3-DHT), 2-hydrazino-1-methylpyridine 
(HMP) and counts per second (cps). 
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4.3.4.4 Precision and accuracy of HMP derivatives 
The values of intra- and inter-assay precision and accuracy for measurements 
were acceptable (<20% RSD for precision and <±20% accuracy at the LOQ of 
1pg (Table 4.4) and <15% above this value) for extracts from water, NEQAS 
plasma, post-menopausal females and male plasma. Acceptable injector 
reproducibility of HMP derivatives upon repeat injection of the same samples 
of standards at (1pg) was demonstrated with higher RSD however; T (12%), 
A4 (14%) and DHT (13%) in comparison to an LC-MS/MS method for 
underivatised androgens which was developed in Chapter 3. 
The concentrations of T and A4 measured following derivatisation were 
compared with data previously collated by NEQAS using LC-MS/MS. 
Correlation plots (Figure 4.7A and B) shows agreement for T and A4 between 
methods. Unfortunately, NEQAS data were not available for DHT. The 
correlation coefficients between concentrations measured by NEQAS and LC-
MS/MS was 0.979 for T, similar to the underivatized method in Chapter 3. 
However, a substantially higher correlation coefficient (0.954) for derivatised 
A4 was observed in comparison to the LC-MS/MS method for underivatised 
A4. 
Bland Altman plots (Figure 4.7 C and D) shows the percentage difference (D%) 
between the in-house LC-MS/MS method and NEQAS measurements and 
most data points fell within ±1.96 SD of D%. T concentrations measured with 
in-house LC-MS/MS were generally higher than the previous NEQAS data 
and lower for A4. These variations between methods could be related to 
various ion suppression between the more efficient clean up step in-house 






Low (1pg) Middle (50pg) High (200pg) 
Analyte T A4 DHT T A4 DHT T A4 DHT 
Precision (%RSD) (n=6) 
Intra-assay 6 8 7 2 2 3 2 1 1 
Inter-assay 10 11 12 5 4 5 7 6 2 
Accuracy (%RME) (n=6) 
Intra-assay 9 10 10 4 5 6 3 2 1 
Inter-assay 13 14 15 7 8 10 7 6 5 
Precision (%RSD) (n=6) 
Human 
plasma 
Male Post-menopausal female 
Analyte T A4 DHT T A4 DHT 
Intra-assay 3 3 4 4 4 5 
Inter-assay 8 7 9 9 8 10 
 Accuracy (%RME) (n=6)             Precision (%RSD) (n=6) 
NEQAS 
plasma* 
Male Female Male Female 
Analyte T A4 T A4 T A4 T A4 
Intra-assay 8 15 15 20 12 11 13 13 
Table 4.4: Precision and accuracy of androgens HMP derivatives analysis. 
DHT data not available from NEQAS (*), Testosterone (T), androstenedione 
(A4), 5α-dihydrotestosterone (DHT), Relative Standard Deviation (RSD), 





Figure 4.7: Correlation and (──) regression lines (A, B) and Bland Altman plots (C,D) of concentrations of testosterone (T) 
and androstenedione (A4) HMP derivatives in plasma measured by in-house LC-MS/MS and national quality control 
scheme (NEQAS). The percentage difference between values of two measurements ((in-house LC-MS/MS- 
NEQAS)/NEQAS x 100) (D%); the horizontal lines are mean of D%; +1.96 standard deviation (+1.96 SD) and –1.96 standard 
deviation (-1.96 SD). 
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4.3.4.5 Stability of HMP derivatives 
The HMP derivatives demonstrated acceptable stability upon storage in an 
auto-sampler (10°C) over 24h, with limited degradation measured for 
derivatised T (9%, 8%), A4 (5%, 6%) and DHT (8%, 7%) in extracts of samples 
from male and post-menopausal female, respectively. The values were similar 
to those in Chapter 3, providing reassurance that the derivative did not reduce 
the robustness of the assay in this aspect.  
Derivatives were stable upon short-term storage in the freezer (-20 and -80°C, 
respectively) for 7days; reduction from original response T (5%,4%), A4 
(8%,7%) and DHT (9%,8%) in male and T (4%,5%), A4 (7%,8%) and DHT 
(8%,9%) in post-menopausal female. Moreover, derivatives were stable upon 
long-term storage in the freezer (-20 and -80°C, respectively) for 30 days; 
reduction from original response T (4%,3%), A4 (7%,6%) and DHT (8%, 7%) in 
male and T (3%,4%), A4 (6%,7%) and DHT (7%,8%) in post-menopausal 
female. 
4.3.5 Method application 
The method was applied to samples from post-menopausal females and males 
and compared to reported reference ranges (Table 4.5) (Kulle et al., 2010). All 
concentrations were within the quantitation limits of the assay (1-200pg) on 
column. In contrast to Chapter 3, the goal of detecting DHT is workable 
quantities of plasma was achieved. In post-menopausal females, 200µL of 
plasma was required to ensure reliable detection of DHT, whereas 100µL was 
required of plasma from males. In the dynamic research setting, frequent 
sampling can happen, with limitations on bloodletting so it is useful to be able 
to make measurements in limited sample volumes. Using smaller volumes of 
sample also offers the advantage of a cleaner extract, less build up on the 
instrument, smaller SPE cartridges, therefore, less cost and time.  
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T and A4 could only be quantified in 20µL samples in males, while 200µL were 
required from post-menopausal females. These value for A4 were similar to 
those in the LC-MS/MS method for underivatised androgens which was 
developed in Chapter 3, the limitation being A4 whose sensitivity was not 
boosted by derivatisation. 500µL of male serum had been previously required 
to detect underivatised DHT in male plasma which is undesirable clinically 
and unsuitable for animals (Ke et al., 2014) whereas 300µL of male rat plasma 
and larger volumes had been used to quantify underivatised T and DHT 
(Kalhorn et al., 2007). A 2-dimensional LC system allowed online purification 
and separation prior to quantitation of T and A4 in 100µL human adult male 
serum (Higashi et al., 2005b) and for DHT in 300µL human adult male and 
female serum (Kalhorn et al., 2007). However, on-line solid phase extraction 
SPE (Salvador et al., 2007) is not commonly available, although undoubtably 
achieves high performance. 
The volumes and LOQs determined here also compared well with previous 
literature when derivatives of DHT were used for LC-MS/MS analysis and the 
HMP derivative had the additional advantage of product ions incorporating 
aspects of the steroid moiety, an advantage for specificity. Volumes of serum 
or plasma from human and even mice in previous MS methods (Janzen et al., 
2008, Kulle et al., 2010, Weng et al., 2010, Santa, 2011, Ke et al., 2014, Zang et 
al., 2017) were 100-500µL with LOQs 1–10pg on column. For example, Ke et al. 
used 500µL of human serum to detect dansyl DHT, while Zang et al. used 
200µL of human serum for quantification of DHT-picolinate with LOQ of 10pg 
(5pg/mL) and 2.5pg (0.5pg/mL) respectively (Ke et al., 2014, Zang et al., 2017). 
An oxime formed with DHT and Girard-T permitting a LOQ of 1pg on column 
was developed requiring 200µL of human serum (Shibayama et al., 2009) 
similarly as FMP-DHT derivatives with LOQ 20pg (4pg/mL) (O'Brien et al., 
2009). DHT-hydroxylamine derivatives were analysed with LOQ 15pg 
(1.5pg/mL) in 100µL of male serum (Borrey et al., 2007). Weng et al reported 
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LOQ 5pg (0.5pg/mL) for DHT, requiring 100µL of male and female mice 








T A4 DHT T A4 DHT 




42 58-60 0.4-1.1 0.7-2.3 0.1-1 0.2-1.9 0.5-2.9 0.1-1.2 
Table 4.5: Concentrations of androgens in plasma from males and post-
menopausal females. testosterone (T), androstenedione (A4), 5α-
dihydrotestosterone (DHT), (1) (Kratz and Lewandrowski, 1998) and (2) 






In summary derivatisation to form HMP derivatives of androgens, in 
conjunction with LC-MS/MS, is suitable for quantitative analysis of 
androgens in low abundance in biological fluids and in rodent models with 
low plasma volumes, offering clear advantages in sensitivity over analysis of 
underivatised steroids. It is important to note that further advances in 
instrumentation have taken place in the last decade likely meaning the LOQs 
could be improved 10-fold should a cutting-edge platform be applied and this 
may allow serial samples in rodents.  
The approach allows concomitant analysis of T, A4 and DHT and this method 
may be extended to include further steroids with ketone functions (e.g. 11-
oxygenated androgens) (Turcu and Auchus, 2017). The derivatisation reaction 
may be more suited to mono-oxosteroids than di-oxosteroids, as analysis of 
A4-HMP offered similar sensitivity to underivatised A4. Robust measurement 
was achieved across typical physiological ranges found in post-menopausal 
women and men offering an attractive alternative to immunoassays, which 
lack specificity in the lower physiological range of concentrations (Grebe and 
Singh, 2011) and typically report only one androgen. Given the success of this 
approach, in the next Chapter derivatisation was applied to improve the 














The previous Chapters have addressed analytical challenges measuring 
circulating androgens, but the picture of sex steroid biology needs a 
concomitant assessment of estrogens in both sexes. Analysis of endogenous 
estrogens is possibly even more challenging due to their extremely low 
concentrations, even lower than DHT e.g. E2 circulates in concentrations less 
than 20pg/mL (<184pmol/L)  in men (Kratz and Lewandrowski, 1998) and 2-
21pg/mL (7-77pmol/L) in postmenopausal women (Kushnir et al., 2008). 
Moreover, again their levels reduce with age and in some diseases e.g. CVD 
(Arnlöv et al., 2006) and type 2 diabetes (Bray, 2003). Although immunoassays 
have been widely use to quantify across the range of circulating concentrations 
of E1; 55-740pmol/L (Kratz and Lewandrowski, 1998) and E2; 118-915pmol/L 
(Stricker et al., 2006), specificity is once again challenging due to interference 
from endogenous isomers and other steroids in the biological matrix (Grebe 
and Singh, 2011). In addition, none of the commercially existing methods have 
satisfactory sensitivity and selectivity for use in older menopausal female 
subjects, in whom levels are lowest (Grebe and Singh, 2011, Gao et al., 2015) 
Pedrouzo et al., 2009). 
The field is once again turning to LC-MS/MS as an alternative analytical 
method of high specificity and indeed this is already replacing immunoassays 
in the analysis of other steroids routinely monitored in clinical practice, e.g. T 
and cortisol (Grebe and Singh, 2011). However, even with MS/MS coupled to 
UHPLC (Gao et al., 2015, Pedrouzo et al., 2009), estrogens are often present in 
concentrations below the LOD of analysis in human plasma and serum. In 
Chapter 3, methods to recover androgens and estrogens in different fractions 
of the same sample were attempted to allow profiling without large volumes 
of biological samples, but these were not efficient. 
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While instrument performance is always improving (and indeed did during 
the duration of this thesis), derivatisation may hold the key to improve 
sensitivity, as with androgens and may always offer gains over the current 
technical state-of-play. LC-MS methods have been reported for underivatised 
and derivatised estrogens, with the latter demonstrating improved limits of 
quantitation (LOQs): for example LOQs of underivatised steroids (E1; 15, E2; 
20pg/mL) (Kratz and Lewandrowski, 1998)versus those of derivatised 
steroids (E1; 1, E2; 0.5pg/mL) (Kushnir et al., 2008). Endogenous estrogens 
have ketone, hydroxyl and phenolic functional groups suitable for targeting 
by derivatisation reagents (Grebe and Singh, 2011, Wang et al., 2015, Wooding 
et al., 2015). 
Previous derivatisation reagents employed include dansyl chloride (Wooding 
et al., 2015, (Anari et al., 2002, Kushnir et al., 2010b, Lin et al., 2007, Li et al., 
2005, Chang et al., 2010), 1,2-dimethylimidazole-4-sulfonyl chloride, pyridine-
3-sulfonyl chloride, 4-(1H-pyrazol-1-yl)benzenesulfonyl chloride (Li et al., 
2005), p-nitrobenzoyl chloride  (Nelson et al., 2004), N-methyl-nicotinic acid N-
hydroxysuccinimide ester  (Xu and Spink, 2008)and 2-hydrazino-1-
methylpyridine (Wang et al., 2015). Reaction of the phenolic hydroxyl with a 
secondary amine moiety of dansyl chloride via nucleophilic aromatic 
substitution has been a common approach (Wooding et al., 2015, Anari et al., 
2002, Kushnir et al., 2010b, Lin et al., 2007, Li et al., 2005, Chang et al., 2010), 
but a disadvantage for MS/MS is that the product ion of the derivatised 
species is generated by the derivative moiety and hence not specific for the 
analyte by mass. Thus, natural mass+2 isotopomers of E1 may generate a 
background signal within the mass transition of the E2 derivative (Wooding 




Some of these problems can be averted by chromatographic separation (e.g. 
separation of 17β-E2 from its endogenous inert 17α-isomer isomer) but 
confounding interference can still arise from unknown estrogen metabolites 
or from applications in vivo tracers and stable isotope labelled estrogens used 
as internal standards, where enrichment often yields species of 2 mass units 
higher. Therefore, a derivative generating analyte-specific precursor and 
product ion is desirable to allow greater distinction from background 
interference (Grebe and Singh, 2011, Wooding et al., 2015, Anari et al., 2002) 
and permit more rapid chromatography. This may be achieved by using FMP-
TS (Figure 5.1) which has been used previously to detect estrogens in water 
(Anari et al., 2002) and commercially available human and bovine serum 
(Yang et al., 2008). 
This chapter was aimed to establish an analytical approach using a 
methylpyridinium derivative of estrogens to detect these hormones in low 
abundance in human plasma and, in particular, to evaluate if the approach 
could quantify circulating steroids in post-menopausal females. A highly 
sensitive method with lower LOQs than previous methods was validated 
using ion-exchange solid phase extraction in conjunction with LC-MS/MS. 
 
Figure 5.1: Formation of methylpyridinium ether derivative of phenolic 
estrogens, showing an example of derivatisation of an estrogen with 2-fluoro-




5.2 Materials and methods 
5.2.1 Standards and solvents 
Reagents were as listed in section 2.1. 
5.2.2 Instrumentation 
Instruments were as listed in section 2.3. 
5.2.3 Generation of FMP derivatives 
FMP-TS (50µL; 5mg/mL in acetonitrile, containing TEA (1%)) was freshly 
prepared prior to reaction and added to the standard/extract. The mixture 
was vortexed (10s) then incubated (40°C, 15min). Mobile phase (water: 
methanol 65:35), containing FA (0.1%, 50µL) was added to quench the reaction. 
5.2.4 Fragmentation analysis of FMP derivatives of estrogens 
For product ion characterisation by MS/MS at nominal mass, molecular ions 
of derivatives were isolated by Q1 and subjected to CID in Q2 (50eV E1, 55eV 
E2) using a TSQ Quantum. Q3 was operated in the scanning mode from m/z 
100 to m/z 50 above the mass of the molecular ion under analysis. Conditions 
for MRM were optimised by autotuning, performed by manual infusion of 
representative E1 and E2 derivative solutions (50ng/mL). Collision energy 
was optimised to achieve a suitable fragmentation for each transition. For 
structural elucidation by FTICR-MS, ions of accurate mass (m/z 250-1500) were 





5.2.5 MS tuning of derivatives for quantitation 
At a later stage, estrogen FMP derivatives were tuned by direct infusion into 
a QTrap 5500 MS, operated as a QQQ in positive ESI mode; this instrument 
became available during this thesis and offered advantages for sensitivity. 
Estrogen FMP derivatives (1µg/mL) were diluted 1:10 in mobile phase (water: 
methanol 65:35), containing FA (0.1%). Precursor ions for the derivatives were 
selected; m/z 362 for E1 and m/z 364 for E2 and 17αE2 (a naturally occurring 
isomer). Auto-optimisation was carried out for each compound and potential 
transitions were determined. Conditions in the positive ESI source were 
optimised to yield transitions achieving maximal sensitivity for detection of 
quantifier and qualifier ions. Optimised conditions are given in Table 5.1, used 
in conjunction with curtain gas (25mTorr), collision gas (medium), ion spray 






















238* 57 10 
136 10 
252$ 57 10 
E2 364 
128* 19 18 
51 10 
110$ 39 10 
13C2E1 364 
240* 55 10 
61 10 
254$ 57 12 
13C2E2 366 
130* 63 28 
76 10 




240* 59 22 
81 10 
254$ 57 24 
d4E2 368 
130* 39 14 
56 10 
111$ 23 10 
Table 5.1: Optimised tuning conditions for analysis of methylpyridinium 
derivatives of estrogens. Voltage (V); estrone (E1); estradiol (E2); 3,4-[13C]2-
estrone (13C2E1); 2,4,16,16-[2H]4-estrone (d4E1);  3,4-[13C]2-estradiol (13C2E2); 
2,4,16,16-[2H]4-estradiol (d4E2); quantifier (*) and qualifier ($). 
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5.2.6 Chromatographic conditions 
Chromatographic analysis was optimised using an Acquity UPLC® BEH C18 
column (50  2.1mm, 1.7µm Waters Corporation, Milford, USA), linked to the 
QTrap 5500 MS. An isocratic solvent system of water: methanol (65:35), 
containing FA (0.1%, 0.4mL/min) was diverted to waste until 2min and 
maintained for 6min followed by a rapid gradient executed over 2min with 
until final conditions of water: methanol (5:95), containing FA (0.1%, 
0.4mL/min) were achieved. The column and autosampler temperatures were 
25°C and 10°C respectively. Injection volume was 20µL in partial loop mode 
with needle overfill. 
5.2.7 Extraction method 
Aliquots of pre-menopausal female serum (0.5mL), post-menopausal female 
plasma (2mL) and male plasma (1mL) were subject to centrifugation for 20min 
(8000g, 4°C) and sediment removed. The volumes were adjusted to 2mL with 
water and internal standards (200pg) added. SPE using Oasis MCX 
(3CC/60mg, Waters) extraction cartridges was performed under gravity. The 
cartridges were conditioned with methanol (2mL) followed by water (2mL) 
before loading samples (2mL). The cartridges were washed with FA (2%v/v, 
2mL) and then steroids eluted in methanol (2mL). Extracts were reduced to 
dryness under oxygen-free nitrogen (40°C) and the residues were derivatised 
as above. 
5.2.8 Assay validation 
5.2.8.1 Optimisation of derivatisation conditions  
Reaction conditions were optimised first using aqueous extracts and then 
extracts of plasma. Conditions evaluated were incubation temperature (25-




5.2.8.2 Extraction efficiency 
Recoveries of IS from water and plasma were assessed by comparison of signal 
intensities, following extraction from samples pre- and post-spiked with IS 
(200pg; n=6). Mean peak areas of derivatives following extraction in pre-
spiked samples were divided by those in post-spiked samples and expressed 
as a percentage. 
5.2.8.3 Specificity 
Mass chromatograms were inspected at the retention times of analytes for 
possible interferences by other endogenous compounds in plasma such as 
17αE2. The ratio of quantifier to qualifier ions of each analyte of IS were 
measured in extracts from plasma and compared with those of standards and 
accepted if within 20%. 
5.2.8.4 Limit of detection (LOD) 
Estrogens (100, 10, 1ng and 100, 10, 1, 0.1pg) were analysed by LC-MS/MS and 
the Signal/Noise (SNR) calculated from peak areas of steroids and adjacent 
background noise. The LOD was assigned as a SNR ~3. 
5.2.8.5 Linearity 
Blank samples and aliquots containing estrogens (1, 2.5, 5, 10, 25, 50, 100, 200, 
400pg) and internal standards (200pg) were analysed by LC-MS/MS. 
Calibration curves were plotted as the peak area ratio (standard/IS) versus 
amount of estrogens. Calibration lines of best fit were acceptable if the 




5.2.8.6 Limit of quantitation (LOQ) 
Replicate aliquots (100, 10, 1ng and 100, 10, 1, 0.1pg; n=6) of estrogens and 
internal standards were prepared as above and analysed. The LOQ was 
calculated as that concentration affording precision and accuracy of ~20% or 
less. 
5.2.8.7 Accuracy and precision 
Injector reproducibility was tested by injecting the same samples of standards 
(1, 50, 400pg). Aliquots of male and female plasma (1mL) were extracted 6 
times on the same day on two occasions. The intra- and inter-assay precision 
and accuracy were assessed using 6 samples (1, 50 and 400pg) prepared on the 
same day and different days respectively, alongside a standard curve (n=6). 
5.2.8.8 Stability 
Stability following storage in the auto-sampler (10°C) was evaluated by 
reinjection of a calibration curve and plasma sample after 24 hours. Short-term 
storage in the freezer (-20 and -80°C) were assessed by injection after 24 and 
48 hours and 28 days storage. 
5.2.8.9 Method Application 
E2 and E1 were quantified in human serum from pre- and plasma from post-
menopausal females and males using the validated approach. The data 
relating to E2 concentrations in pre-menopausal women were compared with 
values obtained by immunoassay at the local routine hospital laboratory, 
Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh UK. 
Menstrual cycle timing had not been recorded. 
5.2.8.10 Data Analysis 
Data was analysed as described in section 2.5. 
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5.3 Results and Discussion 
5.3.1 Method development 
5.3.1.1 Development of derivatisation approach 
The anticipated reaction is shown in Figure 5.1, yielding a positively charged 
derivative. More intense signals from ions were measured with ESI compared 
with APCI, again typical of species with pre-existing charge and as seen for 
androgens in Chapter 4. The precursor ions of the derivatives were the 
expected molecular ions, m/z 362 and 364, respectively. However, after CID 
experiments, product ion spectra of E1 and E2 FMP differed from each other 
and showed an unexpected fragmentation pattern compared with other 
estrogen derivatives such as dansyl chloride (Anari et al., 2002, Lin et al., 2007, 
Li et al., 2005, Chang et al., 2010); the product ion (m/z 110) representing the 
derivatisation group for both steroids did not dominate (Figure 5.2).  
Stable-isotopically labelled estrogens were used to elucidate potential 
fragmentation pathways and the nature of both quantifier and qualifier ions 
proposed, based on a mechanism including α-β cleavages, retro-Diels-Alder, 
methyl migration and hydrogen shift (Mc Lafferty +1 reaction) (Beinhauer et 
al., 2015)(Figures 5.3 and 5.4). High CID at 50eV of the m/z 362 ion formed by 
E1-FMP generated two product ions of significant abundance at m/z 252 and 
238. These masses demonstrated an increment by +2 to m/z 254 and 240 for 
both d4-E1 and 13C2-E1 respectively, suggesting the presence of the A ring in 
the fragment but loss of the steroidal D ring (with 2 deuteriums on C16). The 
formation of m/z 252 was proposed to be a charge-remote concerted 
mechanism involving the elimination of CO as neutral loss before methyl 
migration from the 13C to the C16 position in the steroid ring, followed by loss 
of [C6H10]+ via a four-centre concerted mechanism after α-cleavage of the C14-
C15 bond. This may result in potential isomeric structures through the double 
bond at C9. 
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The product ion at m/z 238 was proposed to form by loss of CH2 (as a radical 
cation) from C9, again creating two possible isomeric structures. FTICR-MS 
analysis confirmed the structural formulae of the product ions of m/z 
252.13821 and 238.12260 within 0.3 and 0.2ppm of the theoretical masses 
(252.13829 and 238.12264 amu; C17H18ON, C16H16ON structural formulae, 
respectively). Similarly, for 13C2-E1, masses of the product ions (m/z 254.15090 
and 240.13509) were within 0.2 and 0.4ppm of the theoretical masses 
(254.15084 and 240.13519 amu; 13C2-C15H18ON, 13C2-C14H16ON structural 
formulae, respectively). 
Conversely, CID experiments carried out at 55eV on the FMP-E2 precursor ion 
at m/z 364 generated two product ions of significant abundance but with lower 
mass, at m/z 128 and 110, which underwent a mass increment to m/z 130 and 
111, respectively for d4-FMP-E2. 13C2- FMP-E2 in contrast generated product 
ions of m/z 130 and 110. The product ion at m/z 110 was assumed to derive 
from the derivatisation tag, proposed to form by β-cleavage of the ether bond 
at C4 followed by a proton migration via a (four or six) centre concerted 
mechanism from either C2 or C4 of the steroid moiety. Therefore, in analysis of 
d4-FMP-E2, an A-ring deuterium may migrate, generating a product ion of 
m/z 111. In contrast, the product ion at m/z 128 was proposed to form from the 
steroid moiety, incorporating the A-ring (and hence two deuteriums or two 
13C atoms). The mechanism may be a charge-remote concerted mechanism 
causing dehydration of the secondary alcohol at C17 with further β-cleavage of 
the ether bond at C4 followed by a retro-Diels-Alder concerted mechanism, 
resulting in two possible conjugated isomers. Due to the lower masses of the 
product ions, further confirmation could not be obtained by FTICR-MS. The 
differences in behaviour between the E1-FMP and E2-FMP fragmentation may 
relate to the unique stabilisation of the conjugated system of the E1 related 




Accordingly, distinct quantifier ions, derived from the steroidal structure, 
were selected (Table 5.1) for E1 and E2 derivatives. Use of m/z 128 as the 
quantifier ion for E2- FMP, as opposed to m/z 110, allowed distinction between 
analyte and A-ring labelled estrogens, used either as internal standards or in 
vivo tracers. Phase 1 metabolism of estrogens via oxidation occurs in the A-
ring, to form hydroxy and methoxy estrogens on the 2 and 4 positions 
(Beinhauer et al., 2015). Again, this derivatisation approach would offer 
greater selectivity against unknown background interferences. Final tune 
conditions in ESI mode for the FMP derivatives of estrogens, using the 




Figure 5.2: Product ion scans of methylpyridinium ether derivatives of estrogens; (A) estrone (E1) (B) estradiol (E2) (C) 3,4-




Figure 5.3: Proposed fragmentation pattern of methylpyridinium ether derivatives of estrogens; (A) estrone (E1) (B) 3,4-




Figure 5.4: Proposed fragmentation pattern of methylpyridinium ether derivatives of estrogens; (A) estradiol (E2) (B) 3,4-
[13C]2-estradiol (13C2E2) (C) 2,4,16,16-[2H]4-estradiol (d4E2). 
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5.3.1.2 Optimisation of derivatisation reaction conditions 
Reaction conditions to generate FMP derivatives were optimised first using 
aqueous extracts and then extracts of male and female plasma and final 
conditions reported. The efficiency of reaction was improved by increasing 
temperature from 25 to 40°C and time from 5 to 15min, but further 
improvement was not seen at higher temperatures or with longer incubations. 
Reassuringly the intensity of signal was not adversely affected upon 
prolonged incubation, proving robustness of the protocol. Sensitivity was 
improved by increasing the volume of FMP from 25 to 50µL and its 
concentration from 0.1 to 5mg/mL.  
5.3.2 Chromatographic conditions 
Baseline resolution between estrogen FMP derivatives within reasonable 
analytical time was achieved using a C18 UHPLC column. Typical retention 
times for E1, E2 and 17-E2 were 4, 4.5 and 7.5min respectively (Figure 5.5A). 
At early time points (until 2min) the flow was diverted to waste and a rapid 
increasing organic gradient was used at the end; both strategies were 
employed to minimise build-up of derivatisation reagent on the column and 










The lipophilic polymeric adsorbent, Oasis®, was selected for extraction of 
estrogens as with androgens (Pedrouzo et al., 2009, Grover et al., 2009). This 
showed excellent retention of analytes and generated a clean extract with 
reproducible high recovery. Initial development using Oasis HLB (Pedrouzo 
et al., 2009, Grover et al., 2009) showed excellent recoveries from water (mean 
±RSD; E1 99±4%, E2 97±2%, 13C2E1 98±10% and 13C2E2 96±5%), but significant 
ion suppression was identified in the plasma extracts (E1 35%, E2 32%). Indeed 
previous problems with ion suppression of derivatised estrogens by 
phospholipids have been reported (Wang et al., 2015). Suppression was 
minimised by employing weak cation exchange to further clean-up the 
sample; ultimately use of bigger sizes (3CC/60mg) of Oasis MCX 
(Rasmussen et al., 2003) extraction cartridges for bigger plasma volumes (2mL) 
was validated. Using this approach efficient and consistent recovery of 
estrogens from plasma was achieved for both analytes (mean ±RSD; E1 95±5% 
and E2 92±3%) and internal standards (13C2E1 97±12% and 13C2E 90±6%).  
5.3.4 Assay validation 
5.3.4.1 Specificity 
Baseline chromatographic separation of estrogens (E1 and E2) and 
endogenous isomers in plasma (17αE2) was achieved (Figure 5.5A). In plasma, 
the ratio of quantifier to qualifier mass transitions was monitored by LC-
MS/MS to ensure specificity (E1 1.1, E2 1.1, 13C2E1 1.1 and 13C2E2 1.4), 
comparable to those in aqueous solutions, showing differences less than 20% 
(E1 10 %, E2 0 %, 13C2E1 8.3% and 13C2E2 17.6%). Interferences were not 





Figure 5.5: Mass chromatograms of quantifier mass transitions of 
methylpyridinium ether (FMP) derivatives of estrogens; (A) 
chromatographic resolution of derivatives of estrone (E1), estradiol (E2) and 
17α-estradiol (17α-E2) (400pg) prepared from aqueous standard solutions. 
Derivatised E1 (B) and E2 (C) from standards prepared with quantities 
equivalent to the limits of detection for quantitation (2pg) on column 
respectively. Quantifier mass transitions of 3,4-[13C]2 derivatised estrone (D,F) 
and 3,4-[13C]2 -estradiol (E,G) in standards (200pg) and blank plasma, 
respectively, demonstrating lack of interferences at the Rts of interest. 
Derivatised E1 (H, J), E2 (I, K) in extracts of female and male plasma 
respectively. Counts per second (cps). 
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5.3.4.2 Linearity  
13C2 labeled estrogens were selected as internal standards, since loss of 
deuterium may happen during derivatisation, particularly from the A-ring. At 
the outset of this work only estrogens with two labelled carbons were 
available, but subsequently those with three have become commercially 
available and may offer enhanced mass distinction of isotopomers in future 
studies. Linear standard curves of estrogen FMP derivatives were generated 
in the range (1-400pg) with a mean r value of 0.9953. Weighting of 1/x2 was 
applied, yielding a mean intercept of 0.0017. 
5.3.4.3 LODs and LOQs 
The LOD and LOQs of FMP derivatives of both estrogens were 1 and 2pg 
respectively (representative chromatograms shown in Figures 5.5B and C). 
5.3.4.4 Precision and accuracy 
The values of intra- and inter- assay precision and accuracy were acceptable 
(<20% RSD for precision and <±20% accuracy) at the LOQ of 2pg (Table 5.2) 
and <15% above this value. Acceptable reproducibility of estrogens upon 
repeat injection of the same sample was demonstrated with RSD; E1 (1%), E2 
(4%) in male and E1 (9%) and E2 (13%) in female plasma. 
Precision (%RSD) High (400pg) Middle (50pg) Low (1pg) 
Analyte E1 E2 E1 E2 E1 E2 
Intra-assay 3 4 7 10 13 14 
Inter-assay 5 6 9 15 15 16 
Accuracy (%RME) High (400pg) Middle (50pg) Low (1pg) 
Intra-assay 12 13 12 15 18 17 
Inter-assay 14 14 14 15 19 19 
Table 5.2: Precision and accuracy of analysis of methylpyridinium 
derivatives of estrogens. Estrone (E1) and estradiol (E2). Relative Standard 




The FMP derivatives demonstrated suitable stability upon storage in an auto-
sampler (10°C) over 24 h, with limited degradation measured for derivatised 
E1 (7%, 5%) and E2 (9%, 6%) in extracts of samples from male and female 
subjects, respectively. Derivatives were stable upon short-term storage in the 
freezer (-20 and -80°C, respectively) for 24h; reduction from original response 
E1 (2.5%, 1.1%), E2 (3.4%, 1.3%) in male and E1 (2.2%, 1.8%), E2 (3.1%, 1.4%) 
in female. However, degradation in the derivative was significant after 48 h at 
-20°C; derivatised E1 (28%, 36%), E2 (29%, 42%) in male and female extracts, 
respectively. At -80°C, stability of derivatives was acceptable after storage for 
28 days; reduction from original response for E1 (8%, 6%), E2 (9%, 8%) in male 
and female plasma, respectively. 
5.3.6 Method application 
The method was applied to samples from pre- and post-menopausal females 
and males and compared to reported biological concentrations (Table 
5.3)(Zhang et al., 2011, Yasui et al., 1999) . In pre-menopausal female serum 
0.5mL of serum was required to ensure reliable detection throughout the cycle; 
concentrations were 135-473pmol/L (36-128pg/mL) for E1 and 193-
722pmol/L (52-196pg/mL) for E2.  In males, E1 and E2 concentrations were 
25-111pmol/L (7-30pg/mL) and 60-180pmol/L (16-50pg/mL) respectively 
which were quantified using 1mL plasma. In post-menopausal female plasma 
2mL of plasma was used; concentrations were 22-78pmol/L (6-21pg/mL) for 
E1 and 29-50pmol/L (8-14pg/mL) for E2. Using these volumes, all 
concentrations fell within the quantitation limits of the assay of (1-400pg) for 





E2, but not E1, is quantified in clinical practice in pre-menopausal women 
usually by immunoassay(Stricker et al., 2006). It is well recognised that this 
approach loses accuracy when concentrations are lower, such as in the males 
and post-menopausal women(Grebe and Singh, 2011). The concentrations of 
E2 (E1 was not available) were compared with data previously collated using 
immunoassay within the Clinical Biochemistry setting (Figure 5.6). Generally, 
and surprisingly, E2 concentrations were measured higher with LC-MS/MS 
than immunoassay: measurements means were (SD) 465 (161) and 384 (192) 
pmol/L respectively. Bland Altman plot (Figure 5.6A) shows the percentage 
difference (D%) between the LC-MS/MS and immunoassay measurements, 
and most data points fell within ±1.96 SD of D%. The positive bias increased 
as the measurements mean of E2 decreased with higher agreement in high 
concentrations than in low concentrations. The correlation between E2 
concentrations measured by immunoassay and LC-MS/MS was poor, 0.813 as 
anticipated, given the existing concerns over immunoassay data (Figure 5.6B). 
These volumes and LOQs compared with previous literature. Volumes of 
serum or plasma from human and bovine in previous MS methods (Lin et al., 
2007, Chang et al., 2010, Xu and Spink, 2008, Nelson et al., 2004, Yang et al., 
2008) were 100-2000µL with LOQs 0.1-32pg on column. For example, Chang 
et al. (Chang et al., 2010)used 1mL of bovine plasma for simultaneous 
quantification of E1 and E2, while Yang et al. (Yang et al., 2008) used 2mL of 
human serum to detect estrogens and their metabolites, in both studies LOQ 
were 24-32pg. Nelson et al (Nelson et al., 2004) and Xu and Spink (Xu and 
Spink, 2008) reported lower LOQs (2.5 and 2pg respectively), requiring 0.5mL 
of male and female human serum for quantitation of dansylated estrogen 
derivatives by LC-MS/MS (Nelson et al., 2004). Similarly, estrogen pyridine-
3-sulfonyl (PS) derivative were developed and analysed by third stage MS 
(MS3) requiring 2mL of bovine serum (Xu and Spink, 2008). Of interest 
Beinhauer et al (Beinhauer et al., 2015) has developed a method to trace 
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estrogen FMP derivatives with very low LOQ 0.2pg in 100µL demonstrated in 
commercially available human and  bovine serum. Kushnir et al (Kushnir et 
al., 2008) has been able to quantify dansylated estrogens at even lower LOQ 
0.1 in 200µL human male and pre- and post-menopausal female serum, but 
only using 2-dimensional (2D) chromatographic separation (Kushnir et al., 
2008) and LC-MS/MS coupled with on-line solid phase extraction SPE 
(Beinhauer et al., 2015). Interesting this approach paid dividends for androgen 







(pg/mL) [1, 2] 
E1 E2 E1 E2 
Males 48 21-85 7-30 16-50 10-60 10-40 
Pre-menopausal 
females 
27 24-52 36-128 52-196 17-200 15-350 
Post-menopausal 
females 
20 58-60 6-21 8-14 7-40 <10 
Table 5.3: Concentrations of estrogens in males, pre- and post-menopausal 





Figure 5.6: Bland Altman plot (A) and correlation plot (B) of estradiol (E2) 
for LC-MS/MS and immunoassay (IA). Difference of E2 amounts in pre-
menopausal female using LC-MS/MS and IA ( ♦ ): the percentage difference 
between values of two measurements ((LC–MS/MS - IA)/IA x 100) (D %); the 
horizontal lines are mean of D% and +1.96 stranded deviation (+1.96 SD) and 
– 1.96 standard deviation (-1.96 SD); estradiol (E2); line of equality (-----); 




In summary derivatisation to form FMP ethers of phenolic estrogens, in 
conjunction with LC-MS/MS, is suitable for quantitative analysis of E2 and E1 
in low abundance in biological fluids. This approach allows robust 
measurement across typical physiological ranges found in pre- and post-
menopausal women and men, overcoming problems with immunoassays, for 
which imprecise measurements are often recorded in the lower physiological 
range of concentrations (Beinhauer et al., 2015). The improvements in sample 
preparation allowed larger volumes to be processed without significant 
problems with ion suppression. 
Use of FMP-TS reagent offers improved specificity over previously reported 
derivatisation approaches e.g. dansylation, but care should be taken to store 
derivatised samples at -80°C if not being analysed within 24h. Under these 
conditions all indices of assay quality were acceptable. The derivatisation 
reaction may be applicable to other naturally occurring phenolic steroids such 















Sex steroids have been implicated in the aetiology of metabolic disease, 
diabetes and obesity, but especially at the start if this thesis studies were 
limited, particularly for low abundance hormones, such as DHT and 
estrogens, due to poor quality of assays. This is a particular challenge since it 
is reported that the levels of sex steroids may be even lower in such patients 
compared with healthy controls. For example, studies report diabetic males 
have lower concentrations of T in the circulation compared to nondiabetics, 
whereas A4, E1 and E2 are unchanged (Varlamov et al., 2014). Few studies 
have considered DHT, the more active androgens that forms from T by 5α-
reductases. 
The biological see-saw between androgens and estrogens can be seen in 5α-
reductase deficiency (a disorder of sexual development) with reduced 
conversion of T to DHT (Miller and Auchus, 2011). However, in this setting 
excess T is diverted to estrogens. 5α-Reductases may regulate steroid 
signalling in metabolic disease. For example, short-term treatment with 5α-
reductase inhibitors used for prostatic hyperplasia, either finasteride (type 2 
selective inhibitor) or dutasteride (both types inhibitor) (Wei et al., 2019) is 
associated with an increased risk of developing type 2 diabetes in men. In the 
report by Upreti et al (Upreti et al., 2014) E2 plasma levels increased by both 
drugs. Moreover, T levels remained normal but DHT concentrations were 
reduced by both inhibitors. Thus, altered metabolism may be due to 
suppressed DHT levels at the level of metabolic tissues (e.g. adipose tissue) 
(Wei et al., 2019), but another possibility pertinent to this thesis would be 





These outcomes of impaired 5α-reduction of steroid hormones can also be seen 
in diet induced obesity models in mice, with reduced glucose tolerance, 
increased weight gain and fatty liver observed in both Srd5a1-/- mice and 
obese rats receiving finasteride (Upreti et al., 2014, Upreti et al., 2015). 
Impaired glucose homeostasis with lower concentrations of androgens in 
males is linked to metabolic dysfunction in adipose and β-cells (Navarro et al., 
2015). Further studies of metabolic effects of 5α-reductase inhibitors in men 
and women are recommended (Mak et al., 2019), but to fully understand the 
phenotype high quality assays, such as those developed in the previous 
chapters are required.  
On other hand, the balance of activity of aromatase has also been shown 
critical in the ultimate steroid profile. Research into aromatase knockout mice 
and humans with aromatase deficiency demonstrate reduction of insulin 
sensitivity and suppressed estrogen synthesis in fat tissue, precipitate higher 
body fat and leptin (Clegg et al., 2003). It is important to recognise in this 
setting that males with aromatase deficiency generate T normally, which can 
then accumulate and drive DHT production. This concept of the 
estrogen:androgen balance influencing metabolic changes could be important 
in premenopausal progressing through the mensopause but also for post-
menopausal women, undertaking aromatase inhibitor therapy for breast 
cancer (Santen et al., 2008). Indeed, these women can show side-effects of 
systemic hyperandrogenism.  
Our group have contributed to this field publishing that inhibitors of both 5α-
reductases and aromatase induce metabolic dysfunction in man, using 
euglycemic hyperinsulinaemic clamps to carefully characterise insulin 
sensitivity and magnetic resonance spectroscopy to assess body fat 
distribution. These studies were able to assess insulin sensitivity in detail by 
euglycemic clamps as type 2 diabetes risk predictor (DeFronzo et al., 1979) , 
allowing revelation of changes in glucose production and disposal at the level 
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of liver, muscle and fat. This approach has benefits over use of more routine 
clinical indicators, such as glycated haemoglobin (HBA1c), which are static 
and only reflecting global body phenotype. In addition, sex hormone binding 
globulin (SHBG) and albumin were assessed free and bound sex hormones. 
SHBG binds to T whereas, albumin binds to all hormones, thus may restrain 
free hormones levels and thus effects. Addition of glycerol tracers to the clamp 
allows assessment of lipolysis, particularly during the low dose insulin clamp. 
Insulin acts to shut-down lipolysis from adipose tissue and thus slow the rate 
of non-esterified fatty acids (NEFAs) and glycerol production. 
Our studies showed that  men with 5α-reductase inhibitors have greater body 
fat stores and features of insulin resistance (Gibb et al., 2016, Gibb et al., 2019a, 
Gibb et al., 2019b, Upreti et al., 2014, Upreti et al., 2015)  and indeed are more 
likely to develop type 2 diabetes (Wei et al). In healthy men, aromatase 
inhibitors reduce insulin sensitivity and peripheral glucose disposal most 
likely through effects on skeletal muscle. Women with breast cancer receiving 
aromatase inhibitors had impaired glucose tolerance (Goodman-Gruen and 
Barrett-Connor, 2000). Therefore, it is possible that androgen deficiency 
contributes to insulin resistance both by acting through AR but also through 
depleting estrogens and thus may have a bigger impact than aromatase 
inhibition alone. Given pharmacological inhibition of 5α-reductase and 
aromatase have profound effects on metabolic integrity, as well as genetic 
mutations, it may be that the balance of these pathways in the general 
population predict their metabolic phenotype and disease propensity and 
insight into at-risk groups might be gained by measuring the balance of 






In this chapter we applied the methods for sex hormones profiling developed 
to better understand androgen/estrogen balance in a cohort of healthy men. 
Androgens and estrogens were quantified in samples collected at baseline in 
the studies described above (Upreti et al., 2014), before pharmacological 
intervention, to address baseline relationships between carefully characterised 
metabolic phenotypes and aromatase/5α-reductase balance. This chapter 
hypothesised that low androgen levels are associated with features of the 
Metabolic Syndrome and that this relationship is influenced by the prevailing 




6.2.1 Clinical  
Forty-six healthy men (age 20–85years) participated a study to address the role 
of sex hormones in metabolic diseases. Metabolic data were collected in the 
previous study (Upreti et al., 2014) and parameters available included 
anthropometry, blood pressure and indices of insulin sensitivity, liver 
function and dyslipidaemia. 
6.2.2 Anthropometric and metabolic measurements 
Anthropometric measurements were obtained for individual participants, 
including height, body weight, blood pressure (BP), hip measurements and 
waist circumference. These measurements were assessed using standard 
techniques and free fat mass was evaluated a body fat densitometry monitor. 
Body fat and liver fat were measured by magnetic resonance imaging (MRI) 
and proton magnetic resonance spectroscopy (MRS) respectively. 
6.2.3 The hyperinsulinemic-euglycemic clamp protocol 
The hyperinsulinaemic-euglycemic clamp protocol (Figure 6.1) was 
performed by tracer infusion of labelled glucose and glycerol with adjustment 
of body weight in three phases (DeFronzo et al., 1979, Upreti et al., 2014). 
Firstly, a basal sample is obtained from the fasted subject and then glucose and 
glycerol stable isotope tracers were infused for first 90min, representative of 
the post-prandial state. This infusion was constant for a second 90min phase 
with (low) dose of insulin infusion (and responsive adjustment of glucose 
levels). During this time, endogenous glucose production (EGP), mainly from 
the liver can be ascertained. Finally, glucose uptake was determined during 
continuous infusion of (high) insulin dose with tracer for the third 90min 
phase, mainly reflecting skeletal muscle uptake. Notably this parameter is the 
usually the first to decline as insulin resistance develops (DeFronzo et al., 1979,  
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Upreti et al., 2014). Glycerol tracers were also administered and used to assess 
sensitivity to lipolysis during the low dose clamp. 
 
Figure 6.1: Hyperinsulinemic-euglycemic clamp protocol. 
6.2.4 Laboratory measurements 
Estrogens and androgens were measured using LC-MS/MS with FMP 
derivatisation and HMP derivatisation respectively in plasma from blood 
collected at 7:30am following an overnight fast, prior to commencement of the 
clamp. A number of baseline parameters were available as follows. SHBG and 
HbA1c were quantified by an automated assay and HPLC respectively. 
Glucose, C-peptide, liver function tests and lipids were measured by an auto-
analyser. Insulin and NEFAs were quantified by an ELISA and an enzyme 
reaction assay respectively, whereas, leptin and resistin were evaluated by an 
immunoassay. 
6.2.5 Statistical analysis  
Statistical analysis was performed using SPSS for Windows, version 24 (IBM). 
Missing values are indicated and were not imputed. Descriptive statistics 
(means and standards deviations) were calculated for individual parameters. 
Quantile-quantile (Q-Q) plots and Shapiro-Wilk test were applied to assess 
data normality. Logarithmic (natural log), reciprocal (1/X), cube root (3√) 
transformations were used for skewed data. The Pearson correlation 





6.3.1 Description of cohort using routine clinical parameters 
Prior to statistical analysis means and SD describing the data were calculated 
and are presented as in Table 6.1. This study aimed to assess the relationship 
between sex hormones levels and metabolic parameters in healthy males. 
Therefore, data describing general health of participants were compared to the 
UK normal values by the NHS and Mayo clinic (https://www.nhs.uk/; 
https://www.mayoclinic.org/; on 10/04/2020). In addition, the data 
describing metabolic features were compared to the most commonly used 
values ascribed as criteria for the Metabolic Syndrome defined by the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP 
III).The definition defines the presence of the syndrome in men when three or 
more of the resulting criteria were met: waist circumference (>40inches), BP 
(>130/85mmHg), fasting triglyceride (>150mg/dL), fasting HDL (<40mg/dL) 
and fasting blood glucose (>100mg/dL). 
In this cohort, the mean (SD) age of subjects was 42 (18)years and covered a 
wide range (20–85)years from young to elderly men. The mean BMI of 
participants 25.8 (3.7) and therefore in the overweight range, according to 
body mass index (BMI) definition (25-29.9kg/m2) With mean body fat of 22.1% 
(7.2), the participants fell into the “average“ category (18-24, average and 
>24%, obese). BP values were mainly in the normal range (to slightly high) for 
systolic (90-140, normal and >140mmHg, high) with mean 135.2 (14.9). Normal 
diastolic (60-90mmHg) were observed with mean 78.9 (9.9). 
When assessing parameter used to describe glucose homeostasis in a fasting 
state, the data showed participants were non-diabetic, as per the recruitment 
strategy, with normal HbAc1 (35.4mol/mol), low to normal C-peptide (500-




Likewise, in terms of circulating lipids, triglycerides and cholesterol data were 
in the normal range, (0.3-2.1mmol/L) and (<5mmol/L) respectively. In 
addition, liver functions and liver fat data were within normal ranges: ALT 
28.7 (0.7-55U/L), AST 26.7 (0 8-48U/L), ALP 70.7 (0.40-129U/L), bilirubin 12.9 
(1.7-21µmol/L), GGT 23.9 (0.8-61U/L) and liver fat 12 (<15%).  In summary, 
features of the Metabolic Syndrome were not present confirming these 
participants were healthy if slightly overweight. 
6.3.2 Normality of data 
Prior to statistical analysis, an evaluation of the normality of data was required 
as normal data distribution is an essential assumption in parametric analysis. 
Two approaches were taken: graphically by Q-Q plots and mathematically 
using tests of normality. Some parameters were and others were not normally 
distributed. Figure 6.2 demonstrates an example from the data for a normal 
(Q-Q) plots of BMI and age data. The data are normally distributed, and the 
data points are close to the sloping line (Figure 6.2A). In contrast for age, data 
points drift from the line in a skewed distributed (Figure 6.2B), requiring 
transformation. 
A second approach to assess normality, namely the Shapiro-Wilk test, was 
applied being particularly appropriate for small sample sizes less than 50 
samples; in this study, the cohort of healthy men comprised n=46. The results 
of the Shapiro-Wilk tests are demonstrated in Table 6.1. If the Shapiro-Wilk 
result is p>0.05 the data is normally distributed while a skewed distribution is 
represented by p<0.05. Normal distributed data (such as BMI, waist to hip 
ratio (WHR), body fat and BP) were confirmed and agreed by two tests. 





Figure 6.2: Examples of quantile-quantile (Q-Q) plots for data with a A) 










Age (years) 42 18 0.03* 
Anthropometry/Metabolic Syndrome 
Body mass index (kg/m2) 25.8 3.7 0.96 
Body weight (kg) 80.5 12.7 0.25 
Waist to hip ratio 0.9 0.1 0.76 
Body fat (%) 22.1 7.2 0.45 
Blood Pressure systolic (mmHg) 135.2 14.9 0.71 
Blood Pressure diastolic (mmHg) 78.9 9.9 0.70 
Liver Fat (%) 12.3 1.6 0.00* 
Insulin sensitivity 
HbA1c (mmol/mol) 35.4 3.3 0.53 
C-peptide (pg/mL) 562 212 0.86 
Fasting insulin (pmol/L) 46.0 21.1 0.41 
Fasting glucose (mmol/L) 5.0 0.4 0.24 
Glucose low dose (mmol/L) 4.8 0.5 0.02* 
Glucose high dose (mmol/L) 4.7 0.6 0.00* 
RA glucose low (mmol/L) 4.5 2.7 0.56 
RD glucose low (mmol/L) 5.8 6.0 0.00* 
RD glucose high (mmol/L) 28.7 13.5 0.51 
EGP (mmol/L) 4.4 2.5 0.56 
RD glycerol low (mmol/L) 1.1 0.7 0.06 
RD glycerol high (mmol/L) 0.9 0.5 0.02* 
NEFAs baseline (μmol/L) 520.7 243.7 0.34 
NEFAs low (μmol/L) 221.3 158.6 0.02* 
NEFAs high (μmol/L) 40.1 23.0 0.03* 
BHB baseline (mg/dL) 33.4 20.8 0.00* 
BHB low (mg/dL) 35.7 39.2 0.06 
BHB high (mg/dL) 37.6 28.8 0.00* 
Dyslipidaemia and adipokines 
Leptin (ng/dL) 5101.5 5787.5 0.00* 
Resistin (ng/mL) 24.5 11.1 0.76 
Triglycerides (mmol/L) 1.2 0.6 0.01* 
Cholesterol (mmol/L) 4.8 0.9 0.12 
HDL (mmol/L) 1.3 0.4 0.32 
Liver function 
Bilirubin (μmol/L) 12.9 7.4 0.03* 
ALT (U/L) 28.7 14.0 0.02* 
AST (U/L) 26.7 8.5 0.26 
ALP (U/L) 70.7 17.2 0.92 




SHBG (nmol/L) 27.3 9.8 0.98 
Albumin (g/dL) 6.2 6.4 0.78 
Testosterone (nmol/L) 7.0 2.2 0.00* 
Androstenedione (nmol/L) 3.2 0.6 0.13 
DHT (nmol/L) 1.4 0.4 0.00* 
Estrone (pmol/L) 79.5 38.0 0.00* 
Estradiol (pmol/L) 103.4 36.8 0.06 
Testosterone / estradiol ratio 0.1 0.1 0.05 
Androstenedione / estrone ratio 0.7 0.15 0.15 
DHT/ estradiol ratio 0.02 0.01 0.07 
Table 6.1: Means, standards deviations and Shapiro-Wilk normality test. 
skewed distribution (*), alanine transaminase (ALT), aspartate amino 
transferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase 
(GGT), high density lipoprotein (HDL), glycated haemoglobin (HbA1c), rate 
of appearance (RA), rate of disposal (RD), endogenous glucose production 
(EGP), non-esterified fatty acids (NEFAs), beta-hydroxybutyrate (BHB), sex 
hormone binding globulin (SHGB), 5α-dihydrotestosterone (DHT) and 
millimetres of mercury (mmHg). Analytes were measured in fasting baseline 
samples, unless phase of clamp is indicated. 
6.3.3 Transformation of skewed data 
For those skewed, an additional assessment was made as to whether data were 
positively or negatively skewed by histogram plots to inform suitable modes 
of transformation (Figure 6.3). For example, age showed a positively skewed 
distribution due to there being a greater number of younger participants and 
this suggested suitable for classic transformations such as natural log. 





Figure 6.3: Example of histogram plot for positively skewed data; showing 
the curve line on the right slop of the histogram is longer than the left slop. 
Another assessment was made as to whether the variables contain negative 
values or zero, since such datasets are not suitable for most transformations 
and require a reflected transformation adjusted by a constant. This issue 
however was not observed in the datasets and thus normal transformations 
were then applied. Transformations were applied and then means and 
standard deviations recalculated (Table 6.2). Shapiro-Wilk normality was 
retested, and in some cases, different transformations were applied in order to 
achieve normality to attain the highest p values. Eventually all transformed 
datasets were normally distributed and suitable for analysis, albeit a few 
datasets, such as age, glucose (high dose), RD Glucose (low) and DHT were 






Parameters Mean Standard deviation Shapiro-Wilk 
Age 1.5 0.1 0.08′ 
Liver Fat 0.7 0.6 0.22′ 
Glucose low dose 0.6 0.04 0.10′ 
Glucose high dose 0.2 0.02 0.06″ 
RD glucose low 1.5 0.6 0.09‴ 
RD glycerol high -0.1 0.1 0.41′ 
NEFAs low 2.2 0.2 0.17′ 
NEFAs high 1.5 0.1 0.85′ 
BHB baseline 1.4 0.2 0.71′ 
BHB 270 1.4 0.2 0.67′ 
Leptin 3.5 0.4 0.19′ 
Triglycerides 0.1 0.1 0.58′ 
Bilirubin 1.1 0.2 0.56′ 
ALT 1.4 0.1 0.64′ 
GGT 1.2 0.2 0.67′ 
Testosterone 0.1 0.03 0.48″ 
DHT 1.2 0.03 0.06‴ 
Estrone 4.0 0.06 0.24‴ 
Table 6.2: Means, standards deviations and Shapiro-Wilk normality test for 
datasets requiring transformation. alanine transaminase (ALT), gamma-
glutamyl transferase (GGT), rate of disposal (RD), non-esterified fatty acids 
(NEFAs), beta-hydroxybutyrate (BHB), log (′),1/X (″) and cube root 3√ (‴). 
6.3.4 Pearson correlation  
Correlations between variables were explored by parametric analysis using 
the normalised datasets. Pearson correlation was used as an assessment of the 
strength of relationship between two related cross-sectional variables. A linear 
relationship between variables, expressed as normally distributed data 
without major outliers, is required for significant correlations to be assigned, 
and results are expressed by the slope (R) of the relationship and the 
significance (β of the correlation. Results from assessment of correlations 
between metabolic/health parameters and sex hormones are presented 
(Tables 6.3 and 6.4) as well as the relationship between sex hormones per se 
and T/E2 and A4/E1 ratios. 
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Pearson correlation Age BMI WHR Body fat 
Anthropometry/Metabolic Syndrome 
BP systolic  +0.333* +0.387** +0.392** 
BP diastolic +0.348*   +0.414** 
Insulin sensitivity 
HbA1c +0.590**  +0.393** +0.435** 
C-peptide  +0.545** +0.614** +0.463** 
Fasting glucose +0.329* +0.343* +0.567** +0.322* 
Fasting insulin  +0.560** +0.593** +0.501** 
RD glucose (high) -0.396** -0.514** -0.632** -0.641** 
NEFAs +0.526**  +0.387** +0.600** 
Dyslipidaemia and adipokines 
Leptin  +0.535** +0.687** +0.612** 
Triglycerides  +0.484** +0.438** +0.377* 
Cholesterol +0.405** +0.333* +0.405** +0.429** 
Table 6.3: Pearson correlation coefficient test for age, body mass index 
(BMI), waist to hip ratio (WHR) and body fat. positive correlation (+), 
negative correlation (-), correlation is significant at the 0.01 (**), correlation is 
significant at the 0.05 (*), blood pressure (BP), glycated haemoglobin (HbA1c), 
rate of disposal (RD) and non-esterified fatty acids (NEFAs).  
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Pearson correlation T A4 DHT E1 E2 T/E2 A4/E1 
Sex hormones 
T     +0.361* +0.434*  
A4       +0.996** 
E2 +0.361*     -0.635**  
Anthropometry/Metabolic Syndrome 
BP systolic +0.329*       
Fat liver  -0.540**     -0.496** 
Insulin sensitivity 
RA glucose (low) +0.297*       
RD glucose (low) -0.332*     -0.404*  
RD glucose (high) -0.469** +0.345*     +0.520** 
EGP +0.297*       
RD glycerol (low)      +0.394*  
RD glycerol (high)      -0.362*  
NEFAs (baseline)   -0.381**     
NEFAs low   -0.320*   +0.389*  
Liver functions 
Bilirubin     -0.501** +0.559**  
GGT       -0.471** 
Dyslipidaemia and adipokines 
HDL    +0.429*    
Resistin  +0.341*     +0.382* 
Table 6.4: Pearson correlation coefficient test. testosterone (T), 
androstenedione (A4), 5α-dihydrotestosterone (DHT), estrone (E1), estradiol 
(E2), positive correlation (+), negative correlation (-), correlation is significant 
at the 0.01 (**), correlation is significant at the 0.05 (*), blood pressure (BP), 
gamma-glutamyl transferase (GGT), high density lipoprotein (HDL), rate of 
appearance (RA), rate of disposal (RD), endogenous glucose production (EGP) 





Relationships between age, anthropometric measurements (BMI, WHR and 
body fat), and metabolic parameters were assessed (Table 6.3). Generally, the 
results showed the expected positive correlations between age, BMI, WHR and 
body fat to BP systolic and diastolic, HbA1c, C-peptide, NEFAs, fasting 
glucose and insulin levels. In addition, these parameters were associated 
positively with lipids including triglycerides, cholesterol and leptin. Negative 
correlations were found with rates of glucose disposal (RD) at both high and 
low dose. Overall, these results paint the expected picture of impaired 
metabolic health with increased age and measures of weight gain (increases in 
BMI, WHR and body fat) even within this healthy group. Since these 
parameters are inter-related it is important to consider their co-variance when 
assessing relationships with sex hormones. 
The inter-relationships between sex steroids was studied next (Table 6.4), and 
results show that T was correlated with E2, whereas DHT, A4, E1, SHGB and 
albumin were not correlated significantly with levels of any other sex 
hormones. In terms of relationships between sex steroids and phenotype, age 
and anthropometric measurements (BMI, WHR and body fat) were not 
associated to any sex hormones, whereas T and A4 were correlated positively 
with systolic BP and liver fat respectively. Positive correlation was observed 
between T and rate of glucose appearance (RA) glucose and EGP and T also 
correlated negatively with RD of glucose at low and high doses. In contrast A4 
was associated positively RD of glucose at high dose while DHT was related 
negatively to NEFA at baseline and low level. A4 was associated positively 
with resistin, whereas positive relationship was observed between E1 and 
HDL. E2 was correlated negatively to bilirubin. These relationships between 
sex steroids and glucose, insulin and lipid metabolism will be discussed in 






When variables are inter-related, multiple linear regression can be applied 
using two continuous variables or more to assess the more significant factor. 
One variable can be an independent variable which is related to the dependent 
parameter(s). The regression coefficient (R2) is used to determine relationships 
between independent parameter(s) and unrelated variable(s). R2 value will fall 
between 0 and 1 and the closer it is to 1, the stronger the prediction model. 
Between variables, the highest coefficient value is used to determine the 
predictor making the greatest contribution. 
For example, anthropometric measurements were not strongly associated to 
any sex hormones but were related to parameters related to glucose, insulin 
and lipids. Therefore, MLR was applied using age and weight to reassess 
whether the relationships observed for sex hormones individually could be 
strengthened by considering further features of the patients. R2 values were 
compared with and without adjustment (Table 6.5). 
T levels are strongly related to those of E2 and the best prediction model is RD 
for glucose at high dose took into account E2 as well as and T/E2 ratio. A very 
strong positive regression coefficient was observed for A4 with A4/E1 ratio, 
but not related to metabolic parameters. DHT data were most strongly 
negative correlated with NEFAs at baseline. Only E1 demonstrated high 
positive regression with HDL and neither of these last two regressions were 
not modified by age, BMI, WHR and body fat. E2 was related more strongly 
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0.867 0.857 0.847 0.865 0.876 
T/E2 1.120** 




-0.881** 0.845 0.826 0.815 0.806 0.825 
E1 1* HDL -0.890** 0.884 0.856 0.834 0.846 0.879 
E2 
1 T/E2 -0.635 0.403 0.383 0.373 0.398 0.405 
2* 
T/E2 -0.976** 
0.904 0.897 0.894 0.876 0.906 
T 0.785 
Table 6.5: Multiple linear regression and coefficient beta values for 
individual sex hormones. testosterone (T), androstenedione (A4), 5α-
dihydrotestosterone (DHT), estrone (E1), estradiol (E2), regression coefficient 
(R2), body mass index (BMI), waist to hip ratio (WHR), the most related 
predictor model (*), the predictor contributing the most (**), high density 





6.4.1 Biochemical shuttling between sex hormones 
Sex steroids are biosynthesised from cholesterol by enzymatic processes 
(Miller and Auchus, 2011). Androgens (T and A4) are converted to estrogens 
(E2 and E1 respectively) by the aromatase enzyme. E2 and T are further inter-
converted to E1 and A4 respectively by 17β-hydroxysteroid dehydrogenases 
(17β-HSD) enzymes. Lastly, DHT is formed mainly from T by the 5α-reductase 
(5α-R) enzymes (Figure 6.4) (Miller and Auchus, 2011, Sanderson, 2006, Krone 
et al., 2007, Parker and Schimmer, 1995). Therefore, the level of T is pivotal in 
driving amounts of both estrogens and DHT and any relationships between 
sex steroids and metabolic disease will benefit from taking into account the 
full steroid profile. Many studies in the literature measure individual steroids 
in isolation, in part due to methodological limitations. The detailed measures 
in subjects in the study presented here gave a unique insight into how sex 
steroid profiles in health relate to metabolic physiology. This is an 
improvement on the cruder measures of fasting glucose and HbA1c and 
allows insight into dynamic responses to insulin in a cross-section of healthy 
individuals. 
 
Figure 6.4: Sex hormones synthesis. testosterone (T), androstenedione (A4), 
5α-dihydrotestosterone (DHT), estrone (E1), estradiol (E2), reductase (R) and 




First relationships between sex hormones themselves were assessed. The 
strong influence of androgens on the available estrogen levels in men could be 
seen readily with T, which showed a positive correlation with E2. However 
surprisingly correlations were not observed between A4 and E1, or T and 
DHT. The lack of theses correlations could be explained by differential 
Michaelis-Menten kinetic constants (Km) between aromatase, 5α-reductase 
and 17β-HSD. Given the choice between conversion of T to E2 and DHT, it is 
more likely that T to E2 reaction will take place due to the lower Km of 
aromatase (27.7nM) rather than 5α-reductase (64.4nM), assuming they are 
positioned within the same compartment of the cell. In terms of E1, possibly 
the relationship with A4 may be harder to see if E1 is rapidly converted to E2 
by the 17β-HSD. Nonetheless it seems likely that relationships observed with 
E2 and metabolic physiology may be driven from the prevailing T 
concentration. 
Sex steroids held relationships with some but not all metabolic parameters. 
Within this group of healthy subjects, a relationship with age was not seen 
which was perhaps surprising as it is known that steroid production declines 
with age (Tchernof et al., 1995). However, this may just reflect the fact that the 
age distribution of the cohort was skewed towards younger men. It was 
interesting to note that direct relationship between sex steroids and obesity 
were not found, whereas relationships with glucose homeostasis were readily 
observed. Adipose tissue is a site of metabolism of sex steroids, but possibly 








6.4.2 Sex hormones and Metabolic Syndrome 
The Metabolic Syndrome is associated with visceral adiposity, 
hyperlipidaemia (cholesterol and triglycerides), glucose intolerance, insulin 
resistance, and hypertension (Barrett-Connor et al., 1990, Bray, 2003, 
Gambineri and Pelusi, 2019). In this setting, T deficiency has been particularly 
related to reduced fasting glucose and glucose intolerance (Colangelo et al., 
2009). Moreover, in men, T replacement therapy prompted improvements in 
health, noted as a significant decrease in fasting plasma glucose, HBA1c, fat 
mass and triglyceride levels (Colangelo et al., 2009). These reports suggest that 
metabolic disease is associated with low androgen levels and relationships 
between androgens and estrogens and individual features of the Metabolic 
Syndrome in health will be discussed in the following sections. 
6.4.2.1 Blood pressure  
T showed a relationship with BP, in agreement with previous reports (Fogari 
et al., 2005) - a positive correlation was observed between T and systolic BP 
but not diastolic BP. This could reflect the influence T to cause vasoconstriction 
through actions on the vessel wall in response to mild stress (Fogari et al., 
2005). Diastolic BP is a better indicator in metabolic disease as increases in 
systolic BP may be a result of “white coat syndrome” and stress such as 
coming to take part in this study. It has been suggested that high T 
replacement doses can enhance arterial rigidity and therefor, development of 
CVD (Arnlöv et al., 2006, Bray, 2003), although in contrast some studies show 
T replacement therapy reduces atheroma development associated with 
vasodilation effects in men (Fogari et al., 2005). Overall, in this healthy cohort 
T positively associated with increase BP and additional studies are needed to 
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address the mechanism as they do not align to the concept of low androgen 
status in the Metabolic Syndrome. 
6.4.2.2 Insulin sensitivity 
Diabetes is one of the main metabolic health conditions that has been explored 
in relation related to sex hormone levels (Gambineri and Pelusi, 2019). A 
number of studies have linked both sex hormones deficiencies and conversely 
replacement treatment to disorders of insulin resistance, suggesting a U-
shaped relationship (Colangelo et al., 2009). Others have contrasted the role of 
androgens and estrogens between genders, emphasising the need for a holistic 
overview of sex steroids, when assessing these relationships. 
In this study, a relationship with obesity was not observed and therefore the 
relationships quoted about features of insulin sensitivity may be independent 
of adiposity. Androgens and estrogen levels were regressed against C-peptide, 
HbA1c, fasting glucose and insulin levels as the general indicators of insulin 
sensitivity which are studied clinically. Fasting glucose and insulin give a 
snapshot at sampling, whereas HbA1c and C-peptide give a longer view. 
Further to that, various aspects of dynamic insulin sensitivity were assessed 
in men during different phases of hyperinsulinaemic-euglycaemic clamp 
(DeFronzo et al., 1979,  Upreti et al., 2014). These dynamic tests allow 
assessment of rate of appearance (RA), disposal (RD) for glucose and glycerol 
at a tissue level to evaluate insulin sensitivity dynamically (Upreti et al., 
2014).and provide more detailed insight than resting fasting values. These 
parameters are more likely to reveal changes that are changing as healthy 
individual progresses to metabolic disease but before disease manifests as well 






Correlations were not found between sex hormones and static measures i.e. C-
peptide, HbA1c, fasting glucose and insulin levels. However, relationships 
were found during the dynamic clamp assessment, the main one being that T 
levels negatively correlated with RD of glucose (at both high and low dose) 
and positively with RA of glucose (at low dose) and EGP. Therefore, in healthy 
individuals these findings suggest in health high T level associate with lesser 
insulin sensitivity i.e. less ability to dispose of glucose or shut down 
endogenous production (Lee et al., 2005), in contrast to the anticipated 
association of low T concentrations with the insulin resistant state in diabetes. 
The RD of glucose demonstrates slightly stronger positive association to T/E2 
than T and this was reported previously (Tchernof et al., 1995, Selvin et al., 
2007). Thus, suggests that when aromatase is less efficient, the levels of T may 
rise further and allow greater accumulation of active androgen. 
It would have been expected that the further androgen, A4 would show the 
same relationship as T and but in fact it was correlated positively with RD of 
glucose levels (low and high dose) but only during high-dose infusion. Again, 
this implicates androgens as modifiers of insulin sensitivity at the level of 
muscle, but why T and A4 show different relationships is unclear. Estrogens, 
in contrast, alone did not associate with any of the insulin sensitivity 
indicators. In summary, these dynamic findings in healthy individuals 
support a role for increased androgens associated with progression to diabetes 
– the opposite of the established disease state. Possibly the low androgen state 






Sensitivity of lipolysis is a further index of insulin sensitivity, this time at the 
levels of adipose. This can be measured by changes in the RA of glycerol or by 
NEFA suppression in response to changing insulin levels. Previous literature 
suggests that fatty acids have an inhibitory effect on 5α-reductase preventing 
the transformation of DHT from T (Liu et al., 2009). The data here illustrated 
that the RD of glycerol at both low and high infusion phases were positively 
correlated T/E2 ratio and more strongly than T or E2 alone. Lastly the study 
reported here demonstrated that NEFAs correlated negatively with DHT but 
positively with T/E2 ratio suggesting that products of the aromatase and 5α-
reductase pathway may contribute to regulating lipolysis in adipocyte, but the 
data conflict and suggest the nexus relates to testosterone accumulation. The 
effects of androgens in influencing adipose lipolysis may relate to their ability 
to influence of liver kinase B1 (LKB1)-driven phosphorylation of adenosine 
monophosphate-activated protein kinase (AMPK) to maintain energy 
homeostasis. Again, the interplay between androgens and estrogens matters 
since T and DHT reduce mRNA expression of LKB1 and whereas E2 enhanced 
LKB1 mRNA by activation AR and ERα respectively (McInnes et al., 2012).  
6.4.2.3 Lipids and liver functions  
To sustain body energy supplies during hypoglycaemia, a shift to consume 
FFAs, glycerol and ketones occurs. Therefore, an evaluation of these 
metabolites and other biochemical markers (as insulin) has been obtained as 
diagnostic approach. NEFAs are a fundamental unit of triglycerides which 
contain of fatty acids connected to a glycerol. When triglycerides are 
consumed in the body from food and drinks, NEFAs released by 
chylomicrons. Alternatively, NEFAs are released by hydrolysis of 
triglycerides from fat stores in adipose tissue during fasting stage to maintain 
body energy This process requires lipase activity, also releasing glycerol. Beta-
hydroxybutyrate (BHB) is a ketone which generated from NEFA metabolism 
and used for energy production at fasting state.  
172 
 
Fat in the liver, is known as liver steatosis and is the liver manifestation of 
insulin resistance and hyperlipidaemia (McInnes et al., 2012). Various indices 
were available within the dataset to assess liver health and functions such as 
an increasing gamma-glutamyl transferase (GGT) and bilirubin, as well as 
measures of % liver fat by MRS (Kao et al., 2017). Studies suggested that GGT 
and bilirubin levels decreased with androgen therapy and estrogens 
deficiency is related to fatty liver (McKenzie et al., 2006, Klair et al., 2016).  
Triglycerides and cholesterol levels were higher in males than females 
whereas, HDL levels were lower in post-menopausal and males than pre-
menopausal (Wang et al., 2011), as anticipated at least in the disease setting. 
E2 is known to increase cholesterol levels, drive lipolysis and reduce fatty acid 
uptake and lipogenesis while T reduce lipogenesis, glucose uptake and 
cholesterol in the liver and enhances glycogen synthesis (Shen and Shi, 2015).  
Adipokines, body fat accumulation and insulin play roles in regulating lipid 
metabolism (Wang et al., 2011). Adipocytokines (leptin and resistin) are 
formed by adipose tissue and are key circulating messengers to the brain 
signalling to the appetite centres of the brain. An increase of resistin 
production has been shown to correlate with high T levels (Siemińska et al., 
2006).  
This study shows a positive relation between E1 and HDL likewise resistin 
concentrations were correlated positively with A4 and A4/E1 ratio. Negative 
correlations between bilirubin and E2 levels in men were observed as well as 
a positive correlation with T/E2 ratio. Since, GGT decrease in estrogens 
deficiencies raising possible explanation of negative correlation between GGT 
levels and A4/E1 with lower T in older males. These relationships could be 





In conclusion, sex steroids were quantified in healthy participants men to 
address relationships between carefully characterised Metabolic Syndrome. 
Concentrations of androgens and estrogens did not show strong relationships 
with fat distribution, BMI, WHR and body fat.  Moreover, no correlation with 
dynamic tests of insulin sensitivity was observed and low androgens were 
associated with improved glucose disposal, in contrast to the association of 
hypogonadism and diabetes. T levels correlated to E2, whereas DHT, A4 and 
E1 were not inter-related. The relationships with estrogens were more likely 
to be influenced by their rate of formation from androgens. Interestingly, T 
and A4 were also related to BP and liver fat respectively and additional studies 
















At the outset of this thesis (around mid-2011), we aimed to establish an 
analytical approach to quantify androgens in human and murine biological 
fluids by MS/MS, and in particular, to evaluate if the approach could quantify 
circulating steroids in post-menopausal females and small volume pre-clinical 
samples. We further evaluated if the same sample aliquot could be used for 
estrogen analysis. A highly sensitive method was validated using solid phase 
extraction, in conjunction with LC–MS/MS and its benefits and limitations 
assessed. Since this thesis has been executed over 9 years, we used a variety of 
available techniques and instruments at each time point and as technical 
innovations became available locally overtime. 
The initial analytical approach was established using HPLC-UV which was 
commonly used at that time in steroid analysis. This approach allowed 
evaluation of extraction protocols from plasma to have two individual 
fractions for estrogens and androgens separately, but its low sensitivity did 
not make it feasible to pursue. As the particular goal was to evaluate 
quantitation of circulating steroids in samples with very low levels, we 
transferred to more sensitive instruments and began using UHPLC-MS. This 
approach allowed evaluation of extraction methods in smaller volumes. 
Extraction was validated using solid phase extraction, in conjunction with LC–








Using UPLC-MS/MS allowed robust measurement of T and A4 across typical 
physiological ranges in plasma from pre- and post-menopausal women and 
men. The method was also found to be suitable for animal models to quantify 
T in small volumes (30-50µL) of plasma. However, for detection of DHT, a 
much large volume (>500µL) was required. Estrogens and DHT suffer from 
inefficient ionisation and therefore further steps were taken to improve the 
sensitivity of analysis. Although some instrument advances have been made 
during the course of this thesis, even with the most up-to-date instruments, 
these challenges with estrogens and DHT remain today.  
The next task was to investigate approaches to derivatise estrogens and 
androgens  separately aiming to improve sensitivity and MS ionisation by 
endowing the analyte with a chargeable or permanently charged group. Prior 
to this thesis, HMP had been applied to androgens for this purpose but the 
necessary chromatographic separation had not been achieved and was not 
ideal, thus methods had not progressed to full validation or biological 
application. 
We aimed to overcome the chromatographic challenges faced with hydrazine 
derivatives by comparing several different reagents, followed by validation of 
the analytical approach to detect low abundance DHT by derivatisation in 
plasma.  The next challenge was to achieve the same for estrogens, again 
improving the sensitivity of analysis for estrogens this time using a 
methylpyridinium derivative to detect these steroids in low abundance in 
human plasma and, in particular, to evaluate if the approach could quantify 





Derivatisation, in conjunction with LC-MS/MS, proved highly suitable for 
quantitative analysis of androgens in low abundance in human plasma with 
low volumes (10-200µL), presenting clear benefits in sensitivity over analysis 
of underivatised steroids. The approach allows concomitant analysis of T, A4 
and DHT and this method could be expanded to include further ketone 
containing steroids such as 11β-hydroxy and 11-ketoandrogens (Rauh et al., 
2006). 
Robust measurement was achieved across typical physiological ranges found 
in post-menopausal women and men. In addition, a highly sensitive method 
with LOQs better than previous methods were validated for estrogen using 
derivatisation by reaction of FMP-TS with phenolic estrogens, in conjunction 
with LC-MS/MS. This approach was found to be suitable for quantitative 
analysis of E1 and E2 in low abundance in plasma. The derivatisation reaction 
may be applicable to other naturally occurring phenolic steroids and their 
metabolites such hydroxyestrogens and catechol estrogens  (Denver et al., 
2019). These analytical approaches to quantify androgens and estrogens could 
be improved using new opportunities coming forward in the analytical field 
for example differential IM to improve SNR. 
Finally, use of these novel analytical approaches to sex hormones profiling as 
developed to better understand androgen/estrogen balance in a cohort of 
health men. Androgens and estrogens were quantified in samples collected 
from healthy subjects, to address baseline relationships between carefully 







Results show that sex steroids, did not show strong relationships with fat 
distribution somewhat surprisingly e.g. no relationship with BMI, WHR and 
body fat. In contrast however levels of androgens and estrogens did correlate 
with dynamic tests of insulin sensitivity. In particular, in these healthy 
individuals, low androgens were associated with improved glucose disposal, 
in contrast to the association of hypogonadism and diabetes. T and A4 related 
to BP and liver fat and additional studies are needed to address the mechanism 
of this relationship. The relationships with estrogens were more likely to be 
influenced by their rate of formation due to prevailing levels of androgens. 
DHT, A4 and E1 were not correlated significantly to other sex hormones. A 
knowledge of these relationships could be expanded by investigating the 
steroid profile in pre- and post-menopausal female candidates. 
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7.2 Conclusion and future perspectives 
In conclusion, sensitive methods for measurements of sex steroids were 
achieved using SPE and enhanced with derivatisation, in conjunction with LC-
MS/MS, thus overcoming the analytical challenges that poor ionization and 
low levels of sex steroids present. The approaches developed allow robust 
quantitative analysis of androgens and estrogens in low abundance in 
biological fluids across typical physiological ranges found in pre- and post-
menopausal women and men. Use of these novel analytical methods allowed 
insight into relationships between sex steroids, adipose tissue and metabolic 
diseases. Sex steroids are associated with Metabolic Syndrome, in particular 
diabetes in males balance of estrogens and androgens by aromatase and 5α-
reductases may play a role in predisposition to metabolic disease. 
The derivatisation methods developed could be further applied to other 
ketone and phenol containing steroids. These methods may also be applied to 
rodent models with low plasma volumes. Using micro extraction methods to 
better handle small volumes of sample may improve sensitivity and open 
windows for rodent clinical studies. In investigating lower flow 
chromatography such as micro and nano LC columns could enhance method 
efficiencies. Furthermore, other analytical techniques could be assessed with 
these methods, such as ultra high performance supercritical fluid 
chromatography (UHPSFC) to improve sensitivity (Storbeck et al., 2018) and 
differential ion mobility to suppress matrix noise (Uetrecht et al., 2010, Ray et 
al., 2015, Chouinard et al., 2016, Chouinard et al., 2017).  
Outcomes and understanding the role of sex steroids in Metabolic Syndrome 
development could be expanded through investigation in more male, pre- and 
post-menopausal female candidates. Moreover, candidates with higher risk 












ABDEL-MAGID, A. F., CARSON, K. G., HARRIS, B. D., MARYANOFF, C. A. & 
SHAH, R. D. 1996. Reductive Amination of Aldehydes and Ketones with 
Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive 
Amination Procedures (1). J Org Chem, 61, 3849-3862. 
ABRAHAM, G. E., MANLIMOS, F. S., SOLIS, M. & WICKMAN, A. C. 1975. 
Combined radioimmunoassay of four steroids in one ml of plasma: II. 
Androgens. Clin Biochem, 8, 374-8. 
ADOMAT, H. H., BAINS, O. S., LUBIENIECKA, J. M., GLEAVE, M. E., GUNS, 
E. S., GRIGLIATTI, T. A., REID, R. E. & RIGGS, K. W. 2012. Validation of 
a sequential extraction and liquid chromatography-tandem mass spectrometric 
method for determination of dihydrotestosterone, androstanediol and 
androstanediol-glucuronide in prostate tissues. J Chromatogr B Analyt Technol 
Biomed Life Sci, 902, 84-95. 
AHONEN, L., KESKI-RAHKONEN, P., SAARELAINEN, T., PAVIALA, J., 
KETOLA, R. A., AURIOLA, S., POUTANEN, M. & KOSTIANEN, R. 2012. 
Comparison of liquid chromatography-microchip/mass spectrometry to 
conventional liquid chromatography-mass spectrometry for the analysis of 
steroids. Anal Chim Acta, 721, 115-21. 
ANARI, M. R., BAKHTIAR, R., ZHU, B., HUSKEY, S., FRANKLIN, R. B. & 
EVANS, D. C. 2002. Derivatization of ethinylestradiol with dansyl chloride to 
enhance electrospray ionization: application in trace analysis of 
ethinylestradiol in rhesus monkey plasma. Anal Chem, 74, 4136-44. 
ARNLÖV, J., PENCINA, M. J., AMIN, S., NAM, B. H., BENJAMIN, E. J., 
MURABITO, J. M., WANG, T. J., KNAPP, P. E., D'AGOSTINO, R. B., 
BHASIN, S. & VASAN, R. S. 2006. Endogenous sex hormones and 
cardiovascular disease incidence in men. Ann Intern Med, 145, 176-84. 
BALAZY, M. 2004. Eicosanomics: targeted lipidomics of eicosanoids in biological 
systems. Prostaglandins Other Lipid Mediat, 73, 173-80. 
BARRETT-CONNOR, E., KHAW, K. T. & YEN, S. S. 1990. Endogenous sex 
hormone levels in older adult men with diabetes mellitus. Am J Epidemiol, 132, 
895-901. 
BARUD, W., PALUSIŃSKI, R., PIOTROWSKA-SWIRSZCZ, A., OSTROWSKI, S. 
& MAKARUK, B. 2005. [Sex hormones, HDL cholesterol and other 
lipoproteins in older males]. Pol Merkur Lekarski, 18, 295-7. 
BEINHAUER, J., BIAN, L., FAN, H., ŠEBELA, M., KUKULA, M., BARRERA, J. 
A. & SCHUG, K. A. 2015. Bulk derivatization and cation exchange restricted 
access media-based trap-and-elute liquid chromatography-mass spectrometry 
method for determination of trace estrogens in serum. Anal Chim Acta, 858, 
74-81. 
BHASIN, S., ZHANG, A., COVIELLO, A., JASUJA, R., ULLOOR, J., SINGH, R., 
VESPER, H. & VASAN, R. S. 2008. The impact of assay quality and reference 
ranges on clinical decision making in the diagnosis of androgen disorders. 
Steroids, 73, 1311-7. 
BOORSMA, A., DE NOBEL, H., TER RIET, B., BARGMANN, B., BRUL, S., 
HELLINGWERF, K. J. & KLIS, F. M. 2004. Characterization of the 
transcriptional response to cell wall stress in Saccharomyces cerevisiae. Yeast, 
21, 413-27. 
BORREY, D., MOERMAN, E., COCKX, A., ENGELRELST, V. & LANGLOIS, M. 
182 
 
R. 2007. Column-switching LC-MS/MS analysis for quantitative 
determination of testosterone in human serum. Clin Chim Acta, 382, 134-7. 
BRAY, G. A. 2003. Risks of obesity. Endocrinol Metab Clin North Am, 32, 787-804, 
viii. 
BROWN, L. M., GENT, L., DAVIS, K. & CLEGG, D. J. 2010. Metabolic impact of 
sex hormones on obesity. Brain Res, 1350, 77-85. 
BROWN, R. S. & LENNON, J. J. 1995. Mass resolution improvement by 
incorporation of pulsed ion extraction in a matrix-assisted laser 
desorption/ionization linear time-of-flight mass spectrometer. Anal Chem, 67, 
1998-2003. 
BUI, H. N., STRUYS, E. A., MARTENS, F., DE RONDE, W., THIENPONT, L. M., 
KENEMANS, P., VERHOEVEN, M. O., JAKOBS, C., DIJSTELBLOEM, H. 
M. & BLANKENSTEIN, M. A. 2010. Serum testosterone levels measured by 
isotope dilution-liquid chromatography-tandem mass spectrometry in 
postmenopausal women versus those in women who underwent bilateral 
oophorectomy. Ann Clin Biochem, 47, 248-52. 
BUNCH, J., CLENCH, M. R. & RICHARDS, D. S. 2004. Determination of 
pharmaceutical compounds in skin by imaging matrix-assisted laser 
desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom, 18, 
3051-60. 
CHADWICK, C. A., OWEN, L. J. & KEEVIL, B. G. 2005. Development of a method 
for the measurement of dehydroepiandrosterone sulphate by liquid 
chromatography-tandem mass spectrometry. Ann Clin Biochem, 42, 468-74. 
CHANG, H., WAN, Y., NAILE, J., ZHANG, X., WISEMAN, S., HECKER, M., 
LAM, M. H., GIESY, J. P. & JONES, P. D. 2010. Simultaneous quantification 
of multiple classes of phenolic compounds in blood plasma by liquid 
chromatography-electrospray tandem mass spectrometry. J Chromatogr A, 
1217, 506-13. 
CHOUINARD, C. D., CRUZEIRO, V. W. D., ROITBERG, A. E. & YOST, R. A. 
2017. Experimental and Theoretical Investigation of Sodiated Multimers of 
Steroid Epimers with Ion Mobility-Mass Spectrometry. J Am Soc Mass 
Spectrom, 28, 323-331. 
CHOUINARD, C. D., WEI, M. S., BEEKMAN, C. R., KEMPERMAN, R. H. & 
YOST, R. A. 2016. Ion Mobility in Clinical Analysis: Current Progress and 
Future Perspectives. Clin Chem, 62, 124-33. 
CLEGG, D., HEVENER, A. L., MOREAU, K. L., MORSELLI, E., CRIOLLO, A., 
VAN PELT, R. E. & VIEIRA-POTTER, V. J. 2017. Sex Hormones and 
Cardiometabolic Health: Role of Estrogen and Estrogen Receptors. 
Endocrinology, 158, 1095-1105. 
CLEGG, D. J., RIEDY, C. A., SMITH, K. A., BENOIT, S. C. & WOODS, S. C. 2003. 
Differential sensitivity to central leptin and insulin in male and female rats. 
Diabetes, 52, 682-7. 
COLANGELO, L. A., OUYANG, P., LIU, K., KOPP, P., GOLDEN, S. H., DOBS, A. 
S., SZKLO, M., VAIDYA, D., CUSHMAN, M. & GAPSTUR, S. M. 2009. 
Association of endogenous sex hormones with diabetes and impaired fasting 
glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care, 32, 1049-
51. 
CORONA, G., ELIA, C., CASETTA, B., DA PONTE, A., DEL PUP, L., OTTAVIAN, 
183 
 
E. & TOFFOLI, G. 2010. Liquid chromatography tandem mass spectrometry 
assay for fast and sensitive quantification of estrone-sulfate. Clin Chim Acta, 
411, 574-80. 
COURANT, F., AKSGLAEDE, L., ANTIGNAC, J. P., MONTEAU, F., SORENSEN, 
K., ANDERSSON, A. M., SKAKKEBAEK, N. E., JUUL, A. & BIZEC, B. L. 
2010. Assessment of circulating sex steroid levels in prepubertal and pubertal 
boys and girls by a novel ultrasensitive gas chromatography-tandem mass 
spectrometry method. J Clin Endocrinol Metab, 95, 82-92. 
CROES, K., STEFFENS, A., MARCHAND, D. H. & SNYDER, L. R. 2005. 
Relevance of pi-pi and dipole-dipole interactions for retention on cyano and 
phenyl columns in reversed-phase liquid chromatography. J Chromatogr A, 
1098, 123-30. 
DEFRONZO, R. A., TOBIN, J. D. & ANDRES, R. 1979. Glucose clamp technique: a 
method for quantifying insulin secretion and resistance. Am J Physiol, 237, 
E214-23. 
DEHENNIN, L. 1989. Estradiol-17 beta determined in plasma by gas 
chromatography-mass spectrometry with selected ion monitoring of mixed 
silyl ether-perfluoroacyl ester derivatives and use of various stable-isotope-
labeled internal standards. Clin Chem, 35, 532-6. 
DENVER, N., KHAN, S., STASINOPOULOS, I., CHURCH, C., HOMER, N. Z., 
MACLEAN, M. R. & ANDREW, R. 2019. Derivatization enhances analysis 
of estrogens and their bioactive metabolites in human plasma by liquid 
chromatography tandem mass spectrometry. Anal Chim Acta, 1054, 84-94. 
DOLAN, J. W., SNYDER, L. R., DJORDJEVIC, N. M., HILL, D. W. & WAEGHE, 
T. J. 1999a. Reversed-phase liquid chromatographic separation of complex 
samples by optimizing temperature and gradient time I. Peak capacity 
limitations. J Chromatogr A, 857, 1-20. 
DOLAN, J. W., SNYDER, L. R., DJORDJEVIC, N. M., HILL, D. W. & WAEGHE, 
T. J. 1999b. Reversed-phase liquid chromatographic separation of complex 
samples by optimizing temperature and gradient time II. Two-run assay 
procedures. J Chromatogr A, 857, 21-39. 
DOLAN, J. W., SNYDER, L. R., WOLCOTT, R. G., HABER, P., BACZEK, T., 
KALISZAN, R. & SANDER, L. C. 1999c. Reversed-phase liquid 
chromatographic separation of complex samples by optimizing temperature 
and gradient time III. Improving the accuracy of computer simulation. J 
Chromatogr A, 857, 41-68. 
DUELL, P. B. & BIERMAN, E. L. 1990. The relationship between sex hormones and 
high-density lipoprotein cholesterol levels in healthy adult men. Arch Intern 
Med, 150, 2317-20. 
DUNN, W. B., BROADHURST, D. I., ATHERTON, H. J., GOODACRE, R. & 
GRIFFIN, J. L. 2011. Systems level studies of mammalian metabolomes: the 
roles of mass spectrometry and nuclear magnetic resonance spectroscopy. 
Chem Soc Rev, 40, 387-426. 
EMMETT, M. R. & CAPRIOLI, R. M. 1994. Micro-electrospray mass spectrometry: 
Ultra-high-sensitivity analysis of peptides and proteins. J Am Soc Mass 
Spectrom, 5, 605-13. 
ETTER, M. L., EICHHORST, J. & LEHOTAY, D. C. 2006. Clinical determination of 
17-hydroxyprogesterone in serum by LC-MS/MS: comparison to Coat-A-
184 
 
Count RIA method. J Chromatogr B Analyt Technol Biomed Life Sci, 840, 69-
74. 
FAIX, J. D. 2013. Principles and pitfalls of free hormone measurements. Best Pract 
Res Clin Endocrinol Metab, 27, 631-45. 
FANELLI, F., BELLUOMO, I., DI LALLO, V. D., CUOMO, G., DE IASIO, R., 
BACCINI, M., CASADIO, E., CASETTA, B., VICENNATI, V., 
GAMBINERI, A., GROSSI, G., PASQUALI, R. & PAGOTTO, U. 2011. 
Serum steroid profiling by isotopic dilution-liquid chromatography-mass 
spectrometry: comparison with current immunoassays and reference intervals 
in healthy adults. Steroids, 76, 244-53. 
FAQEHI, A. M. M., COBICE, D. F., NAREDO, G., MAK, T. C. S., UPRETI, R., 
GIBB, F. W., BECKETT, G. J., WALKER, B. R., HOMER, N. Z. M. & 
ANDREW, R. 2016. Derivatization of estrogens enhances specificity and 
sensitivity of analysis of human plasma and serum by liquid chromatography 
tandem mass spectrometry. Talanta, 151, 148-156. 
FENN, J. B., MANN, M., MENG, C. K., WONG, S. F. & WHITEHOUSE, C. M. 
1989. Electrospray ionization for mass spectrometry of large biomolecules. 
Science, 246, 64-71. 
FOGARI, R., PRETI, P., ZOPPI, A., FOGARI, E., RINALDI, A., CORRADI, L. & 
MUGELLINI, A. 2005. Serum testosterone levels and arterial blood pressure 
in the elderly. Hypertens Res, 28, 625-30. 
FUKUI, K., TAKADA, Y., SUMIYOSHI, T., IMAI, T. & TAKAHASHI, K. 2006. 
Infrared multiphoton dissociation spectroscopic analysis of peptides and 
oligosaccharides by using fourier transform ion cyclotron resonance mass 
spectrometry with a midinfrared free-electron laser. J Phys Chem B, 110, 
16111-6. 
GALLAGHER, L. M., OWEN, L. J. & KEEVIL, B. G. 2007. Simultaneous 
determination of androstenedione and testosterone in human serum by liquid 
chromatography-tandem mass spectrometry. Ann Clin Biochem, 44, 48-56. 
GAMBINERI, A. & PELUSI, C. 2019. Sex hormones, obesity and type 2 diabetes: is 
there a link? Endocr Connect, 8, R1-R9. 
GAO, W., STALDER, T. & KIRSCHBAUM, C. 2015. Quantitative analysis of 
estradiol and six other steroid hormones in human saliva using a high 
throughput liquid chromatography-tandem mass spectrometry assay. Talanta, 
143, 353-358. 
GASKELL, S. J. & BROWNSEY, B. G. 1983. Immunoadsorption to improve gas 
chromatography/high-resolution mass spectrometry of estradiol-17 beta in 
plasma. Clin Chem, 29, 677-80. 
GIBB, F. W., DIXON, J. M., CLARKE, C., HOMER, N. Z., FAQEHI, A. M. M., 
ANDREW, R. & WALKER, B. R. 2019a. Higher Insulin Resistance & 
Adiposity in Post-menopausal Women With Breast Cancer Treated With 
Aromatase Inhibitors. J Clin Endocrinol Metab. 
GIBB, F. W., DIXON, J. M., CLARKE, C., HOMER, N. Z., FAQEHI, A. M. M., 
ANDREW, R. & WALKER, B. R. 2019b. Higher Insulin Resistance and 
Adiposity in Postmenopausal Women With Breast Cancer Treated With 
Aromatase Inhibitors. J Clin Endocrinol Metab, 104, 3670-3678. 
GIBB, F. W., HOMER, N. Z., FAQEHI, A. M., UPRETI, R., LIVINGSTONE, D. E., 
MCINNES, K. J., ANDREW, R. & WALKER, B. R. 2016. Aromatase 
185 
 
Inhibition Reduces Insulin Sensitivity in Healthy Men. J Clin Endocrinol 
Metab, 101, 2040-6. 
GOODMAN-GRUEN, D. & BARRETT-CONNOR, E. 2000. Sex differences in the 
association of endogenous sex hormone levels and glucose tolerance status in 
older men and women. Diabetes Care, 23, 912-8. 
GREBE, S. K. & SINGH, R. J. 2011. LC-MS/MS in the Clinical Laboratory - Where 
to From Here? Clin Biochem Rev, 32, 5-31. 
GROSSMANN, M. 2014. Testosterone and glucose metabolism in men: current 
concepts and controversies. J Endocrinol, 220, R37-55. 
GROVER, D. P., ZHANG, Z. L., READMAN, J. W. & ZHOU, J. L. 2009. A 
comparison of three analytical techniques for the measurement of steroidal 
estrogens in environmental water samples. Talanta, 78, 1204-10. 
GUILLARME, D., RUTA, J., RUDAZ, S. & VEUTHEY, J. L. 2010. New trends in 
fast and high-resolution liquid chromatography: a critical comparison of 
existing approaches. Anal Bioanal Chem, 397, 1069-82. 
GUO, T., GU, J., SOLDIN, O. P., SINGH, R. J. & SOLDIN, S. J. 2008. Rapid 
measurement of estrogens and their metabolites in human serum by liquid 
chromatography-tandem mass spectrometry without derivatization. Clin 
Biochem, 41, 736-41. 
GUO, T., TAYLOR, R. L., SINGH, R. J. & SOLDIN, S. J. 2006. Simultaneous 
determination of 12 steroids by isotope dilution liquid chromatography-
photospray ionization tandem mass spectrometry. Clin Chim Acta, 372, 76-82. 
HANOLD, K. A., FISCHER, S. M., CORMIA, P. H., MILLER, C. E. & SYAGE, J. 
A. 2004. Atmospheric pressure photoionization. 1. General properties for 
LC/MS. Anal Chem, 76, 2842-51. 
HANSEN, F. M., FAHMY, N. & NIELSEN, J. H. 1980. The influence of sexual 
hormones on lipogenesis and lipolysis in rat fat cells. Acta Endocrinol 
(Copenh), 95, 566-70. 
HARVEY, D. J. 2009. Analysis of carbohydrates and glycoconjugates by matrix-
assisted laser desorption/ionization mass spectrometry: An update for 2003-
2004. Mass Spectrom Rev, 28, 273-361. 
HIGASHI, T. 2006. Trace determination of steroids causing age-related diseases using 
LC/MS combined with detection-oriented derivatization. Chem Pharm Bull 
(Tokyo), 54, 1479-85. 
HIGASHI, T., NINOMIYA, Y., IWAKI, N., YAMAUCHI, A., TAKAYAMA, N. & 
SHIMADA, K. 2006. Studies on neurosteroids XVIII LC-MS analysis of 
changes in rat brain and serum testosterone levels induced by immobilization 
stress and ethanol administration. Steroids, 71, 609-17. 
HIGASHI, T., NINOMIYA, Y. & SHIMADA, K. 2008a. Studies on neurosteroids 
XX. Liquid chromatography-tandem mass spectrometric method for 
simultaneous determination of testosterone and 5alpha-dihydrotestosterone in 
rat brain and serum. J Chromatogr Sci, 46, 653-8. 
HIGASHI, T., NISHIO, T., HAYASHI, N. & SHIMADA, K. 2007a. Alternative 
procedure for charged derivatization to enhance detection responses of steroids 
in electrospray ionization-MS. Chem Pharm Bull (Tokyo), 55, 662-5. 
HIGASHI, T., NISHIO, T., UCHIDA, S., SHIMADA, K., FUKUSHI, M. & MAEDA, 
M. 2008b. Simultaneous determination of 17alpha-hydroxypregnenolone and 
17alpha-hydroxyprogesterone in dried blood spots from low birth weight 
186 
 
infants using LC-MS/MS. J Pharm Biomed Anal, 48, 177-82. 
HIGASHI, T. & OGAWA, S. 2016. Chemical derivatization for enhancing sensitivity 
during LC/ESI-MS/MS quantification of steroids in biological samples: a 
review. J Steroid Biochem Mol Biol, 162, 57-69. 
HIGASHI, T., SHIBAYAMA, Y. & SHIMADA, K. 2007b. Determination of salivary 
dehydroepiandrosterone using liquid chromatography--tandem mass 
spectrometry combined with charged derivatization. J Chromatogr B Analyt 
Technol Biomed Life Sci, 846, 195-201. 
HIGASHI, T. & SHIMADA, K. 2004. Derivatization of neutral steroids to enhance 
their detection characteristics in liquid chromatography-mass spectrometry. 
Anal Bioanal Chem, 378, 875-82. 
HIGASHI, T., YAMAUCHI, A. & SHIMADA, K. 2005a. 2-hydrazino-1-
methylpyridine: a highly sensitive derivatization reagent for oxosteroids in 
liquid chromatography-electrospray ionization-mass spectrometry. J 
Chromatogr B Analyt Technol Biomed Life Sci, 825, 214-22. 
HIGASHI, T., YAMAUCHI, A., SHIMADA, K., KOH, E., MIZOKAMI, A. & 
NAMIKI, M. 2005b. Determination of prostatic androgens in 10 mg of tissue 
using liquid chromatography-tandem mass spectrometry with charged 
derivatization. Anal Bioanal Chem, 382, 1035-43. 
HILLENKAMP, F. & KARAS, M. 1990. Mass spectrometry of peptides and proteins 
by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol, 
193, 280-95. 
HOLLEMEYER, K., ALTMEYER, W., HEINZLE, E. & PITRA, C. 2008. Species 
identification of Oetzi's clothing with matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry based on peptide 
pattern similarities of hair digests. Rapid Commun Mass Spectrom, 22, 2751-
67. 
HU, Q., NOLL, R. J., LI, H., MAKAROV, A., HARDMAN, M. & GRAHAM 
COOKS, R. 2005. The Orbitrap: a new mass spectrometer. J Mass Spectrom, 
40, 430-43. 
HUHTANIEMI, I. T., TAJAR, A., LEE, D. M., O'NEILL, T. W., FINN, J. D., 
BARTFAI, G., BOONEN, S., CASANUEVA, F. F., GIWERCMAN, A., 
HAN, T. S., KULA, K., LABRIE, F., LEAN, M. E., PENDLETON, N., 
PUNAB, M., SILMAN, A. J., VANDERSCHUEREN, D., FORTI, G., WU, F. 
C. & GROUP, E. 2012. Comparison of serum testosterone and estradiol 
measurements in 3174 European men using platform immunoassay and mass 
spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol, 
166, 983-91. 
HUYSMAN, S., VAN MEULEBROEK, L., VANRYCKEGHEM, F., VAN 
LANGENHOVE, H., DEMEESTERE, K. & VANHAECKE, L. 2017. 
Development and validation of an ultra-high performance liquid 
chromatographic high resolution Q-Orbitrap mass spectrometric method for 
the simultaneous determination of steroidal endocrine disrupting compounds 
in aquatic matrices. Anal Chim Acta, 984, 140-150. 
JANZEN, N., SANDER, S., TERHARDT, M., PETER, M. & SANDER, J. 2008. Fast 
and direct quantification of adrenal steroids by tandem mass spectrometry in 




JASUJA, G. K., TRAVISON, T. G., DAVDA, M., ROSE, A. J., ZHANG, A., 
KUSHNIR, M. M., ROCKWOOD, A. L., MEIKLE, W., COVIELLO, A. D., 
D'AGOSTINO, R., VASAN, R. S. & BHASIN, S. 2013. Circulating estrone 
levels are associated prospectively with diabetes risk in men of the 
Framingham Heart Study. Diabetes Care, 36, 2591-6. 
JOLY, N., EL ANEED, A., MARTIN, P., CECCHELLI, R. & BANOUB, J. 2005. 
Structural determination of the novel fragmentation routes of morphine opiate 
receptor antagonists using electrospray ionization quadrupole time-of-flight 
tandem mass spectrometry. Rapid Commun Mass Spectrom, 19, 3119-30. 
KALHORN, T. F., PAGE, S. T., HOWALD, W. N., MOSTAGHEL, E. A. & 
NELSON, P. S. 2007. Analysis of testosterone and dihydrotestosterone from 
biological fluids as the oxime derivatives using high-performance liquid 
chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom, 
21, 3200-6. 
KAO, T. L., CHEN, Y. L., KUAN, Y. P., CHANG, W. C., HO, Y. C., YEH, S., JENG, 
L. B. & MA, W. L. 2017. Estrogen-Estrogen Receptor α Signaling Facilitates 
Bilirubin Metabolism in Regenerating Liver Through Regulating Cytochrome 
P450 2A6 Expression. Cell Transplant, 26, 1822-1829. 
KARAS, M. & HILLENKAMP, F. 1988. Laser desorption ionization of proteins with 
molecular masses exceeding 10,000 daltons. Anal Chem, 60, 2299-301. 
KE, Y., BERTIN, J., GONTHIER, R., SIMARD, J. N. & LABRIE, F. 2014. A 
sensitive, simple and robust LC-MS/MS method for the simultaneous 
quantification of seven androgen- and estrogen-related steroids in 
postmenopausal serum. J Steroid Biochem Mol Biol, 144 Pt B, 523-34. 
KENNY, L. C., BROADHURST, D. I., DUNN, W., BROWN, M., NORTH, R. A., 
MCCOWAN, L., ROBERTS, C., COOPER, G. J., KELL, D. B., BAKER, P. 
N. & CONSORTIUM, S. F. P. E. 2010. Robust early pregnancy prediction of 
later preeclampsia using metabolomic biomarkers. Hypertension, 56, 741-9. 
KERWIN, J. L., WIENS, A. M. & ERICSSON, L. H. 1996. Identification of fatty 
acids by electrospray mass spectrometry and tandem mass spectrometry. J 
Mass Spectrom, 31, 184-92. 
KESKI-RAHKONEN, P., DESAI, R., JIMENEZ, M., HARWOOD, D. T. & 
HANDELSMAN, D. J. 2015. Measurement of Estradiol in Human Serum by 
LC-MS/MS Using a Novel Estrogen-Specific Derivatization Reagent. Anal 
Chem, 87, 7180-6. 
KIM, J. H., CHO, H. T. & KIM, Y. J. 2014. The role of estrogen in adipose tissue 
metabolism: insights into glucose homeostasis regulation. Endocr J, 61, 1055-
67. 
KLAIR, J. S., YANG, J. D., ABDELMALEK, M. F., GUY, C. D., GILL, R. M., 
YATES, K., UNALP-ARIDA, A., LAVINE, J. E., CLARK, J. M., DIEHL, A. 
M., SUZUKI, A. & NETWORK, N. S. C. R. 2016. A longer duration of 
estrogen deficiency increases fibrosis risk among postmenopausal women with 
nonalcoholic fatty liver disease. Hepatology, 64, 85-91. 
KLEY, H. K., EDELMANN, P. & KRÜSKEMPER, H. L. 1980. Relationship of 
plasma sex hormones to different parameters of obesity in male subjects. 
Metabolism, 29, 1041-5. 
KRATZ, A. & LEWANDROWSKI, K. B. 1998. Case records of the Massachusetts 
General Hospital. Weekly clinicopathological exercises. Normal reference 
188 
 
laboratory values. N Engl J Med, 339, 1063-72. 
KRONE, N., HANLEY, N. A. & ARLT, W. 2007. Age-specific changes in sex steroid 
biosynthesis and sex development. Best Pract Res Clin Endocrinol Metab, 21, 
393-401. 
KRUVE, A., REBANE, R., KIPPER, K., OLDEKOP, M. L., EVARD, H., 
HERODES, K., RAVIO, P. & LEITO, I. 2015. Tutorial review on validation 
of liquid chromatography-mass spectrometry methods: part II. Anal Chim Acta, 
870, 8-28. 
KULLE, A. E., RIEPE, F. G., MELCHIOR, D., HIORT, O. & HOLTERHUS, P. M. 
2010. A novel ultrapressure liquid chromatography tandem mass spectrometry 
method for the simultaneous determination of androstenedione, testosterone, 
and dihydrotestosterone in pediatric blood samples: age- and sex-specific 
reference data. J Clin Endocrinol Metab, 95, 2399-409. 
KUSHNIR, M. M., BLAMIRES, T., ROCKWOOD, A. L., ROBERTS, W. L., YUE, 
B., ERDOGAN, E., BUNKER, A. M. & MEIKLE, A. W. 2010a. Liquid 
chromatography-tandem mass spectrometry assay for androstenedione, 
dehydroepiandrosterone, and testosterone with pediatric and adult reference 
intervals. Clin Chem, 56, 1138-47. 
KUSHNIR, M. M., NEILSON, R., ROBERTS, W. L. & ROCKWOOD, A. L. 2004. 
Cortisol and cortisone analysis in serum and plasma by atmospheric pressure 
photoionization tandem mass spectrometry. Clin Biochem, 37, 357-62. 
KUSHNIR, M. M., ROCKWOOD, A. L., BERGQUIST, J., VARSHAVSKY, M., 
ROBERTS, W. L., YUE, B., BUNKER, A. M. & MEIKLE, A. W. 2008. High-
sensitivity tandem mass spectrometry assay for serum estrone and estradiol. 
Am J Clin Pathol, 129, 530-9. 
KUSHNIR, M. M., ROCKWOOD, A. L., ROBERTS, W. L., PATTISON, E. G., 
BUNKER, A. M., FITZGERALD, R. L. & MEIKLE, A. W. 2006a. 
Performance characteristics of a novel tandem mass spectrometry assay for 
serum testosterone. Clin Chem, 52, 120-8. 
KUSHNIR, M. M., ROCKWOOD, A. L., ROBERTS, W. L., PATTISON, E. G., 
OWEN, W. E., BUNKER, A. M. & MEIKLE, A. W. 2006b. Development and 
performance evaluation of a tandem mass spectrometry assay for 4 adrenal 
steroids. Clin Chem, 52, 1559-67. 
KUSHNIR, M. M., ROCKWOOD, A. L., ROBERTS, W. L., YUE, B., BERGQUIST, 
J. & MEIKLE, A. W. 2011. Liquid chromatography tandem mass spectrometry 
for analysis of steroids in clinical laboratories. Clin Biochem, 44, 77-88. 
KUSHNIR, M. M., ROCKWOOD, A. L., YUE, B. & MEIKLE, A. W. 2010b. High 
sensitivity measurement of estrone and estradiol in serum and plasma using 
LC-MS/MS. Methods Mol Biol, 603, 219-28. 
LACEY, J. M., MINUTTI, C. Z., MAGERA, M. J., TAUSCHER, A. L., CASETTA, 
B., MCCANN, M., LYMP, J., HAHN, S. H., RINALDO, P. & MATERN, D. 
2004. Improved specificity of newborn screening for congenital adrenal 
hyperplasia by second-tier steroid profiling using tandem mass spectrometry. 
Clin Chem, 50, 621-5. 
LAURIAN VLASE1, S. I., DANIELA-LUCIA MUNTEAN2, BIANCA ŐSZ2, 
AMALIA & MIKLOS2, A. T.-V., CAMIL-EUGEN VARI2 2016. NEW LC-
MS/MS METHOD FOR TESTOSTERONE AND  




LAW, M. R., CHENG, R., HACKSHAW, A. K., ALLAWAY, S. & HALE, A. K. 
1997. Cigarette smoking, sex hormones and bone density in women. Eur J 
Epidemiol, 13, 553-8. 
LEE, C. H., KUO, S. W., HUNG, Y. J., HSIEH, C. H., HE, C. T., YANG, T. C., LIAN, 
W. C., CHYI-FAN, S. & PEI, D. 2005. The effect of testosterone supplement 
on insulin sensitivity, glucose effectiveness, and acute insulin response after 
glucose load in male type 2 diabetics. Endocr Res, 31, 139-48. 
LEE, M. J. & FRIED, S. K. 2017. Sex-dependent Depot Differences in Adipose Tissue 
Development and Function; Role of Sex Steroids. J Obes Metab Syndr, 26, 
172-180. 
LI, W., LI, Y. H., LI, A. C., ZHOU, S. & NAIDONG, W. 2005. Simultaneous 
determination of norethindrone and ethinyl estradiol in human plasma by high 
performance liquid chromatography with tandem mass spectrometry--
experiences on developing a highly selective method using derivatization 
reagent for enhancing sensitivity. J Chromatogr B Analyt Technol Biomed Life 
Sci, 825, 223-32. 
LIANG, Y., LIU, J., ZHONG, Q., HUANG, T. & ZHOU, T. 2020. An automatic 
online solid-phase dehydrate extraction-ultra-high performance supercritical 
fluid chromatography-tandem mass spectrometry system using a dilution 
strategy for the screening of doping agents in human urine. Anal Chim Acta, 
1101, 184-192. 
LIN, Y. H., CHEN, C. Y. & WANG, G. S. 2007. Analysis of steroid estrogens in water 
using liquid chromatography/tandem mass spectrometry with chemical 
derivatizations. Rapid Commun Mass Spectrom, 21, 1973-83. 
LIU, J., SHIMIZU, K. & KONDO, R. 2009. Anti-androgenic activity of fatty acids. 
Chem Biodivers, 6, 503-12. 
LIU, Y., LU, J., YANG, S., ZHANG, Q. & XU, Y. 2016. New drostanolone 
metabolites in human urine by liquid chromatography time-of-flight tandem 
mass spectrometry and their application for doping control. Steroids, 108, 61-
7. 
LIVINGSTONE, D. E., DI ROLLO, E. M., MAK, T. C., SOOY, K., WALKER, B. R. 
& ANDREW, R. 2017. Metabolic dysfunction in female mice with disruption 
of 5α-reductase 1. J Endocrinol, 232, 29-36. 
LÓPEZ DE ALDA, M. J. & BARCELÓ, D. 2001. Review of analytical methods for 
the determination of estrogens and progestogens in waste waters. Fresenius J 
Anal Chem, 371, 437-47. 
MAK, T. C. S., LIVINGSTONE, D. E. W., NIXON, M., WALKER, B. R. & 
ANDREW, R. 2019. Role of Hepatic Glucocorticoid Receptor in Metabolism 
in Models of 5αR1 Deficiency in Male Mice. Endocrinology, 160, 2061-2073. 
MARSHALL, A. G., HENDRICKSON, C. L. & JACKSON, G. S. 1998. Fourier 
transform ion cyclotron resonance mass spectrometry: a primer. Mass 
Spectrom Rev, 17, 1-35. 
MCINNES, K. J., BROWN, K. A., HUNGER, N. I. & SIMPSON, E. R. 2012. 
Regulation of LKB1 expression by sex hormones in adipocytes. Int J Obes 
(Lond), 36, 982-5. 
MCKENZIE, J., FISHER, B. M., JAAP, A. J., STANLEY, A., PATERSON, K. & 
SATTAR, N. 2006. Effects of HRT on liver enzyme levels in women with type 
190 
 
2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf), 65, 
40-4. 
MCLAFFERTY, F. W. 1959. Mass Spectrometric Analysis. Molcular Rearrangements   
. . Anal Chem. 
MEZZULLO, M., PELUSI, C., FAZZINI, A., REPACI, A., DI DALMAZI, G., 
GAMBINERI, A., PAGOTTO, U. & FANELLI, F. 2020. Female and male 
serum reference intervals for challenging sex and precursor steroids by liquid 
chromatography - tandem mass spectrometry. J Steroid Biochem Mol Biol, 
197, 105538. 
MIKESH, L. M., UEBERHEIDE, B., CHI, A., COON, J. J., SYKA, J. E., 
SHABANOWITZ, J. & HUNT, D. F. 2006. The utility of ETD mass 
spectrometry in proteomic analysis. Biochim Biophys Acta, 1764, 1811-22. 
MILLER, W. L. & AUCHUS, R. J. 2011. The molecular biology, biochemistry, and 
physiology of human steroidogenesis and its disorders. Endocr Rev, 32, 81-
151. 
MOAL, V., MATHIEU, E., REYNIER, P., MALTHIÈRY, Y. & GALLOIS, Y. 2007. 
Low serum testosterone assayed by liquid chromatography-tandem mass 
spectrometry. Comparison with five immunoassay techniques. Clin Chim Acta, 
386, 12-9. 
MORSELLI, E., SANTOS, R. S., CRIOLLO, A., NELSON, M. D., PALMER, B. F. 
& CLEGG, D. J. 2017. The effects of oestrogens and their receptors on 
cardiometabolic health. Nat Rev Endocrinol, 13, 352-364. 
MULLER, M., VAN DER SCHOUW, Y. T., THIJSSEN, J. H. & GROBBEE, D. E. 
2003. Endogenous sex hormones and cardiovascular disease in men. J Clin 
Endocrinol Metab, 88, 5076-86. 
NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT 
PANEL ON DETECTION, E. A., AND TREATMENT OF HIGH BLOOD 
CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III) 2002. 
Third Report of the National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) final report. Circulation, 106, 3143-421. 
NAVARRO, G., ALLARD, C., XU, W. & MAUVAIS-JARVIS, F. 2015. The role of 
androgens in metabolism, obesity, and diabetes in males and females. Obesity 
(Silver Spring), 23, 713-9. 
NELSON, R. E., GREBE, S. K., OKANE, D. J. & SINGH, R. J. 2004. Liquid 
chromatography-tandem mass spectrometry assay for simultaneous 
measurement of estradiol and estrone in human plasma. Clin Chem, 50, 373-
84. 
NOKOFF, N., THURSTON, J., HILKIN, A., PYLE, L., ZEITLER, P. S., NADEAU, 
K. J., SANTORO, N. & KELSEY, M. M. 2019. Sex Differences in Effects of 
Obesity on Reproductive Hormones and Glucose Metabolism in Early Puberty. 
J Clin Endocrinol Metab, 104, 4390-4397. 
O'BRIEN, Z., POST, N., BROWN, M., MADAN, A., COON, T., LUO, R. & 
KOHOUT, T. A. 2009. Validation and application of a liquid chromatography-
tandem mass spectrometric method for the simultaneous determination of 
testosterone and dihydrotestosterone in rat prostatic tissue using a 96-well 
format. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 3515-21. 
OWEN, L. J. & KEEVIL, B. G. 2013. Supported liquid extraction as an alternative to 
191 
 
solid phase extraction for LC-MS/MS aldosterone analysis? Ann Clin Biochem, 
50, 489-91. 
OWEN, L. J., WU, F. C., BÜTTLER, R. M. & KEEVIL, B. G. 2016. A direct assay 
for the routine measurement of testosterone, androstenedione, 
dihydrotestosterone and dehydroepiandrosterone by liquid chromatography 
tandem mass spectrometry. Ann Clin Biochem, 53, 580-7. 
PAILLER, J. Y., KREIN, A., PFISTER, L., HOFFMANN, L. & GUIGNARD, C. 
2009. Solid phase extraction coupled to liquid chromatography-tandem mass 
spectrometry analysis of sulfonamides, tetracyclines, analgesics and hormones 
in surface water and wastewater in Luxembourg. Sci Total Environ, 407, 4736-
43. 
PARKER, K. L. & SCHIMMER, B. P. 1995. Transcriptional regulation of the genes 
encoding the cytochrome P-450 steroid hydroxylases. Vitam Horm, 51, 339-
70. 
PAYNE, A. H. & HALES, D. B. 2004. Overview of steroidogenic enzymes in the 
pathway from cholesterol to active steroid hormones. Endocr Rev, 25, 947-70. 
PAZZAGLI, M., FORTI, G., CAPPELLINI, A. & SERIO, M. 1975. 
Radioimmunoassay of plasma dihydrotestosterone in normal and hypogonodal 
men. Clin Endocrinol (Oxf), 4, 513-20. 
PEDROUZO, M., BORRULL, F., POCURULL, E. & MARCÉ, R. M. 2009. Estrogens 
and their conjugates: Determination in water samples by solid-phase extraction 
and liquid chromatography-tandem mass spectrometry. Talanta, 78, 1327-31. 
PIRKE, K. M. & DOERR, P. 1975. Plasma dihydrotestosterone in normal adult males 
and its relation to testosterone. Acta Endocrinol (Copenh), 79, 357-65. 
POLITIS, A., PARK, A. Y., HYUNG, S. J., BARSKY, D., RUOTOLO, B. T. & 
ROBINSON, C. V. 2010. Integrating ion mobility mass spectrometry with 
molecular modelling to determine the architecture of multiprotein complexes. 
PLoS One, 5, e12080. 
PREBIHALO, S. E., BERRIER, K. L., FREYE, C. E., BAHAGHIGHAT, H. D., 
MOORE, N. R., PINKERTON, D. K. & SYNOVEC, R. E. 2018. 
Multidimensional Gas Chromatography: Advances in Instrumentation, 
Chemometrics, and Applications. Anal Chem, 90, 505-532. 
PREIS, A., MUGISHA, L., HAUSER, B., WELTRING, A. & DESCHNER, T. 2011. 
Androgen and androgen metabolite levels in serum and urine of East African 
chimpanzees (Pan troglodytes schweinfurthii): comparison of EIA and LC-MS 
analyses. Gen Comp Endocrinol, 174, 335-43. 
PURCELL, A. W. & GORMAN, J. J. 2001. The use of post-source decay in matrix-
assisted laser desorption/ionisation mass spectrometry to delineate T cell 
determinants. J Immunol Methods, 249, 17-31. 
RASMUSSEN, T. H., NIELSEN, F., ANDERSEN, H. R., NIELSEN, J. B., WEIHE, 
P. & GRANDJEAN, P. 2003. Assessment of xenoestrogenic exposure by a 
biomarker approach: application of the E-Screen bioassay to determine 
estrogenic response of serum extracts. Environ Health, 2, 12. 
RAUH, M., GRÖSCHL, M., RASCHER, W. & DÖRR, H. G. 2006. Automated, fast 
and sensitive quantification of 17 alpha-hydroxy-progesterone, 
androstenedione and testosterone by tandem mass spectrometry with on-line 
extraction. Steroids, 71, 450-8. 
RAY, J. A., KUSHNIR, M. M., YOST, R. A., ROCKWOOD, A. L. & WAYNE 
192 
 
MEIKLE, A. 2015. Performance enhancement in the measurement of 5 
endogenous steroids by LC-MS/MS combined with differential ion mobility 
spectrometry. Clin Chim Acta, 438, 330-6. 
REGAL, P., VÁZQUEZ, B. I., FRANCO, C. M., CEPEDA, A. & FENTE, C. 2009. 
Quantitative LC-MS/MS method for the sensitive and simultaneous 
determination of natural hormones in bovine serum. J Chromatogr B Analyt 
Technol Biomed Life Sci, 877, 2457-64. 
REMANE, D., WISSENBACH, D. K., MEYER, M. R. & MAURER, H. H. 2010. 
Systematic investigation of ion suppression and enhancement effects of 
fourteen stable-isotope-labeled internal standards by their native analogues 
using atmospheric-pressure chemical ionization and electrospray ionization 
and the relevance for multi-analyte liquid chromatographic/mass spectrometric 
procedures. Rapid Commun Mass Spectrom, 24, 859-67. 
RENNE, A., LUO, L., JAROW, J., WRIGHT, W. W., BROWN, T. R., CHEN, H., 
ZIRKIN, B. R. & FRIESEN, M. D. 2012. Simultaneous quantification of 
steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass 
spectrometry. J Androl, 33, 691-8. 
ROBB, D. B., COVEY, T. R. & BRUINS, A. P. 2000. Atmospheric pressure 
photoionization: an ionization method for liquid chromatography-mass 
spectrometry. Anal Chem, 72, 3653-9. 
ROSNER, W., VESPER, H., SOCIETY, E., CHEMISTRY, A. A. F. C., 
ENDOCRINOLOGISTS, A. A. O. C., SOCIETY, A. E. P., RESEARCH, A. 
S. F. B. A. M., MEDICINE, A. S. F. R., ASSOCIATION, A. U., 
LABORATORIES, A. O. P. H., AMERICA, L. C. O., SOCIETY, N. A. M. & 
SOCIETY, P. E. 2010. Toward excellence in testosterone testing: a consensus 
statement. J Clin Endocrinol Metab, 95, 4542-8. 
RUSSELL, D. W. & WILSON, J. D. 1994. Steroid 5 alpha-reductase: two genes/two 
enzymes. Annu Rev Biochem, 63, 25-61. 
SALERNO, R., MONETI, G., FORTI, G., MAGINI, A., NATALI, A., SALTUTTI, 
C., DI CELLO, V., COSTANTINI, A. & SERIO, M. 1988. Simultaneous 
determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 
alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and 
prostatic tissue of patients affected by benign prostatic hyperplasia. Effects of 
3-month treatment with a GnRH analog. J Androl, 9, 234-40. 
SALVADOR, A., MORETTON, C., PIRAM, A. & FAURE, R. 2007. On-line solid-
phase extraction with on-support derivatization for high-sensitivity liquid 
chromatography tandem mass spectrometry of estrogens in influent/effluent of 
wastewater treatment plants. J Chromatogr A, 1145, 102-9. 
SAMARAS, K., HAYWARD, C. S., SULLIVAN, D., KELLY, R. P. & CAMPBELL, 
L. V. 1999. Effects of postmenopausal hormone replacement therapy on central 
abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 
2 diabetes: a prospective study. Diabetes Care, 22, 1401-7. 
SANDERSON, J. T. 2006. The steroid hormone biosynthesis pathway as a target for 
endocrine-disrupting chemicals. Toxicol Sci, 94, 3-21. 
SANTA, T. 2011. Derivatization reagents in liquid chromatography/electrospray 
ionization tandem mass spectrometry. Biomed Chromatogr, 25, 1-10. 
SANTA, T. 2013. Derivatization in liquid chromatography for mass spectrometric 
detection. Drug Discov Ther, 7, 9-17. 
193 
 
SANTA, T., AL-DIRBASHI, O. Y. & FUKUSHIMA, T. 2007. Derivatization 
reagents in liquid chromatography/electrospray ionization tandem mass 
spectrometry for biomedical analysis. Drug Discov Ther, 1, 108-18. 
SANTEN, R. J., DEMERS, L., OHORODNIK, S., SETTLAGE, J., LANGECKER, 
P., BLANCHETT, D., GOSS, P. E. & WANG, S. 2007. Superiority of gas 
chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol 
for monitoring of aromatase inhibitor therapy. Steroids, 72, 666-71. 
SANTEN, R. J., LEE, J. S., WANG, S., DEMERS, L. M., MAURAS, N., WANG, H. 
& SINGH, R. 2008. Potential role of ultra-sensitive estradiol assays in 
estimating the risk of breast cancer and fractures. Steroids, 73, 1318-21. 
SECKL, J. R. & WALKER, B. R. 2004. 11beta-hydroxysteroid dehydrogenase type 1 
as a modulator of glucocorticoid action: from metabolism to memory. Trends 
Endocrinol Metab, 15, 418-24. 
SELVIN, E., FEINLEIB, M., ZHANG, L., ROHRMANN, S., RIFAI, N., NELSON, 
W. G., DOBS, A., BASARIA, S., GOLDEN, S. H. & PLATZ, E. A. 2007. 
Androgens and diabetes in men: results from the Third National Health and 
Nutrition Examination Survey (NHANES III). Diabetes Care, 30, 234-8. 
SEMMES, O. J., FENG, Z., ADAM, B. L., BANEZ, L. L., BIGBEE, W. L., CAMPOS, 
D., CAZARES, L. H., CHAN, D. W., GRIZZLE, W. E., IZBICKA, E., 
KAGAN, J., MALIK, G., MCLERRAN, D., MOUL, J. W., PARTIN, A., 
PRASANNA, P., ROSENZWEIG, J., SOKOLL, L. J., SRIVASTAVA, S., 
THOMPSON, I., WELSH, M. J., WHITE, N., WINGET, M., YASUI, Y., 
ZHANG, Z. & ZHU, L. 2005. Evaluation of serum protein profiling by surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry for the 
detection of prostate cancer: I. Assessment of platform reproducibility. Clin 
Chem, 51, 102-12. 
SHEN, M. & SHI, H. 2015. Sex Hormones and Their Receptors Regulate Liver Energy 
Homeostasis. Int J Endocrinol, 2015, 294278. 
SHIBAYAMA, Y., HIGASHI, T., SHIMADA, K., KASHIMADA, K., ONISHI, T., 
ONO, M., MIYAI, K. & MIZUTANI, S. 2008. Liquid chromatography-tandem 
mass spectrometric method for determination of salivary 17alpha-
hydroxyprogesterone: a noninvasive tool for evaluating efficacy of hormone 
replacement therapy in congenital adrenal hyperplasia. J Chromatogr B Analyt 
Technol Biomed Life Sci, 867, 49-56. 
SHIBAYAMA, Y., HIGASHI, T., SHIMADA, K., ODANI, A., MIZOKAMI, A., 
KONAKA, H., KOH, E. & NAMIKI, M. 2009. Simultaneous determination of 
salivary testosterone and dehydroepiandrosterone using LC-MS/MS: Method 
development and evaluation of applicability for diagnosis and medication for 
late-onset hypogonadism. J Chromatogr B Analyt Technol Biomed Life Sci, 
877, 2615-23. 
SIEMIŃSKA, L., CICHOŃ-LENART, A., KAJDANIUK, D., KOS-KUDŁA, B., 
MAREK, B., LENART, J. & NOWAK, M. 2006. [Sex hormones and 
adipocytokines in postmenopausal women]. Pol Merkur Lekarski, 20, 727-30. 
SINGH, R. J. 2008. Validation of a high throughput method for serum/plasma 
testosterone using liquid chromatography tandem mass spectrometry (LC-
MS/MS). Steroids, 73, 1339-44. 
SOLDIN, S. J. & SOLDIN, O. P. 2009. Steroid hormone analysis by tandem mass 
spectrometry. Clin Chem, 55, 1061-6. 
194 
 
STAR-WEINSTOCK, M., WILLIAMSON, B. L., DEY, S., PILLAI, S. & 
PURKAYASTHA, S. 2012. LC-ESI-MS/MS analysis of testosterone at sub-
picogram levels using a novel derivatization reagent. Anal Chem, 84, 9310-7. 
STORBECK, K. H., GILLIGAN, L., JENKINSON, C., BARANOWSKI, E. S., 
QUANSON, J. L., ARLT, W. & TAYLOR, A. E. 2018. The utility of ultra-
high performance supercritical fluid chromatography-tandem mass 
spectrometry (UHPSFC-MS/MS) for clinically relevant steroid analysis. J 
Chromatogr B Analyt Technol Biomed Life Sci, 1085, 36-41. 
STRICKER, R., EBERHART, R., CHEVAILLER, M. C., QUINN, F. A. & 
BISCHOF, P. 2006. Establishment of detailed reference values for luteinizing 
hormone, follicle stimulating hormone, estradiol, and progesterone during 
different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. 
Clin Chem Lab Med, 44, 883-7. 
TAKÁTS, Z., WISEMAN, J. M., GOLOGAN, B. & COOKS, R. G. 2004. Mass 
spectrometry sampling under ambient conditions with desorption electrospray 
ionization. Science, 306, 471-3. 
TAMAE, D., BYRNS, M., MARCK, B., MOSTAGHEL, E. A., NELSON, P. S., 
LANGE, P., LIN, D., TAPLIN, M. E., BALK, S., ELLIS, W., TRUE, L., 
VESSELLA, R., MONTGOMERY, B., BLAIR, I. A. & PENNING, T. M. 
2013. Development, validation and application of a stable isotope dilution 
liquid chromatography electrospray ionization/selected reaction 
monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for 
quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol, 
138, 281-9. 
TAZUKE, S., KHAW, K. T. & BARRETT-CONNOR, E. 1992. Exogenous estrogen 
and endogenous sex hormones. Medicine (Baltimore), 71, 44-51. 
TCHERNOF, A., DESPRÉS, J. P., DUPONT, A., BÉLANGER, A., NADEAU, A., 
PRUD'HOMME, D., MOORJANI, S., LUPIEN, P. J. & LABRIE, F. 1995. 
Relation of steroid hormones to glucose tolerance and plasma insulin levels in 
men. Importance of visceral adipose tissue. Diabetes Care, 18, 292-9. 
TER HORST, K. W., GILIJAMSE, P. W., DE WEIJER, B. A., KILICARSLAN, M., 
ACKERMANS, M. T., NEDERVEEN, A. J., NIEUWDORP, M., ROMIJN, J. 
A. & SERLIE, M. J. 2015. Sexual Dimorphism in Hepatic, Adipose Tissue, 
and Peripheral Tissue Insulin Sensitivity in Obese Humans. Front Endocrinol 
(Lausanne), 6, 182. 
TRANCHIDA, P. Q., FRANCHINA, F. A., DUGO, P. & MONDELLO, L. 2016. 
Comprehensive two-dimensional gas chromatography-mass spectrometry: 
Recent evolution and current trends. Mass Spectrom Rev, 35, 524-34. 
TURCU, A. F. & AUCHUS, R. J. 2017. Clinical significance of 11-oxygenated 
androgens. Curr Opin Endocrinol Diabetes Obes, 24, 252-259. 
UETRECHT, C., ROSE, R. J., VAN DUIJN, E., LORENZEN, K. & HECK, A. J. 
2010. Ion mobility mass spectrometry of proteins and protein assemblies. 
Chem Soc Rev, 39, 1633-55. 
UPRETI, R., HUGHES, K. A., LIVINGSTONE, D. E., GRAY, C. D., MINNS, F. C., 
MACFARLANE, D. P., MARSHALL, I., STEWART, L. H., WALKER, B. 
R. & ANDREW, R. 2014. 5α-reductase type 1 modulates insulin sensitivity in 
men. J Clin Endocrinol Metab, 99, E1397-406. 
UPRETI, R., NAREDO, G., FAQEHI, A. M., HUGHES, K. A., STEWART, L. H., 
195 
 
WALKER, B. R., HOMER, N. Z. & ANDREW, R. 2015. Simultaneous 
pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors 
and androgens by liquid chromatography tandem mass spectrometry. Talanta, 
131, 728-35. 
VAN ROOYEN, G. F., SMIT, M. J., DE JAGER, A. D., HUNDT, H. K., SWART, K. 
J. & HUNDT, A. F. 2002. Sensitive liquid chromatography-tandem mass 
spectrometry method for the determination of clarithromycin in human plasma. 
J Chromatogr B Analyt Technol Biomed Life Sci, 768, 223-9. 
VARLAMOV, O., BETHEA, C. L. & ROBERTS, C. T. 2014. Sex-specific differences 
in lipid and glucose metabolism. Front Endocrinol (Lausanne), 5, 241. 
VESPER, H. W. & BOTELHO, J. C. 2010. Standardization of testosterone 
measurements in humans. J Steroid Biochem Mol Biol, 121, 513-9. 
VESPER, H. W., BOTELHO, J. C., SHACKLADY, C., SMITH, A. & MYERS, G. L. 
2008. CDC project on standardizing steroid hormone measurements. Steroids, 
73, 1286-92. 
WANG, C., IRANMANESH, A., BERMAN, N., MCDONALD, V., STEINER, B., 
ZIEL, F., FAULKNER, S. M., DUDLEY, R. E., VELDHUIS, J. D. & 
SWERDLOFF, R. S. 1998. Comparative pharmacokinetics of three doses of 
percutaneous dihydrotestosterone gel in healthy elderly men--a clinical 
research center study. J Clin Endocrinol Metab, 83, 2749-57. 
WANG, C., SHIRAISHI, S., LEUNG, A., BARAVARIAN, S., HULL, L., GOH, V., 
LEE, P. W. & SWERDLOFF, R. S. 2008. Validation of a testosterone and 
dihydrotestosterone liquid chromatography tandem mass spectrometry assay: 
Interference and comparison with established methods. Steroids, 73, 1345-52. 
WANG, Q., BOTTALICO, L., MESAROS, C. & BLAIR, I. A. 2015a. Analysis of 
estrogens and androgens in postmenopausal serum and plasma by liquid 
chromatography-mass spectrometry. Steroids, 99, 76-83. 
WANG, Q., RANGIAH, K., MESAROS, C., SNYDER, N. W., VACHANI, A., 
SONG, H. & BLAIR, I. A. 2015b. Ultrasensitive quantification of serum 
estrogens in postmenopausal women and older men by liquid chromatography-
tandem mass spectrometry. Steroids, 96, 140-52. 
WANG, X., MAGKOS, F. & MITTENDORFER, B. 2011. Sex differences in lipid 
and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol 
Metab, 96, 885-93. 
WANG, Y., GAY, G. D., BOTELHO, J. C., CAUDILL, S. P. & VESPER, H. W. 2014. 
Total testosterone quantitative measurement in serum by LC-MS/MS. Clin 
Chim Acta, 436, 263-7. 
WEI, L., LAI, E. C., KAO-YANG, Y. H., WALKER, B. R., MACDONALD, T. M. 
& ANDREW, R. 2019. Incidence of type 2 diabetes mellitus in men receiving 
steroid 5α-reductase inhibitors: population based cohort study. BMJ, 365, 
l1204. 
WENG, Y., XIE, F., XU, L., ZAGOREVSKI, D., SPINK, D. C. & DING, X. 2010. 
Analysis of testosterone and dihydrotestosterone in mouse tissues by liquid 
chromatography-electrospray ionization-tandem mass spectrometry. Anal 
Biochem, 402, 121-8. 
WERAWATGOOMPA, S., DUSITSIN, N., SOOKSAMITI, P., 
LEEPIPATPAIBOON, S., VIRUTAMASEN, P. & BOONSIRI, B. 1982. A 
rapid method for the determination of 5 alpha-dihydrotestosterone in Thai 
196 
 
males receiving medroxyprogesterone acetate. Contraception, 25, 523-33. 
WHITEHOUSE, C. M., DREYER, R. N., YAMASHITA, M. & FENN, J. B. 1985. 
Electrospray interface for liquid chromatographs and mass spectrometers. Anal 
Chem, 57, 675-9. 
WILLIAMS, T. M., KIND, A. J., HOUGHTON, E. & HILL, D. W. 1999. Electrospray 
collision-induced dissociation of testosterone and testosterone hydroxy 
analogs. J Mass Spectrom, 34, 206-16. 
WISEMAN, J. M., IFA, D. R., SONG, Q. & COOKS, R. G. 2006. Tissue imaging at 
atmospheric pressure using desorption electrospray ionization (DESI) mass 
spectrometry. Angew Chem Int Ed Engl, 45, 7188-92. 
WOODING, K. M., HANKIN, J. A., JOHNSON, C. A., CHOSICH, J. D., BAEK, S. 
W., BRADFORD, A. P., MURPHY, R. C. & SANTORO, N. 2015. 
Measurement of estradiol, estrone, and testosterone in postmenopausal human 
serum by isotope dilution liquid chromatography tandem mass spectrometry 
without derivatization. Steroids, 96, 89-94. 
WU, A. H., GERONA, R., ARMENIAN, P., FRENCH, D., PETRIE, M. & LYNCH, 
K. L. 2012. Role of liquid chromatography-high-resolution mass spectrometry 
(LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila), 50, 733-42. 
WU, H., RAMSAY, C., OZAETA, P., LIU, L. & ABOLENEEN, H. 2002. Serum 
estradiol quantified by isotope dilution-gas chromatography/mass 
spectrometry. Clin Chem, 48, 364-6. 
XING, S., CEKAN, S. Z., DICZFALUSY, U., FALK, O., GUSTAFSSON, S. A., 
AKERLÖF, E. & BJÖRKHEM, I. 1983. Validation of radioimmunoassay for 
estradiol-17 beta by isotope dilution-mass spectrometry and by a test of 
radiochemical purity. Clin Chim Acta, 135, 189-201. 
XU, L. & SPINK, D. C. 2008. Analysis of steroidal estrogens as pyridine-3-sulfonyl 
derivatives by liquid chromatography electrospray tandem mass spectrometry. 
Anal Biochem, 375, 105-14. 
YAMASHITA, K., MIYASHIRO, Y., MAEKUBO, H., OKUYAMA, M., HONMA, 
S., TAKAHASHI, M. & NUMAZAWA, M. 2009. Development of highly 
sensitive quantification method for testosterone and dihydrotestosterone in 
human serum and prostate tissue by liquid chromatography-electrospray 
ionization tandem mass spectrometry. Steroids, 74, 920-6. 
YAMASHITA, K., OKUYAMA, M., WATANABE, Y., HONMA, S., KOBAYASHI, 
S. & NUMAZAWA, M. 2007. Highly sensitive determination of estrone and 
estradiol in human serum by liquid chromatography-electrospray ionization 
tandem mass spectrometry. Steroids, 72, 819-27. 
YANG, M., FAZIO, S., MUNCH, D. & DRUMM, P. 2005. Impact of methanol and 
acetonitrile on separations based on pi-pi interactions with a reversed-phase 
phenyl column. J Chromatogr A, 1097, 124-9. 
YANG, W. C., REGNIER, F. E., SLIVA, D. & ADAMEC, J. 2008. Stable isotope-
coded quaternization for comparative quantification of estrogen metabolites by 
high-performance liquid chromatography-electrospray ionization mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 870, 233-40. 
YASUI, T., YAMADA, M., KINOSHITA, H., UEMURA, H., YONEDA, N., 
IRAHARA, M., AONO, T., SUNAHARA, S., MITO, Y., KURIMOTO, F. & 
HATA, K. 1999. Combination of automatic HPLC-RIA method for 
determination of estrone and estradiol in serum. J Clin Lab Anal, 13, 266-72. 
197 
 
YUE, B., ROCKWOOD, A. L., SANDROCK, T., LA'ULU, S. L., KUSHNIR, M. M. 
& MEIKLE, A. W. 2008. Free thyroid hormones in serum by direct equilibrium 
dialysis and online solid-phase extraction--liquid chromatography/tandem 
mass spectrometry. Clin Chem, 54, 642-51. 
YUN, Y. M., BOTELHO, J. C., CHANDLER, D. W., KATAYEV, A., ROBERTS, 
W. L., STANCZYK, F. Z., VESPER, H. W., NAKAMOTO, J. M., 
GARIBALDI, L., CLARKE, N. J. & FITZGERALD, R. L. 2012. Performance 
criteria for testosterone measurements based on biological variation in adult 
males: recommendations from the Partnership for the Accurate Testing of 
Hormones. Clin Chem, 58, 1703-10. 
ZANG, T., TAMAE, D., MESAROS, C., WANG, Q., HUANG, M., BLAIR, I. A. & 
PENNING, T. M. 2017. Simultaneous quantitation of nine hydroxy-androgens 
and their conjugates in human serum by stable isotope dilution liquid 
chromatography electrospray ionization tandem mass spectrometry. J Steroid 
Biochem Mol Biol, 165, 342-355. 
ZHANG, H. C., YU, X. J., YANG, W. C., PENG, J. F., XU, T., YIN, D. Q. & HU, X. 
L. 2011. MCX based solid phase extraction combined with liquid 
chromatography tandem mass spectrometry for the simultaneous determination 
of 31 endocrine-disrupting compounds in surface water of Shanghai. J 
Chromatogr B Analyt Technol Biomed Life Sci, 879, 2998-3004. 
ZHANG, X., QUINN, K., CRUICKSHANK-QUINN, C., REISDORPH, R. & 
REISDORPH, N. 2018. The application of ion mobility mass spectrometry to 
metabolomics. Curr Opin Chem Biol, 42, 60-66. 
 
 
 
198 
 
 
 
 
 
 
Publications 
 
 
 
 
 
 
 
